International Nonproprietary Names for Pharmaceutical Substances (INN)

RECOMMENDED International Nonproprietary Names: List 76

Notice is hereby given that, in accordance with paragraph 7 of the Procedure for the Selection of Recommended International Nonproprietary Names for Pharmaceutical Substances [*Off. Rec. Wld Health Org.*, 1955, **60**, 3 (Resolution EB15.R7); 1969, **173**, 10 (Resolution EB43.R9); Resolution EB115.R4 (EB115/2005/REC/1)], the following names are selected as Recommended International Nonproprietary Names. The inclusion of a name in the lists of Recommended International Nonproprietary Names does not imply any recommendation of the use of the substance in medicine or pharmacy.
Lists of Proposed (1–113) and Recommended (1–74) International Nonproprietary Names can be found in *Cumulative List No. 16, 2015* (available in CD-ROM only).

Dénominations communes internationales des Substances pharmaceutiques (DCI)

Dénominations communes internationales RECOMMANDÉES: Liste 76

Il est notifié que, conformément aux dispositions du paragraphe 7 de la Procédure à suivre en vue du choix de Dénominations communes internationales recommandées pour les Substances pharmaceutiques [*Actes off. Org. mond. Santé*, 1955, **60**, 3 (résolution EB15.R7); 1969, **173**, 10 (résolution EB43.R9); résolution EB115.R4 (EB115/2005/REC/1)] les dénominations ci-dessous sont choisies par l'Organisation mondiale de la Santé en tant que dénominations communes internationales recommandées. L'inclusion d'une dénomination dans les listes de DCI recommandées n'implique aucune recommandation en vue de l'utilisation de la substance correspondante en médecine ou en pharmacie.
On trouvera d'autres listes de Dénominations communes internationales proposées (1–113) et recommandées (1–74) dans la *Liste récapitulative No. 16, 2015* (disponible sur CD-ROM seulement).

Denominaciones Comunes Internacionales para las Sustancias Farmacéuticas (DCI)

Denominaciones Comunes Internacionales RECOMENDADAS: Lista 76

De conformidad con lo que dispone el párrafo 7 del Procedimiento de Selección de Denominaciones Comunes Internacionales Recomendadas para las Sustancias Farmacéuticas [*Act. Of. Mund. Salud*, 1955, **60**, 3 (Resolución EB15.R7); 1969, **173**, 10 (Resolución EB43.R9); Résolution EB115.R4 (EB115/2005/REC/1) EB115.R4 (EB115/2005/REC/1)], se comunica por el presente anuncio que las denominaciones que a continuación se expresan han sido seleccionadas como Denominaciones Comunes Internacionales Recomendadas. La inclusión de una denominación en las listas de las Denominaciones Comunes Recomendadas no supone recomendación alguna en favor del empleo de la sustancia respectiva en medicina o en farmacia.
Las listas de Denominaciones Comunes Internacionales Propuestas (1–113) y Recomendadas (1–74) se encuentran reunidas en *Cumulative List No. 16, 2015* (disponible sólo en CD-ROM).

Latin, English, French, Spanish: *Recommended INN*	*Chemical name or description; Molecular formula; Graphic formula*
DCI Recommandée	*Nom chimique ou description; Formule brute; Formule développée*
DCI Recomendada	*Nombre químico o descripción; Fórmula molecular; Fórmula desarrollada*

acebilustatum

acebilustat

4-{[(1*S*,4*S*)-5-({4-[4-(1,3-oxazol-2-yl)phenoxy]phenyl}methyl)-2,5-diazabicyclo[2.2.1]heptan-2-yl]methyl}benzoic acid

acébilustat

acide 4-{[(1*S*,4*S*)-5-({4-[4-(1,3-oxazol-2-yl)phénoxy]phényl}méthyl)-2,5-diazabicyclo[2.2.1]heptan-2-yl]méthyl}benzoïque

acebilustat

ácido 4-{[(1*S*,4*S*)-5-({4-[4-(1,3-oxazol-2-il)fenoxi]fenil}metil)-2,5-diazabiciclo[2.2.1]heptan-2-il]metil}benzoico

$C_{29}H_{27}N_3O_4$



alalevonadifloxacinum

alalevonadifloxacin

(5*S*)-8-[4-(L-alanyloxy)piperidin-1-yl]-9-fluoro-5-methyl-1-oxo-6,7-dihydro-1*H*,5*H*-pyrido[3,2,1-*ij*]quinoline-2-carboxylic acid

alalévonadifloxacine

acide (5*S*)-8-[4-(L-alanyloxy)pipéridin-1-yl]-9-fluoro-5-méthyl-1-oxo-6,7-dihydro-1*H*,5*H*-pyrido[3,2,1-*ij*]quinoline-2-carboxylique

alalevonadifloxacino

ácido (5*S*)-8-[4-(L-alaniloxi)piperidin-1-il]-9-fluoro-5-metil-1-oxo-6,7-dihidro-1*H*,5*H*-pirido[3,2,1-*ij*]quinolina-2-carboxílico

$C_{22}H_{26}FN_3O_5$



albusomatropinum #

albusomatropin — human serum albumin (residues 1-585) fusion protein with human somatotropin (growth hormone) (residues 586-776), produced in yeast cells (*Saccharomyces cerevisiae*)

albusomatropine — albumine sérique humaine (résidus 1-585) protéine de fusion avec la somatotropine humaine (hormone de croissance) (résidus 586-776), produit par culture de levure (*Saccharomyces cerevisiae*)

albusomatropina — albúmina sérica humana (restos 1-585) proteína de fusión con la somatotropina humana (hormona de crecimiento) (restos 586-776), producida mediante cultivo de levadura (*Saccharomyces cerevisiae*)

Sequence/ Séquence / Secuencia

```
DAHKSEVAHR FKDLGEENFK ALVLIAFAQY LQQCPFEDHV KLVNEVTEFA 50
KTCVADESAE NCDKSLHTLF GDKLCTVATL RETYGEMADC CAKQEPERNE 100
CFLQHKDDNP NLPRLVRPEV DVMCTAFHDN EETFLKKYLY EIARRHPYFY 150
APELLFFAKR YKAAFTECCQ AADKAACLLP KLDELRDEGK ASSAKQRLKC 200
ASLQKFGERA FKAWAVARLS QRFPKAEFAE VSKLVTDLTK VHTECCHGDL 250
LECADDRADL AKYICENQDS ISSKLKECCE KPLLEKSHCI AEVENDEMPA 300
DLPSLAADFV ESKDVCKNYA EAKDVFLGMF LYEYARRHPD YSVVLLLRLA 350
KTYETTLEKC CAAADPHECY AKVFDEFKPL VEEPQNLIKQ NCELFEQLGE 400
YKFQNALLVR YTKKVPQVST PTLVEVSRNL GKVGSKCCKH PEAKRMPCAE 450
DYLSVVLNQL CVLHEKTPVS DRVTKCCTES LVNRRPCFSA LEVDETYVPK 500
EFNAETFTFH ADICTLSEKE RQIKKQTALV ELVKHKPKAT KEQLKAVMDD 550
FAAFVEKCCK ADDKETCFAE EGKKLVAASQ AALGLFPTIP LSRLFDNAML 600
RAHRLHQLAF DTYQEFEEAY IPKEQKYSFL QNPQTSLCFS ESIPTPSNRE 650
ETQQKSNLEL LRISLLLIQS WLEPVQFLRS VFANSLVYGA SDSNVYDLLK 700
DLEEGIQTLM GRLEDGSPRT GQIFKQTYSK FDTNSHNDDA LLKNYGLLYC 750
FRKDMDKVET FLRIVQCRSV EGSCGF                         776
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

53-62	75-91	90-101	124-169	168-177	200-246	245-253
265-279	278-289	316-361	360-369	392-438	437-448	461-477
476-487	514-559	558-567	638-750	767-774		

asunerceptum #

asunercept — fusion protein for immune applications (FPIA) comprising the *Homo sapiens* FAS (Fas cell surface death receptor, TNFRSF6, tumor necrosis factor receptor (TNFR) superfamily member 6, FAS1, APO-1, CD95) extracellular domain, fused with *Homo sapiens* immunoglobulin G1 Fc fragment;
Homo sapiens FAS precursor fragment 26-172 (1-147) - gamma1 chain H-CH2-CH3 fragment [*Homo sapiens* IGHG1*03 (hinge 5-15 (148-158), CH2 (159-268), CH3 (269-373), CHS (374-375))] (148-375); dimer (148-148':154-154':157-157')-trisdisulfide

asunercept — protéine de fusion pour applications immunitaires (FPIA) comprenant le domaine extracellulaire d'*Homo sapiens* FAS (récepteur de mort membranaire Fas, TNFRSF6, membre 6 de la superfamille des récepteurs du facteur de nécrose tumorale (TNFR), FAS1, APO-1, CD95), fusionné au fragment Fc de l'immunoglobuline G1 d'*Homo sapiens*; *Homo sapiens* FAS fragment 26-172 du précurseur (1-147)-fragment H-CH2-CH3 de la chaîne gamma1 [*Homo sapiens* IGHG1*03 (charnière 5-15 (148-158), CH2 (159-268), CH3 (269-373), CHS (374-375))] (148-375); dimère (148-148':154-154':157-157')-trisdisulfure

asunercept

proteína de fusión para aplicaciones inmunitarias (FPIA) que comprende el dominio extracelular de *Homo sapiens* FAS (receptor de muerte Fas de membrana, TNFRSF6, miembro 6 de la superfamilia de receptores del factor de necrosis tumoral (TNFR), FAS1, APO-1, CD95), fusionado con el fragmento Fc de la inmunoglobulina G1 de *Homo sapiens;*
FAS de *Homo sapiens* fragmento 26-172 del precursor (1-147) -fragmento H-CH2-CH3 de la cadena gamma1 [*Homo sapiens* IGHG1*03 (bisagra 5-15 (148-158), CH2 (159-268), CH3 (269-373), CHS (374-375))] (148-375); dímero (148-148':154-154':157-157')-trisdisulfuro

Fused chain / chaine fusionnée / cadena fusionada

```
QVTDINSKGL ELRKTVTTVE TQNLEGLHHD GQFCHKPCPP GERKARDCTV  50
NGDEPDCVPC QEGKEYTDKA HFSSKCRRCR LCDEGHGLEV EINCTRTQNT 100
KCRCKPNFFC NSTVCEHCDP CTKCEHGIIK ECTLTSNTKC KEEGSRSCDK 150
THTCPPCPAP ELLGGPSVFL FPPKPKDTLM ISRTPEVTCV VVDVSHEDPE 200
VKFNWYVDGV EVHNAKTKPR EEQYNSTYRV VSVLTVLHQD WLNGKEYKCK 250
VSNKALPAPI EKTISKAKGQ PREPQVYTLP PSREEMTKNQ VSLTCLVKGF 300
YPSDIAVEWE SNGQPENNYK TTPPVLDSDG SFFLYSKLTV DKSRWQQGNV 350
FSCSVMHEAL HNHYTQKSLS LSPGK                            375
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intrachain	FAS	34-48	38-57	60-76	79-94
		82-102	104-118	121-132	124-140
		34'-48'	38'-57'	60'-76'	79'-94'
		82'-102'	104'-118'	121'-132'	124'-140'
	IGHG1 (C23-C104)	189-249	295-353		
		189'-249'	295'-353'		
Interchain	IGHG1 (h5, h 11, h 14)	148-148'	154-154'	157-157'	

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
FAS:
93, 111, 93', 111': complex mono-, bi-, tri- and tetra-antennary oligosaccharides, partially sialylated, oligosaccharides complexes de structure ramifiée (de 1 à 4 branches), partiellement sialylés, oligosacáridos complejos mono-bi, tri y tetra-antenado, parcialmente sialilados
IGHG1 CH2 N84.4:
225, 225': complex mono- and biantennary non-sialylated oligosaccharides, oligosaccharides complexes de structure ramifiée (de 1 à 2 branches) non-sialylés, oligosacáridos complejo mono- and biantenado non-sialilado

Other post-translational modifications / Autres modifications post-traductionnelles / Otras modificaciones post-traduccionales:
H CHS K2 C-terminal lysine clipping, coupure de la lysine C-terminale, supresión de lisina C-terminal: 375, 375'

avacopanum

avacopan

(2*R*,3*S*)-2-[4-(cyclopentylamino)phenyl]-1-(2-fluoro-6-methylbenzoyl)-*N*-[4-methyl-3-(trifluoromethyl)phenyl]piperidine-3-carboxamide

avacopan

(2*R*,3*S*)-2-[4-(cyclopentylamino)phényl]-1-(2-fluoro-6-méthylbenzoyl)-*N*-[4-méthyl-3-(trifluorométhyl)phényl]pipéridine-3-carboxamide

avacopán

(2*R*,3*S*)-2-[4-(ciclopentilamino)fenil]-1-(2-fluoro-6-metilbenzoil)-*N*-[4-metil-3-(trifluorometil)fenil]piperidina-3-carboxamida

$C_{33}H_{35}F_4N_3O_2$



bazlitoranum

bazlitoran

all-P-ambo-2'-deoxy-*P*-thiocytidylyl-(3'→5')-*P*-thiothymidylyl-(3'→5')-2'-deoxy-*P*-thioadenylyl-(3'→5')-*P*-thiothymidylyl-(3'→5')-2'-deoxy-*P*-thiocytidylyl-(3'→5')-*P*-thiothymidylyl-(3'→5')-2'-*O*-methyl-*P*-thioguanylyl-(3'→5')-2'-*O*-methyl-*P*-thiouridylyl-(3'→5')-2'-deoxy-5-methyl-*P*-thiocytidylyl-(3'→5')-7-carba-2'-deoxy-*P*-thioguanylyl-(3'→5')-*P*-thiothymidylyl-(3'→5')-*P*-thiothymidylyl-(3'→5')-2'-deoxy-*P*-thiocytidylyl-(3'→5')-*P*-thiothymidylyl-(3'→5')-2'-deoxy-*P*-thiocytidylyl-(3'→5')-*P*-thiothymidylyl-(3'→5')-2'-*O*-methyl-*P*-thioguanylyl-(3'→5')-2'-*O*-methyluridine

bazlitoran

tout-P-ambo-2'-déoxy-*P*-thiocytidylyl-(3'→5')-*P*-thiothymidylyl-(3'→5')-2'-déoxy-*P*-thioadénylyl-(3'→5')-*P*-thiothymidylyl-(3'→5')-2'-déoxy-*P*-thiocytidylyl-(3'→5')-*P*-thiothymidylyl-(3'→5')-2'-*O*-méthyl-*P*-thioguanylyl-(3'→5')-2'-*O*-méthyl-*P*-thiouridylyl-(3'→5')-2'-déoxy-5-méthyl-*P*-thiocytidylyl-(3'→5')-7-carba-2'-déoxy-*P*-thioguanylyl-(3'→5')-*P*-thiothymidylyl-(3'→5')-*P*-thiothymidylyl-(3'→5')-2'-déoxy-*P*-thiocytidylyl-(3'→5')-*P*-thiothymidylyl-(3'→5')-2'-déoxy-*P*-thiocytidylyl-(3'→5')-*P*-thiothymidylyl-(3'→5')-2'-*O*-méthyl-*P*-thioguanylyl-(3'→5')-2'-*O*-méthyluridine

bazlitorán

todo-P-ambo-2'-desoxi-*P*-tiocitidilil-(3'→5')-*P*-tiotimidilil-(3'→5')-2'-desoxi-*P*-tioadenilil-(3'→5')-*P*-tiotimidilil-(3'→5')-2'-desoxi-*P*-tiocitidilil-(3'→5')-*P*-tiotimidilil-(3'→5')-2'-*O*-metil-*P*-tioguanilil-(3'→5')-2'-*O*-metil-*P*-tiouridilil-(3'→5')-2'-desoxi-5-metil-*P*-tiocitidilil-(3'→5')-7-carba-2'-desoxi-*P*-tioguanilil-(3'→5')-*P*-tiotimidilil-(3'→5')-*P*-tiotimidilil-(3'→5')-2'-desoxi-*P*-tiocitidilil-(3'→5')-*P*-tiotimidilil-(3'→5')-2'-desoxi-*P*-tiocitidilil-(3'→5')-*P*-tiotimidilil-(3'→5')-2'-*O*-metil-*P*-tioguanilil-(3'→5')-2'-*O*-metiluridina

$C_{179}H_{233}N_{52}O_{101}P_{17}S_{17}$

(3'-5')d(P-thio)(C-T-A-T-C-T-rGm-rUm-m5C-c7G-T-T-C-T-C-T-rGm-rUm)

Legend:
rGm = 2'-O-méthylguanosine
rUm = 2'-O-méthyluridine
m5C = 2'-deoxy-5-methylcytidine
c7G = 2'-deoxy-7-carbaguanosine (*C* replaces *N*)

bevacizumabum beta #

bevacizumab beta

immunoglobulin G1-kappa, anti-[*Homo sapiens* VEGFA (vascular endothelial growth factor A, VEGF-A, VEGF)], humanized monoclonal antibody;

	gamma1 heavy chain (1-453) [humanized VH (*Homo sapiens* IGHV3-30*02 (76.80%) -(IGHD) -IGHJ4*01) [8.8.16] (1-123) -*Homo sapiens* IGHG1*03 (CH1 R120>K (220) (124-221), hinge (222-236), CH2 (237-346), CH3 (347-451), CHS (452-453)) (124-453)], (226-214')-disulfide with kappa light chain (1'-214') [humanized V-KAPPA (*Homo sapiens* IGKV1-16*01 (88.40%) -IGKJ1*01) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01, Km3 (108'-214')]; dimer (232-232":235-235")-bisdisulfide
bévacizumab bêta	immunoglobuline G1-kappa, anti-[*Homo sapiens* VEGFA (facteur de croissance A de l'endothélium vasculaire, VEGF-A, VEGF)], anticorps monoclonal humanisé; chaîne lourde gamma1 (1-453) [VH humanisé (*Homo sapiens* IGHV3-30*02 (76.80%) -(IGHD) -IGHJ4*01) [8.8.16] (1-123) -*Homo sapiens* IGHG1*03 (CH1 R120>K (220) (124-221), charnière (222-236), CH2 (237-346), CH3 (347-451), CHS (452-453)) (124-453)], (226-214')-disulfure avec la chaîne légère kappa (1'-214') [V-KAPPA humanisé (*Homo sapiens* IGKV1-16*01 (88.40%) -IGKJ1*01) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01, Km3 (108'-214')]; dimère (232-232":235-235")-bisdisulfure
bevacizumab beta	inmunoglobulina G1-kappa, anti-[*Homo sapiens* VEGFA (factor de crecimiento A endotelial vascular, VEGF-A, VEGF)], anticuerpo monoclonal humanizado; cadena pesada gamma1 (1-453) [VH humanizado (*Homo sapiens* IGHV3-30*02 (76.80%) -(IGHD) -IGHJ4*01) [8.8.16] (1-123) -*Homo sapiens* IGHG1*03 (CH1 R120>K (220) (124-221), bisagra (222-236), CH2 (237-346), CH3 (347-451), CHS (452-453)) (124-453)], (226-214')-disulfuro con la cadena ligera kappa (1'-214') [V-KAPPA humanizado (*Homo sapiens* IGKV1-16*01 (88.40%) -IGKJ1*01) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01, Km3 (108'-214')]; dímero (232-232":235-235")-bisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada

```
EVQLVESGGG LVQPGGSLRL SCAASGYTFT NYGMNWVRQA PGKGLEWVGW  50
INTYTGEPTY AADFKRRFTF SLDTSKSTAY LQMNSLRAED TAVYYCAKYP 100
HYYGSSHWYF DVWGQGTLVT VSSASTKGPS VFPLAPSSKS TSGGTAALGC 150
LVKDYFPEPV TVSWNSGALT SGVHTFPAVL QSSGLYSLSS VVTVPSSSLG 200
TQTYICNVNH KPSNTKVDKK VEPKSCDKTH TCPPCPAPEL LGGPSVFLFP 250
PKPKDTLMIS RTPEVTCVVV DVSHEDPEVK FNWYVDGVEV HNAKTKPREE 300
QYNSTYRVVS VLTVLHQDWL NGKEYKCKVS NKALPAPIEK TISKAKGQPR 350
EPQVYTLPPS REEMTKNQVS LTCLVKGFYP SDIAVEWESN GQPENNYKTT 400
PPVLDSDGSF FLYSKLTVDK SRWQQGNVFS CSVMHEALHN HYTQKSLSLS 450
PGK                                                     453
```

Light chain / Chaîne légère / Cadena ligera

```
DIQMTQSPSS LSASVGDRVT ITCSASQDIS NYLNWYQQKP GKAPKVLIYF  50
TSSLHSGVPS RFSGSGSGTD FTLTISSLQP EDFATYYCQQ YSTVPWTFGQ 100
GTKVEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV 150
DNALQSGNSQ ESVTEQDSKD STYSLSSTLT LSKADYEKHK VYACEVTHQG 200
LSSPVTKSFN RGEC                                         214
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H (C23-C104)	22-96	150-206	267-327	373-431
	22"-96"	150"-206"	267"-327"	373"-431"
Intra-L (C23-C104)	23'-88'	134'-194'		
	23'"-88'"	134'"-194'"		
Inter-H-L (h 5-CL 126)	226-214'	226"-214'"		
Inter-H-H (h 11, h 14)	232-232"	235-235"		

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
H CH2 N84.4:
303, 303"

Fucosylated complex bi-antennary CHO-type glycans, with a level of galactosylated A2G2F > 1.5% and of high mannose Man5 > 0.9% / glycanes de type CHO bi-antennaires complexes fucosylés, avec un taux de galactosylé A2G2F > 1.5% et de riche en mannose Man5 > 0.9% / glicanos de tipo CHO biantenarios complejos fucosilados, con una tasa de galactosilado A2G2F > 1.5% y de alta manosa Man5 > 0.9%

blontuvetmabum # blontuvetmab	immunoglobulin G2_V-kappa-C-lambda, anti-[*Homo sapiens* MS4A1 (membrane-spanning 4-domains subfamily A member 1, CD20)], caninized monoclonal antibody; gamma2 heavy chain chimeric (1-448) [*Mus musculus* VH (*Mus musculus* IGHV1-15*01 -(IGHD) -IGHJ1*03) [8.8.6] (1-113) -*Canis lupus familiaris* IGHG2*02 (CH1 T26>Q (131) (114-211), hinge (212-229), CH2 (230-339), CH3 (340-446), CHS (447-448)) (114-448)], (128-218')-disulfide with V-kappa-C-lambda light chain chimeric (1'-219') [*Mus musculus* V-KAPPA (*Mus musculus* IGKV8-30*01 -IGKJ5*01) [12.3.9] (1'-112') -*Canis lupus familiaris* IGL1CS1*01 V45.3>I (162) (114'-219')]; dimer (225-225":228-228")-bisdisulfide
blontuvetmab	immunoglobuline G2_V-kappa-C-lambda, anti-[*Homo sapiens* MS4A1 (membre 1 de la sous-famille A à 4 domaines transmembranaires, CD20)], anticorps monoclonal caninisé; chaîne lourde gamma2 chimérique (1-448) [*Mus musculus* VH (*Mus musculus* IGHV1-15*01 -(IGHD) -IGHJ1*03) [8.8.6] (1-113) -*Canis lupus familiaris* IGHG2*02 (CH1 T26>Q (131) (114-211), charnière (212-229), CH2 (230-339), CH3 (340-446), CHS (447-448)) (114-448)], (128-218')-disulfure avec la chaîne légère V-kappa-C-lambda chimérique (1'-219') [*Mus musculus* V-KAPPA (*Mus musculus* IGKV8-30*01 -IGKJ5*01) [12.3.9] (1'-112') -*Canis lupus familiaris* IGL1CS1*01 V45.3>I (162) (114'-219')]; dimère (225-225":228-228")-bisdisulfure
blontuvetmab	inmunoglobulina G2_V-kappa-C-lambda, anti-[*Homo sapiens* MS4A1 (miembro 1 de la subfamilia A con 4 dominios transmembranarios, CD20)], anticuerpo monoclonal caninizado; cadena pesada gamma2 quimérica (1-448) [*Mus musculus* VH (*Mus musculus* IGHV1-15*01 -(IGHD) -IGHJ1*03) [8.8.6] (1-113) -*Canis lupus familiaris* IGHG2*02 (CH1 T26>Q (131) (114-211), bisagra (212-229), CH2 (230-339), CH3 (340-446), CHS (447-448)) (114-448)], (128-218')-disulfuro con la cadena ligera V-kappa-C-lambda quimérica (1'-219') [*Mus musculus* V-KAPPA (*Mus musculus* IGKV8-30*01 -IGKJ5*01) [12.3.9] (1'-112') -*Canis lupus familiaris* IGL1CS1*01 V45.3>I (162) (114'-219')]; dímero (225-225":228-228")-bisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada

```
QVQLQQSRAE LVRPGASVTL SCKPSGYTFT DYEVHWVKQT PVHGLEWIGA  50
IDPETGGTAD NQKFKGKAIL TADKSSSTAY MELRSLTSED SAVYYCTNFV 100
DVWGTGTTVT VSSASTTAPS VFPLAPSCGS QSGSTVALAC LVSGYFPEPV 150
TVSWNSGSLT SGVHTFPSVL QSSGLYSLSS MVTVPSSRWP SETFTCNVAH 200
PASKTKVDKP VPKRENGRVP RPPDCPKCPA PEMLGGPSVF IFPPKPKDTL 250
LIARTPEVTC VVVDLDPEDP EVQISWFVDG KQMQTAKTQP REEQFNGTYR 300
VVSVLPIGHQ DWLKGKQFTC KVNNKALPSP IERTISKARG QAHQPSVYVL 350
PPSREELSKN TVSLTCLIKD FFPPDIDVEW QSNGQQEPES KYRTTPPQLD 400
EDGSYFLYSK LSVDKSRWQR GDTFICAVMH EALHNHYTQK SLSHSPGK   448
```

Light chain / Chaîne légère / Cadena ligera

```
DVVMSQSPSS LAVSVGEKVT MSCKSSQSLL YSGNQKNYLA WYQQKPGQSP  50
RLLIYWASTR ESGVPDRFTG SGSGTDFTLT ISSVKAEDLA VFYCQQYYNY 100
PLTFGGGTHL TVLGQPKASP SVTLFPPSSE ELGANKATLV CLISDFYPSG 150
VTVAWKADGS PITQGVETTK PSKQSNNKYA ASSYLSLTPD KWKSHSSFSC 200
LVTHEGSTVE KKVAPAECS                                   219
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H (C23-C104)	22-96	140-196	260-320	366-426
	22"-96"	140"-196"	260"-320"	366"-426"
Intra-L (C23-C104)	23'-94'	141'-200		
	23'"-94'"	141'"-200'"		
Inter-H-L (CH1 11-CL 126)	128-218'	128"-218'"		
Inter-H-H (h 14, h 17)	225-225"	228-228"		

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
H CH2 N84.4:
296, 296"

brimapitidum

brimapitide

D-α-aspartyl-D-glutaminyl-D-seryl-D-arginyl-D-prolyl-D-valyl-D-glutaminyl-D-prolyl-D-phenylalanyl-D-leucyl-D-asparaginyl-D-leucyl-D-threonyl-D-threonyl-D-prolyl-D-arginyl-D-lysyl-D-prolyl-D-arginyl-D-prolyl-D-prolyl-D-arginyl-D-arginyl-D-arginyl-D-glutaminyl-D-arginyl-D-arginyl-D-lysyl-D-lysyl-D-arginylglycinamide

brimapitide

D-α-aspartyl-D-glutaminyl-D-séryl-D-arginyl-D-prolyl-D-valyl-D-glutaminyl-D-prolyl-D-phénylalanyl-D-leucyl-D-asparaginyl-D-leucyl-D-thréonyl-D-thréonyl-D-prolyl-D-arginyl-D-lysyl-D-prolyl-D-arginyl-D-prolyl-D-prolyl-D-arginyl-D-arginyl-D-arginyl-D-glutaminyl-D-arginyl-D-arginyl-D-lysyl-D-lysyl-D-arginylglycinamide

brimapitida

D-α-aspartil-D-glutaminil-D-seril-D-arginil-D-prolil-D-valil-D-glutaminil-D-prolil-D-fenilalanil-D-leucil-D-asparaginil-D-leucil-D-treonil-D-treonil-D-prolil-D-arginil-D-lisil-D-prolil-D-arginil-D-prolil-D-prolil-D-arginil-D-arginil-D-arginil-D-glutaminil-D-arginil-D-arginil-D-lisil-D-lisil-D-arginilglicinamida

$C_{164}H_{286}N_{66}O_{40}$

D-Aminoacids sequence / Séquence des D-aminoacides / Secuencia de D-aminoácidos

DQSRPVQPFL NLTTPRKPRP PRRRQRRKKR G 31

Modified residue / Résidu modifié / Resto modificado

G = glycinamide

cabiralizumabum #	
cabiralizumab	immunoglobulin G4-kappa, anti-[*Homo sapiens* CSF1R (colony stimulating factor 1 receptor, CSF-1R, CSF-1-R, macrophage colony-stimulating factor 1 receptor, c-fms, FMS, CD115)], humanized monoclonal antibody; gamma4 heavy chain (1-449) [humanized VH (*Homo sapiens* IGHV1-46*01 (83.70%) -(IGHD) -IGHJ4*01) [8.8.15] (1-122)), IGHG4*01 (CH1 (123-220), hinge S10>P (230) (221-232), CH2 (233-342), CH3 (343-447), CHS (448-449)) (123-449)], (136-218')-disulfide with kappa light chain (1'-218') [humanized V-KAPPA (*Homo sapiens* IGKV3-11*01 (84.90%) -IGKJ4*01) [10.3.9] (1'-111') -*Homo sapiens* IGKC*01, Km3 (112'-218')]; dimer (228-228":231-231")-bisdisulfide
cabiralizumab	immunoglobuline G4-kappa, anti-[*Homo sapiens* CSF1R (récepteur du facteur 1 stimulant de colonies, CSF-1R, CSF-1-R, récepteur du facteur 1 stimulant des colonies de macrophages, c-fms, FMS, CD115)], anticorps monoclonal humanisé; chaîne lourde gamma4 (1-449) [VH humanisé (*Homo sapiens* IGHV1-46*01 (83.70%) -(IGHD) -IGHJ4*01) [8.8.15] (1-122)), IGHG4*01 (CH1 (123-220), charnière S10>P (230) (221-232), CH2 (233-342), CH3 (343-447), CHS (448-449)) (123-449)], (136-218')-disulfure avec la chaîne légère kappa (1'-218') [V-KAPPA humanisé (*Homo sapiens* IGKV3-11*01 (84.90%) -IGKJ4*01) [10.3.9] (1'-111') -*Homo sapiens* IGKC*01, Km3 (112'-218')]; dimère (228-228":231-231")-bisdisulfure
cabiralizumab	inmunoglobulina G4-kappa, anti-[*Homo sapiens* CSF1R (receptor del factor 1 de estimulación de colonias, CSF-1R, CSF-1-R, receptor del factor 1 de estimulación de colonias de macrófagos, c-fms, FMS, CD115)], anticuerpo monoclonal humanizado; cadena pesada gamma4 (1-449) [VH humanizado (*Homo sapiens* IGHV1-46*01 (83.70%) -(IGHD) -IGHJ4*01) [8.8.15] (1-122)), IGHG4*01 (CH1 (123-220), bisagra S10>P (230) (221-232), CH2 (233-342), CH3 (343-447), CHS (448-449)) (123-449)], (136-218')-disulfuro con la cadena ligera kappa (1'-218') [V-KAPPA humanizado (*Homo sapiens* IGKV3-11*01 (84.90%) -IGKJ4*01) [10.3.9] (1'-111') -*Homo sapiens* IGKC*01, Km3 (112'-218')]; dímero (228-228":231-231")-bisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada

```
QVQLVQSGAE VKKPGSSVKV SCKASGYTFT DNYMIWVRQA PGQGLEWMGD  50
INPYNGGTTF NQKFKGRVTI TADKSTSTAY MELSSLRSED TAVYYCARES 100
PYFSNLYVMD YWGQGTLVTV SSASTKGPSV FPLAPCSRST SESTAALGCL 150
VKDYFPEPVT VSWNSGALTS GVHTFPAVLQ SSGLYSLSSV VTVPSSSLGT 200
KTYTCNVDHK PSNTKVDKRV ESKYGPPCPP CPAPEFLGGP SVFLFPPKPK 250
DTLMISRTPE VTCVVVDVSQ EDPEVQFNWY VDGVEVHNAK TKPREEQFNS 300
TYRVVSVLTV LHQDWLNGKE YKCKVSNKGL PSSIEKTISK AKGQPREPQV 350
YTLPPSQEEM TKNQVSLTCL VKGFYPSDIA VEWESNGQPE NNYKTTPPVL 400
DSDGSFFLYS RLTVDKSRWQ EGNVFSCSVM HEALHNHYTQ KSLSLSLGK  449
```

Light chain / Chaîne légère / Cadena ligera

```
EIVLTQSPAT LSLSPGERAT LSCKASQSVD YDGDNYMNWY QQKPGQAPRL  50
LIYAASNLES GIPARFSGSG SGTDFTLTIS SLEPEDFAVY YCHLSNEDLS 100
TFGGGTKVEI KRTVAAPSVF IFPPSDEQLK SGTASVVCLL NNFYPREAKV 150
QWKVDNALQS GNSQESVTEQ DSKDSTYSLS STLTLSKADY EKHKVYACEV 200
THQGLSSPVT KSFNRGEC                                    218
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H (C23-C104)	22-96	149-205	263-323	369-427
	22"-96"	149"-205"	263"-323"	369"-427"
Intra-L (C23-C104)	23'-92'	138'-198'		
	23'"-92"'	138'"-198"'		
Inter-H-L (CH1 10-CL 126)	136-218'	136"-218"'		
Inter-H-H (h 8, h 11)	228-228"	231-231"		

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
H CH2 N84.4:
299, 299"
Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires complexes fucosylés / glicanos de tipo CHO biantenarios complejos fucosilados

carotuximabum #

carotuximab — immunoglobulin G1-kappa, anti-[*Homo sapiens* ENG (endoglin, Osler-Rendu-Weber syndrome 1, ORW1, ORW, HHT1, CD105)], chimeric monoclonal antibody; gamma1 heavy chain (1-448) [*Mus musculus* VH (IGHV6-6*01 -(IGHD) -IGHJ2*01) [8.10.9] (1-118) -*Homo sapiens* IGHG1*01, Gm17,1 (CH1 (119-216), hinge (217-231), CH2 (232-341), CH3 (342-446), CHS (447-448)) (119-448)], (221-213')-disulfide with kappa light chain (1'-213') [chimeric V-KAPPA (*Mus musculus* IGKV4-72*01 -*Homo sapiens* IGKJ5*01) [5.3.9] (1'-106') -*Homo sapiens* IGKC*01, Km3 (107'-213')]; dimer (227-227":230-230")-bisdisulfide

carotuximab — immunoglobuline G1-kappa, anti-[*Homo sapiens* ENG (endogline, syndrome 1 d'Osler-Rendu-Weber, ORW1, ORW, HHT1, CD105)], anticorps monoclonal chimérique; chaîne lourde gamma1 (1-448) [*Mus musculus* VH (IGHV6-6*01 -(IGHD) -IGHJ2*01) [8.10.9] (1-118) -*Homo sapiens* IGHG1*01, Gm17,1 (CH1 (119-216), charnière (217-231), CH2 (232-341), CH3 (342-446), CHS (447-448)) (119-448)], (221-213')-disulfure avec la chaîne légère kappa (1'-213') [V-KAPPA chimérique (*Mus musculus* IGKV4-72*01 -*Homo sapiens* IGKJ5*01) [5.3.9] (1'-106') -*Homo sapiens* IGKC*01, Km3 (107'-213')]; dimère (227-227":230-230")-bisdisulfure

carotuximab — inmunoglobulina G1-kappa, anti-[*Homo sapiens* ENG (endoglina, síndrome 1 de Osler-Rendu-Weber, ORW1, ORW, HHT1, CD105)], anticuerpo monoclonal quimérico;

cadena pesada gamma1 (1-448) [*Mus musculus* VH (IGHV6-6*01 -(IGHD) -IGHJ2*01) [8.10.9] (1-118) -*Homo sapiens* IGHG1*01, Gm17,1 (CH1 (119-216), bisagra (217-231), CH2 (232-341), CH3 (342-446), CHS (447-448)) (119-448)], (221-213')-disulfuro con la cadena ligera kappa (1'-213') [V-KAPPA quimérico (*Mus musculus* IGKV4-72*01 -*Homo sapiens* IGKJ5*01) [5.3.9] (1'-106') -*Homo sapiens* IGKC*01, Km3 (107'-213')]; dímero (227-227''':230-230'')-bisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada

```
EVKLEESGGG LVQPGGSMKL SCAASGFTFS DAWMDWVRQS PEKGLEWVAE  50
IRSKASNHAT YYAESVKGRF TISRDDSKSS VYLQMNSLRA EDTGIYYCTR 100
WRRFFDSWGQ GTTLTVSSAS TKGPSVFPLA PSSKSTSGGT AALGCLVKDY 150
FPEPVTVSWN SGALTSGVHT FPAVLQSSGL YSLSSVVTVP SSSLGTQTYI 200
CNVNHKPSNT KVDKKVEPKS CDKTHTCPPC PAPELLGGPS VFLFPPKPKD 250
TLMISRTPEV TCVVVDVSHE DPEVKFNWYV DGVEVHNAKT KPREEQYNST 300
YRVVSVLTVL HQDWLNGKEY KCKVSNKALP APIEKTISKA KGQPREPQVY 350
TLPPSRDELT KNQVSLTCLV KGFYPSDIAV EWESNGQPEN NYKTTPPVLD 400
SDGSFFLYSK LTVDKSRWQQ GNVFSCSVMH EALHNHYTQK SLSLSPGK   448
```

Light chain / Chaîne légère / Cadena ligera

```
QIVLSQSPAI LSASPGEKVT MTCRASSSVS YMHWYQQKPG SSPKPWIYAT  50
SNLASGVPVR FSGSGSGTSY SLTISRVEAE DAATYYCQQW SSNPLTFGAG 100
TKLELKRTVA APSVFIFPPS DEQLKSGTAS VVCLLNNFYP REAKVQWKVD 150
NALQSGNSQE SVTEQDSKDS TYSLSSTLTL SKADYEKHKV YACEVTHQGL 200
SSPVTKSFNR GEC                                         213
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H (C23-C104)	22-98	145-201	262-322	368-426
	22''-98''	145''-201''	262''-322''	368''-426''
Intra-L (C23-C104)	23'-87'	133'-193'		
	23'''-87'''	133'''-193'''		
Inter-H-L (h 5-CL 126)	221-213'	221''-213'''		
Inter-H-H (h 11, h 14)	227-227''	230-230''		

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
H CH2 N84.4:
298, 298''
Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires complexes fucosylés / glicanos de tipo CHO biantenarios complejos fucosilados

cefiderocolum

cefiderocol	(6*R*,7*R*)-7-[(2*Z*)-2-(2-amino-1,3-thiazol-4-yl)-2-{[(2-carboxypropan-2-yl)oxy]imino}acetamido]-3-({1-[2-(2-chloro-3,4-dihydroxybenzamido)ethyl]pyrrolidin-1-ium-1-yl}methyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate
céfidérocol	(6*R*,7*R*)-7-[(2*Z*)-2-(2-amino-1,3-thiazol-4-yl)-2-{[(2-carboxypropan-2-yl)oxy]imino}acétamido]-3-({1-[2-(2-chloro-3,4-dihydroxybenzamido)éthyl]pyrrolidin-1-ium-1-yl}méthyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ène-2-carboxylate
cefiderocol	(6*R*,7*R*)-7-[(2*Z*)-2-(2-amino-1,3-tiazol-4-il)-2-{[(2-carboxipropan-2-il)oxi]imino}acetamido]-3-({1-[2-(2-cloro-3,4-dihidroxibenzamido)etil]pirrolidin-1-ium-1-il}metil)-8-oxo-5-tia-1-azabiciclo[4.2.0]oct-2-ene-2-carboxilato

$C_{30}H_{34}ClN_7O_{10}S_2$



cemdisiranum

cemdisiran

duplex of [(2*S*,4*R*)-1-{1-[(2-acetamido-2-deoxy-β-D-galactopyranosyl)oxy]-16,16-bis({3-[(3-{5-[(2-acetamido-2-deoxy-β-D-galactopyranosyl)oxy]pentanamido}propyl)amino]-3-oxopropoxy}methyl)-5,11,18-trioxo-14-oxa-6,10,17-triazanonacosan-29-oyl}-4-hydroxypyrrolidin-2-yl]methyl hydrogen *all-P-ambo*-2'-*O*-methyl-*P*-thioadenylyl-(3'→5')-2'-*O*-methyl-*P*-thioadenylyl-(3'→5')-2'-deoxy-2'-fluoroguanylyl-(3'→5')-2'-*O*-methylcytidylyl-(3'→5')-2'-deoxy-2'-fluoroadenylyl-(3'→5')-2'-*O*-methyladenylyl-(3'→5')-2'-deoxy-2'-fluoroguanylyl-(3'→5')-2'-*O*-methyladenylyl-(3'→5')-2'-deoxy-2'-fluorouridylyl-(3'→5')-2'-deoxy-2'-fluoroadenylyl-(3'→5')-2'-deoxy-2'-fluorouridylyl-(3'→5')-2'-*O*-methyluridylyl-(3'→5')-2'-deoxy-2'-fluorouridylyl-(3'→5')-2'-*O*-methyluridylyl-(3'→5')-2'-*O*-methyluridylyl-(3'→5')-2'-deoxy-2'-fluoroadenylyl-(3'→5')-2'-*O*-methyluridylyl-(3'→5')-2'-deoxy-2'-fluoroadenylyl-(3'→5')-2'-*O*-methyladenylyl-(3'→5')-2'-*O*-methyluridylyl-(3'→5')-2'-*O*-methyl-3'-adenylate and *all-P-ambo*-thymidylyl-(5'→3')-thymidylyl-(5'→3')-2'-*O*-methyl-*P*-thiouridylyl-(5'→3')-2'-*O*-methyl-*P*-thiouridylyl-(5'→3')-2'-*O*-methyluridylyl-(5'→3')-2'-*O*-methyluridylyl-(5'→3')-2'-*O*-methylcytidylyl-(5'→3')-2'-deoxy-2'-fluoroguanylyl-(5'→3')-2'-*O*-methyluridylyl-(5'→3')-2'-deoxy-2'-fluorouridylyl-(5'→3')-2'-*O*-methylcytidylyl-(5'→3')-2'-deoxy-2'-fluorouridylyl-(5'→3')-2'-*O*-methyladenylyl-(5'→3')-2'-*O*-methyluridylyl-(5'→3')-2'-*O*-methyladenylyl-(5'→3')-2'-deoxy-2'-fluoroadenylyl-(5'→3')-2'-*O*-methyladenylyl-(5'→3')-2'-deoxy-2'-fluoroadenylyl-(5'→3')-2'-*O*-methyladenylyl-(5'→3')-2'-*O*-methyluridylyl-(5'→3')-2'-deoxy-2'-fluoroadenylyl-(5'→3')-2'-*O*-methyluridylyl-(5'→3')-2'-deoxy-2'-fluoro-*P*-thiouridylyl-(5'→3')-2'-deoxy-2'-fluoro-*P*-thioadenylyl-(5'→3')-2'-*O*-methyluridine

cemdisiran

duplex de l'hydrogéno-*tout-P-ambo*-2'-*O*-méthyl-*P*-thioadénylyl-(3'→5')-2'-*O*-méthyl-*P*-thioadénylyl-(3'→5')-2'-déoxy-2'-fluoroguanylyl-(3'→5')-2'-*O*-méthylcytidylyl-(3'→5')-2'-déoxy-2'-fluoroadénylyl-(3'→5')-2'-*O*-méthyladénylyl-(3'→5')-2'-déoxy-2'-fluoroguanylyl-(3'→5')-2'-*O*-méthyladénylyl-(3'→5')-2'-déoxy-2'-fluorouridylyl-(3'→5')-2'-déoxy-2'-fluoroadénylyl-(3'→5')-2'-déoxy-2'-fluorouridylyl-(3'→5')-2'-*O*-méthyluridylyl-(3'→5')-2'-déoxy-2'-fluorouridylyl-(3'→5')-2'-*O*-méthyluridylyl-(3'→5')-2'-*O*-méthyluridylyl-(3'→5')-2'-déoxy-2'-fluoroadénylyl-(3'→5')-2'-*O*-méthyluridylyl-(3'→5')-2'-déoxy-2'-fluoroadénylyl-(3'→5')-2'-*O*-méthyladénylyl-(3'→5')-2'-*O*-méthyluridylyl-(3'→5')-2'-*O*-méthyl-3'-adénylate de

	[(2*S*,4*R*)-1-{1-[(2-acétamido-2-déoxy-β-D-galactopyranosyl)oxy]-16,16-bis({3-[(3-{5-[(2-acétamido-2-déoxy-β-D-galactopyranosyl)oxy]pentanamido}propyl)amino]-3-oxopropoxy}méthyl)-5,11,18-trioxo-14-oxa-6,10,17-triazanonacosan-29-oyl}-4-hydroxypyrrolidin-2-yl]méthyle et de *tout-P-ambo*-thymidylyl-(5'→3')-thymidylyl-(5'→3')-2'-*O*-méthyl-*P*-thiouridylyl-(5'→3')-2'-*O*-méthyl-*P*-thiouridylyl-(5'→3')-2'-*O*-méthyluridylyl-(5'→3')-2'-*O*-méthyluridylyl-(5'→3')-2'-*O*-méthylcytidylyl-(5'→3')-2'-déoxy-2'-fluoroguanylyl-(5'→3')-2'-*O*-méthyluridylyl-(5'→3')-2'-déoxy-2'-fluorouridylyl-(5'→3')-2'-*O*-méthylcytidylyl-(5'→3')-2'-déoxy-2'-fluorouridylyl-(5'→3')-2'-*O*-méthyladénylyl-(5'→3')-2'-*O*-méthyluridylyl-(5'→3')-2'-*O*-méthyladénylyl-(5'→3')-2'-déoxy-2'-fluoroadénylyl-(5'→3')-2'-*O*-méthyladénylyl-(5'→3')-2'-déoxy-2'-fluoroadénylyl-(5'→3')-2'-*O*-méthyladénylyl-(5'→3')-2'-*O*-méthyluridylyl-(5'→3')-2'-déoxy-2'-fluoroadénylyl-(5'→3')-2'-*O*-méthyluridylyl-(5'→3')-2'-déoxy-2'-fluoro-*P*-thiouridylyl-(5'→3')-2'-déoxy-2'-fluoro-*P*-thioadénylyl-(5'→3')-2'-*O*-méthyluridine
cemdisirán	dúplex del hidrógeno-*todo-P-ambo*-2'-*O*-metil-*P*-tioadenilil-(3'→5')-2'-*O*-metil-*P*-tioadenilil-(3'→5')-2'-desoxi-2'-fluoroguanilil-(3'→5')-2'-*O*-metilcitidilil-(3'→5')-2'-desoxi-2'-fluoroadenilil-(3'→5')-2'-*O*-metiladenilil-(3'→5')-2'-desoxi-2'-fluoroguanilil-(3'→5')-2'-*O*-metiladenilil-(3'→5')-2'-desoxi-2'-fluorouridilil-(3'→5')-2'-desoxi-2'-fluoroadenilil-(3'→5')-2'-desoxi-2'-fluorouridilil-(3'→5')-2'-*O*-metiluridilil-(3'→5')-2'-desoxi-2'-fluorouridilil-(3'→5')-2'-*O*-metiluridilil-(3'→5')-2'-*O*-metiluridilil-(3'→5')-2'-desoxi-2'-fluoroadenilil-(3'→5')-2'-*O*-metiluridilil-(3'→5')-2'-desoxi-2'-fluoroadenilil-(3'→5')-2'-*O*-metiladenilil-(3'→5')-2'-*O*-metiluridilil-(3'→5')-2'-*O*-metil-3'-adenilato de [(2*S*,4*R*)-1-{1-[(2-acetamido-2-desoxi-β-D-galactopiranosil)oxi]-16,16-bis({3-[(3-{5-[(2-acetamido-2-desoxi-β-D-galactopiranosil)oxi]pentanamido}propil)amino]-3-oxopropoxi}metil)-5,11,18-trioxo-14-oxa-6,10,17-triazanonacosan-29-oil}-4-hidroxipirrolidín-2-yl]metil y de *todo-P-ambo*-timidilil-(5'→3')-timidilil-(5'→3')-2'-*O*-metil-*P*-tiouridilil-(5'→3')-2'-*O*-metil-*P*-tiouridilil-(5'→3')-2'-*O*-metiluridilil-(5'→3')-2'-*O*-metiluridilil-(5'→3')-2'-*O*-metilcitidilil-(5'→3')-2'-desoxi-2'-fluoroguanilil-(5'→3')-2'-*O*-metiluridilil-(5'→3')-2'-desoxi-2'-fluorouridilil-(5'→3')-2'-*O*-metilcitidilil-(5'→3')-2'-desoxi-2'-fluorouridilil-(5'→3')-2'-*O*-metiladenilil-(5'→3')-2'-*O*-metiluridilil-(5'→3')-2'-*O*-metiladenilil-(5'→3')-2'-desoxi-2'-fluoroadenilil-(5'→3')-2'-*O*-metiladenilil-(5'→3')-2'-desoxi-2'-fluoroadenilil-(5'→3')-2'-*O*-metiladenilil-(5'→3')-2'-*O*-metiluridilil-(5'→3')-2'-desoxi-2'-fluoroadenilil-(5'→3')-2'-*O*-metiluridilil-(5'→3')-2'-desoxi-2'-fluoro-*P*-tiouridilil-(5'→3')-2'-desoxi-2'-fluoro-*P*-tioadenilil-(5'→3')-2'-*O*-metiluridina



clivatuzumabum tetraxetanum #

clivatuzumab tetraxetan

immunoglobulin G1-kappa, anti-[*Homo sapiens* MUC1 (mucin 1, polymorphic epithelial mucin, PEM, CD227)], humanized monoclonal antibody, tetraxetan conjugate; gamma1 heavy chain (1-449) [humanized VH (*Homo sapiens* IGHV1-2*02 (79.60%) -(IGHD)-IGHJ4*01) [8.8.12] (1-119) - *Homo sapiens* IGHG1*03, G1m3 (CH1 (120-217), (hinge 218-232), CH2 (233-342), CH3 (343-447), CH-S (448-449)) (120-449)], (222-215')-disulfide with kappa light chain (1'-215') [humanized V-KAPPA (*Homo sapiens* IGKV1-13*02 (78.90%) -IGKJ2*01) [7.3.9] (1'-108') -*Homo sapiens* IGKC*01 (109'-215')]; (228-228":231-231")-bisdisulfide dimer; tetraxetan (DOTA) conjugate (on an average of 4 to 7 lysyl, linked to the chelator by their N^6)

clivatuzumab tétraxétan

immunoglobuline G1-kappa, anti-[*Homo sapiens* MUC1 (mucine 1, mucine épithéliale polymorphique, PEM, CD227)], anticorps monoclonal humanisé, conjugué au tétraxétan;
chaîne lourde gamma1 (1-449) [VH humanisé (*Homo sapiens* IGHV1-2*02 (79.60%) -(IGHD)-IGHJ4*01) [8.8.12] (1-119) - *Homo sapiens* IGHG1*03, G1m3 (CH1 (120-217), (hinge 218-232), CH2 (233-342), CH3 (343-447), CH-S (448-449)) (120-449)], (222-215')-disulfure avec la chaîne légère kappa (1'-215') [V-KAPPA humanisé (*Homo sapiens* IGKV1-13*02 (78.90%) -IGKJ2*01) [7.3.9] (1'-108') -*Homo sapiens* IGKC*01 (109'-215')]; dimère (228-228":231-231")-bisdisulfure; conjugué au tétraxétan (DOTA) (avec une moyenne de 4 à 7 lysyl liés au chélateur par leur N^6)

clivatuzumab tetraxetán

inmunoglobulina G1-kappa, anti-[*Homo sapiens* MUC1 (mucina 1, mucina epitelial polimórfica, PEM, CD227)], anticuerpo monoclonal humanizado, conjugado con tetraxetán;

cadena pesada gamma1 (1-449) [VH humanizado (*Homo sapiens* IGHV1-2*02 (79.60%) -(IGHD)-IGHJ4*01) [8.8.12] (1-119) - *Homo sapiens* IGHG1*03, G1m3 (CH1 (120-217), (bisagra 218-232), CH2 (233-342), CH3 (343-447), CH-S (448-449)) (120-449)], (222-215')-disulfuro con la cadena ligera kappa (1'-215') [V-KAPPA humanizado (*Homo sapiens* IGKV1-13*02 (78.90%) -IGKJ2*01) [7.3.9] (1'-108') -*Homo sapiens* IGKC*01 (109'-215')]; dímero (228-228":231-231")-bisdisulfuro; conjugado con tetraxetán (DOTA) (con una media de 4 a 7 restos lisil unidos al quelante por sus respectivos N^6)

Heavy chain / Chaîne lourde / Cadena pesada

```
QVQLQQSGAE VKKPGASVKV SCEASGYTFP SYVLHWVKQA PGQGLEWIGY  50
INPYNDGTQY NEKFKGKATL TRDTSINTAY MELSRLRSDD TAVYYCARGF 100
GGSYGFAYWG QGTLVTVSSA STKGPSVFPL APSSKSTSGG TAALGCLVKD 150
YFPEPVTVSW NSGALTSGVH TFPAVLQSSG LYSLSSVVTV PSSSLGTQTY 200
ICNVNHKPSN TKVDKRVEPK SCDKTHTCPP CPAPELLGGP SVFLFPPKPK 250
DTLMISRTPE VTCVVVDVSH EDPEVKFNWY VDGVEVHNAK TKPREEQYNS 300
TYRVVSVLTV LHQDWLNGKE YKCKVSNKAL PAPIEKTISK AKGQPREPQV 350
YTLPPSREEM TKNQVSLTCL VKGFYPSDIA VEWESNGQPE NNYKTTPPVL 400
DSDGSFFLYS KLTVDKSRWQ QGNVFSCSVM HEALHNHYTQ KSLSLSPGK  449
```

Light chain / Chaîne légère / Cadena ligera

```
DIQLTQSPSS LSASVGDRVT MTCSASSSVS SSYLYWYQQK PGKAPKLWIY  50
STSNLASGVP ARFSGSGSGT DFTLTISSLQ PEDSASYFCH QWNRYPYTFG 100
GGTRLEIKRT VAAPSVFIFP PSDEQLKSGT ASVVCLLNNF YPREAKVQWK 150
VDNALQSGNS QESVTEQDSK DSTYSLSSTL TLSKADYEKH KVYACEVTHQ 200
GLSSPVTKSF NRGEC                                       215
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H (C23-C104)	22-96	146-202	263-323	369-427
	22"-96"	146"-202"	263"-323"	369"-427"
Intra-L (C23-C104)	23'-89'	135'-195'		
	23'"-89'"	135'"-195'"		
Inter-H-L (h 5-CL 126)	222-215'	222"-215'"		
Inter-H-H (h 11, h 14)	228-228"	231-231"		

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
H CH2 N84.4:
299, 299"
Fucosylated complex bi-antennary Sp2/0-type glycans / glycanes de type Sp2/0 bi-antennaires complexes fucosylés / glicanos de tipo Sp2/0 biantenarios complejos fucosilados

Modified residues / Résidus modifies / Restos modificados

4 to 7 lysyl (K)
4 à 7 lysyl (K)
4 a 7 lisil (K)

N^6-(tetraxetan)-L-lysyl

crotedumabum #
crotedumab

immunoglobulin G4-kappa, anti-[*Homo sapiens* GCGR (glucagon receptor)], *Homo sapiens* monoclonal antibody; gamma4 heavy chain (1-455) [*Homo sapiens* VH (IGHV3-7*01 (92.90%) -(IGHD) -IGHJ6*01) [8.8.21] (1-128) - IGHG4*01 (CH1 (129-226), hinge S10>P (236) (227-238), CH2 (239-348), CH3 (349-453), CHS (454-455)) (129-455)], (142-214')-disulfide with kappa light chain (1'-214') [*Homo sapiens* (V-KAPPA (IGKV1-17*01 (95.80%) - IGKJ3*01) [6.3.9] (1'-107') -IGKC*01, Km3 (108'-214')]; dimer (234-234":237-237")-bisdisulfide

crotédumab	immunoglobuline G4-kappa, anti-[*Homo sapiens* GCGR (récepteur du glucagon)], *Homo sapiens* anticorps monoclonal; chaîne lourde gamma4 (1-455) [*Homo sapiens* VH (IGHV3-7*01 (92.90%) -(IGHD) -IGHJ6*01) [8.8.21] (1-128) -IGHG4*01 (CH1 (129-226), charnière S10>P (236) (227-238), CH2 (239-348), CH3 (349-453), CHS (454-455)) (129-455)], (142-214')-disulfure avec la chaîne légère kappa (1'-214') [*Homo sapiens* (V-KAPPA (IGKV1-17*01 (95.80%) -IGKJ3*01) [6.3.9] (1'-107') -IGKC*01, Km3 (108'-214')]; dimère (234-234":237-237")-bisdisulfure
crotedumab	inmunoglobulina G4-kappa, anti-[*Homo sapiens* GCGR (receptor de glucagón)], *Homo sapiens* anticuerpo monoclonal; cadena pesada gamma4 (1-455) [*Homo sapiens* VH (IGHV3-7*01 (92.90%) -(IGHD) -IGHJ6*01) [8.8.21] (1-128) -IGHG4*01 (CH1 (129-226), bisagra S10>P (236) (227-238), CH2 (239-348), CH3 (349-453), CHS (454-455)) (129-455)], (142-214')-disulfuro con la cadena ligera kappa (1'-214') [*Homo sapiens* (V-KAPPA (IGKV1-17*01 (95.80%) -IGKJ3*01) [6.3.9] (1'-107') -IGKC*01, Km3 (108'-214')]; dímero (234-234":237-237")-bisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada

```
EVQLVESGGG LVQPGGSLRL SCAASGFTFS NYLMNWVRQA PGKGLEWLAN  50
IQEDGIEKYY VDSVKGRFTI SRDNAKNSLY LQMNSLRAED TAVYYCAREP 100
SHYDILTGYD YYYGMDVWGQ GTTVTVSSAS TKGPSVFPLA PCSRSTSEST 150
AALGCLVKDY FPEPVTVSWN SGALTSGVHT FPAVLQSSGL YSLSSVVTVP 200
SSSLGTKTYT CNVDHKPSNT KVDKRVESKY GPPCPPCPAP EFLGGPSVFL 250
FPPKPKDTLM ISRTPEVTCV VVDVSQEDPE VQFNWYVDGV EVHNAKTKPR 300
EEQFNSTYRV VSVLTVLHQD WLNGKEYKCK VSNKGLPSSI EKTISKAKGQ 350
PREPQVYTLP PSQEEMTKNQ VSLTCLVKGF YPSDIAVEWE SNGQPENNYK 400
TTPPVLDSDG SFFLYSRLTV DKSRWQEGNV FSCSVMHEAL HNHYTQKSLS 450
LSLGK                                                   455
```

Light chain / Chaîne légère / Cadena ligera

```
DIQMTQSPSS LSASVGDRVT ITCRASQGIR NDLGWYQQKP GKAPKRLIYA  50
ASSLQSGVPS RFSGSGSGTE FILTVSSLQP EDFATYYCLQ YNSNPFTFGP 100
GTKVDIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV 150
DNALQSGNSQ ESVTEQDSKD STYSLSSTLT LSKADYEKHK VYACEVTHQG 200
LSSPVTKSFN RGEC                                         214
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H (C23-C104)	22-96	155-211	269-329	375-433
	22"-96"	155"-211"	269"-329"	375"-433"
Intra-L (C23-C104)	23'-88'	134'-194'		
	23'"-88"'	134'"-194"'		
Inter-H-L (CH1 10-CL 126)	142-214'	142"-214"'		
Inter-H-H (h 8, h 11)	234-234"	237-237"		

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
H CH2 N84.4:
305, 305"
Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires complexes fucosylés / glicanos de tipo CHO biantenarios complejos fucosilados

dapansutrilum

dapansutrile	3-(methanesulfonyl)propanenitrile
dapansutrile	3-(méthanesulfonyl)propanenitrile
dapansutrilo	3-(metanosulfonil)propanonitrilo

$C_4H_7NO_2S$



deudextromethorphanum

deudextromethorphan — 3-[($^2H_3$)methoxy]-17-[($^2H_3$)methyl]-*ent*-morphinan

deudextromethorphane — 3-[($^2H_3$)méthoxy]-17-[($^2H_3$)méthyl]-*ent*-morphinane

deudextrometorfano — 3-[($^2H_3$)metoxi]-17-[($^2H_3$)metil]-*ent*-morfinano

$C_{18}H_{19}{}^2H_6NO$



dociparstatum natricum

dociparstat sodium — sodium salt of 2,3-di-*O*-desulfoheparin, the starting material is an unfractionated heparin from porcine intestinal mucosa, the relative average molecular mass is approximately 12,000 daltons with about 40% ranging between 8,000 and 16,000 daltons, the degree of sulfation is about 2.0 per disaccharidic unit

dociparstat sodique — sel de sodium de la 2,3-di-*O*-désulfohéparine, obtenu à partir d'héparine non-fractionnée de la muqueuse intestinale porcine; sa masse moléculaire relative dont environ 40% est comprise entre 8.000 et 16.000 daltons, est voisine de 12.000 daltons; son degré de sulfatation est d'environ 2,0 par unité disaccharide

dociparstat sodico — sal de sodio de la 2,3-di-*O*-desulfoheparina, obtenida a partir de la heparina no fraccionad de la mucosa intestinal porcina; la masa molecular relativa media es aproximadamente de 12000 daltons con el 40% comprendido entre 8000 y 16000 daltons; el grado de sulfatación es de 2,0 por unidad de disacárido.



dolcanatidum

dolcanatide

1D,16D-[3-L-glutamic acid]human uroguanylin: S^4,S^{12}:S^7,S^{15}-dicyclo(D-asparaginyl-L-α-aspartyl-L-α-glutamyl-L-cysteinyl-L-α-glut-amyl-L-leucyl-L-cysteinyl-L-valyl-L-asparaginyl-L-valyl-L-alanyl-L-cysteinyl-L-threonylglycyl-L-cysteinyl-D-leucine)

dolcanatide

1D,16D-[3-acide L-glutamique]uroguanyline humaine: S^4,S^{12}:S^7,S^{15}-dicyclo(D-asparaginyl-L-α-aspartyl -L-α-glutamyl-L-cystéinyl-L-α-glut-amyl-L-leucyl-L-cystéinyl-L-valyl-L-asparaginyl-L-valyl-L-alanyl-L-cystéinyl-L-thréonylglycyl-L-cystéinyl-D-leucine)

dolcanatida

1D,16D-[3-L-ácido glutámico]uroguanilina humana: S^4,S^{12}:S^7,S^{15}-diciclo(D-asparaginil-L-α-aspartil-L-α-glutamil-L-cisteinil-L-α-glut-amil-L-leucil-L-cisteinil-L-valil-L-asparaginil-L-valil-L-alanil-L-cisteinil-L-treonilglicil-L-cisteinil-D-leucina)

$C_{65}H_{104}N_{18}O_{26}S_4$



domagrozumabum #

domagrozumab

immunoglobulin G1-kappa, anti-[*Homo sapiens* MSTN (growth differentiation factor 8, GDF8, myostatin,GDF-8)], humanized monoclonal antibody;
gamma1 heavy chain (1-446) [humanized VH (*Homo sapiens* IGHV3-23*03 (94.90%) -(IGHD) -IGHJ4*01) [8.8.9] (1-116) -IGHG1*01 (CH1 (117-214), hinge (215-229), CH2 L1.3>A (233), L1.2>A (234), G1>A (236) (230-339), CH3 D12>E (355), L14>M (357) (340-444), CHS (445-446)) (117-446)], (219-214')-disulfide with kappa light chain (1'-214') [humanized V-KAPPA (*Homo sapiens* IGKV1-39*01 (86.30%) -IGKJ1*01) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01, Km3 (108'-214')]; dimer (225-225":228-228")-bisdisulfide

domagrozumab

immunoglobuline G1-kappa, anti-[*Homo sapiens* MSTN (facteur de croissance et de différenciation 8, GDF8, myostatine, GDF-8)], anticorps monoclonal humanisé;
chaîne lourde gamma1 (1-446) [VH humanisé (*Homo sapiens* IGHV3-23*03 (94.90%) -(IGHD) -IGHJ4*01) [8.8.9] (1-116) -IGHG1*01, G1m17,1 (CH1 (117-214), charnière (215-229), CH2 L1.3>A (233), L1.2>A (234), G1>A (236) (230-339), CH3 D12>E (355), L14>M (357) (340-444), CHS (445-446)) (117-446)], (219-214')- disulfure avec la chaîne légère (1'-214') [V-KAPPA humanisé (*Homo sapiens* IGKV1-39*01 (86.30%) -IGKJ1*01) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01, Km3 (108'-214')]; dimère (225-225":228-228")-bisdisulfure

domagrozumab

inmunoglobulina G1-kappa, anti-[*Homo sapiens* MSTN (factor de crecimiento y de diferenciación 8, GDF8, miostatina, GDF-8)], anticuerpo monoclonal humanizado; cadena pesada gamma1 (1-446) [VH humanizado (*Homo sapiens* IGHV3-23*03 (94.90%) -(IGHD) -IGHJ4*01) [8.8.9] (1-116) -IGHG1*01 (CH1 (117-214), bisagra (215-229), CH2 L1.3>A (233), L1.2>A (234), G1>A (236) (230-339), CH3 D12>E (355), L14>M (357) (340-444), CHS (445-446)) (117-446)], (219-214')-disulfuro con la cadena ligera kappa (1'-214') [V-KAPPA humanizado (*Homo sapiens* IGKV1-39*01 (86.30%) -IGKJ1*01) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01, Km3 (108'-214')]; dímero (225-225":228-228")-bisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada

```
EVQLLESGGG LVQPGGSLRL SCAASGFTFS SYAMSWVRQA PGKGLEWVST  50
ISSGGSYTSY PDSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKQD 100
YAMNYWGQGT LVTVSSASTK GPSVFPLAPS SKSTSGGTAA LGCLVKDYFP 150
EPVTVSWNSG ALTSGVHTFP AVLQSSGLYS LSSVVTVPSS SLGTQTYICN 200
VNHKPSNTKV DKKVEPKSCD KTHTCPPCPA PEAAGAPSVF LFPPKPKDTL 250
MISRTPEVTC VVVDVSHEDP EVKFNWYVDG VEVHNAKTKP REEQYNSTYR 300
VVSVLTVLHQ DWLNGKEYKC KVSNKALPAP IEKTISKAKG QPREPQVYTL 350
PPSREEMTKN QVSLTCLVKG FYPSDIAVEW ESNGQPENNY KTTPPVLDSD 400
GSFFLYSKLT VDKSRWQQGN VFSCSVMHEA LHNHYTQKSL SLSPGK     446
```

Light chain / Chaîne légère / Cadena ligera

```
DIQMTQSPSS LSASVGDRVT ITCKASQDVS TAVAWYQQKP GKAPKLLIYS  50
ASYRYTGVPS RFSGSGSGTD FTLTISSLQP EDFATYYCQQ HYSTPWTFGG 100
GTKVEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV 150
DNALQSGNSQ ESVTEQDSKD STYSLSSTLT LSKADYEKHK VYACEVTHQG 200
LSSPVTKSFN RGEC                                        214
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H (C23-C104)	22-96	143-199	260-320	366-424
	22"-96"	143"-199"	260"-320"	366"-424"
Intra-L (C23-C104)	23'-88'	134'-194'		
	23'"-88'"	134'"-194'"		
Inter-H-L (h 5-CL 126)	219-214'	219"-214'"		
Inter-H-H (h 11, h 14)	225-225"	228-228"		

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
H CH2 N84.4:
296, 296"
Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires complexes fucosylés / glicanos de tipo CHO biantenarios complejos fucosilados
Other post-translational modifications / Autres modifications post-traductionnelles / Otras modificaciones post-traduccionales
C-terminal trimming of the *C*-terminal lysine (K)
H CHS K2:
446, 446"

edasalonexentum

edasalonexent

N-{2-[(4*Z*,7*Z*,10*Z*,13*Z*,16*Z*,19*Z*)-docosa-4,7,10,13,16,19-hexaenamido]ethyl}-2-hydroxybenzamide

édasalonexent

N-{2-[(4*Z*,7*Z*,10*Z*,13*Z*,16*Z*,19*Z*)-docosa-4,7,10,13,16,19-hexaénamido]éthyl}-2-hydroxybenzamide

edasalonexento

N-{2-[(4*Z*,7*Z*,10*Z*,13*Z*,16*Z*,19*Z*)-docosa-4,7,10,13,16,19-hexaenamido]etil}-2-hidroxibenzamida

$C_{28}H_{39}N_3O_2$



edonerpicum

edonerpic 1-{3-[2-(1-benzothiophen-5-yl)ethoxy]propyl}azetidin-3-ol

édonerpic 1-{3-[2-(1-benzothiophén-5-yl)éthoxy]propyl}azétidin-3-ol

edonerpico 1-{3-[2-(1-benzotiofen-5-il)etoxi]propil}azetidin-3-ol

$C_{16}H_{21}NO_2S$



enoblituzumabum #

enoblituzumab immunoglobulin G1-kappa, anti-[*Homo sapiens* CD276 (B7H3, B7-H3, B7RP-2)], humanized monoclonal antibody; gamma1 heavy chain (1-452) [humanized VH (*Homo sapiens* IGHV3-48*02 (91.80%) -(IGHD) -IGHJ6*01) [8.8.15] (1-122) -*Homo sapiens* IGHG1*03 (CH1 (123-220), hinge (221-235), CH2 L1.2>V (240), F7>L (248), R83>P (297), Y85.2>L (305) (236-345), CH3 P83>L (401) (346-450), CHS (451-452)) (123-452)], (225-214')-disulfide with kappa light chain (1'-214') [humanized V-KAPPA (*Homo sapiens* IGKV1D-13*01 (85.10%) -IGKJ2*01) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01, Km3 (108'-214')]; dimer (231-231":234-234")-bisdisulfide

énoblituzumab immunoglobuline G1-kappa, anti-[*Homo sapiens* CD276 (B7H3, B7-H3, B7RP-2)], anticorps monoclonal humanisé; chaîne lourde gamma1 (1-452) [VH humanisé (*Homo sapiens* IGHV3-48*02 (91.80%) -(IGHD) -IGHJ6*01) [8.8.15] (1-122) -*Homo sapiens* IGHG1*03 (CH1 (123-220), charnière (221-235), CH2 L1.2>V (240), F7>L (248), R83>P (297), Y85.2>L (305) (236-345), CH3 P83>L (401) (346-450), CHS (451-452)) (123-452)], (225-214')-disulfure avec la chaîne légère kappa (1'-214') [V-KAPPA humanisé (*Homo sapiens* IGKV1D-13*01 (85.10%) -IGKJ2*01) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01, Km3 (108'-214')]; dimère (231-231":234-234")-bisdisulfure

enoblituzumab inmunoglobulina G1-kappa, anti-[*Homo sapiens* CD276 (B7H3, B7-H3, B7RP-2)], anticuerpo monoclonal humanizado;
cadena pesada gamma1 (1-452) [VH humanizado (*Homo sapiens* IGHV3-48*02 (91.80%) -(IGHD) -IGHJ6*01) [8.8.15] (1-122) -*Homo sapiens* IGHG1*03 (CH1 (123-220), bisagra (221-235), CH2 L1.2>V (240), F7>L (248), R83>P (297), Y85.2>L (305) (236-345), CH3 P83>L (401) (346-450), CHS (451-452)) (123-452)], (225-214')-disulfuro con la cadena ligera kappa (1'-214') [V-KAPPA humanizado (*Homo sapiens* IGKV1D-13*01 (85.10%) -IGKJ2*01) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01, Km3 (108'-214')]; dímero (231-231":234-234")-bisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada

```
QVELVESGGG LVQPGGSLRL SCAASGFTFT SYWMSWVRQA PGKGLELVSS  50
ITSYGSFTYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCARNM 100
YTHFDSWGQG TLVTVSSAST KGPSVFPLAP SSKSTSGGTA ALGCLVKDYF 150
PEPVTVSWNS GALTSGVHTF PAVLQSSGLY SLSSVVTVPS SSLGTQTYIC 200
NVNHKPSNTK VDKKVEPKSC DKTHTCPPCP APELLGGPSV FLFPPKPKDT 250
LMISRTPEVT CVVVDVSHED PEVKFNWYVD GVEVHNAKTK PREEQYNSTY 300
RVVSVLTVLH QDWLNGKEYK CKVSNKALPA PIEKTISKAK GQPREPQVYT 350
LPPSRDELTK NQVSLTCLVK GFYPSDIAVE WESNGQPENN YKTTPPVLDS 400
DGSFFLYSKL TVDKSRWQQG NVFSCSVMHE ALHNHYTQKS LSLSPGK    447
```

Light chain / Chaîne légère / Cadena ligera

```
DIVLTQPPSV SGAPGQRVTI SCSGSSSNIG SNSVSWYQQL PGTAPKLLIY  50
DNSKRPSGVP DRFSGSKSGT SASLAITGLQ SEDEADYYCQ SRDTYGYYWV 100
FGGGTKLTVL GQPKAAPSVT LFPPSSEELQ ANKATLVCLI SDFYPGAVTV 150
AWKGDSSPVK AGVETTTPSK QSNNKYAASS YLSLTPEQWK SHRSYSCQVT 200
HEGSTVEKTV APTECS                                      216
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H (C23-C104)	22-96	144-200	261-321	367-425
	22"-96"	144"-200"	261"-321"	367"-425"
Intra-L (C23-C104)	22'-89'	138'-197'		
	22'"-89'"	138'"-197'"		
Inter-H-L (h 5-CL 126)	220-215'	220"-215'"		
Inter-H-H (h 11, h 14)	226-226'	229-229"		

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
H CH2 N84.4:
297, 297"
Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires complexes fucosylés / glicanos de tipo CHO biantenarios complejos fucosilados

epacadostatum

epacadostat — (*Z*)-*N*-(3-bromo-4-fluorophenyl)-*N′*-hydroxy-4-{[2-(sulfamoylamino)ethyl]amino}-1,2,5-oxadiazole-3-carboximidamide

épacadostat — (*Z*)-*N*-(3-bromo-4-fluorophényl)-*N′*-hydroxy-4-{[2-(sulfamoylamino)éthyl]amino}-1,2,5-oxadiazole-3-carboximidamide

epacadostat — (*Z*)-*N*-(3-bromo-4-fluorofenil)-*N′*-hidroxi-4-{[2-(sulfamoilamino)etil]amino}-1,2,5-oxadiazol-3-carboximidamida

$C_{11}H_{13}BrFN_7O_4S$



esaxerenonum

esaxerenone — (5*P*)-1-(2-hydroxyethyl)-*N*-[4-(methanesulfonyl)phenyl]-4-methyl-5-[2-(trifluoromethyl)phenyl]-1*H*-pyrrole-3-carboxamide

ésaxérénone — (5*P*)-1-(2-hydroxyéthyl)-*N*-[4-(méthanesulfonyl)phényl]-4-méthyl-5-[2-(trifluorométhyl)phényl]-1*H*-pyrrole-3-carboxamide

esaxerenona — (5*P*)-1-(2-hidroxietil)-*N*-[4-(metanosulfonil)fenil]-4-metil-5-[2-(trifluorometil)fenil]-1*H*-pirrol-3-carboxamida

$C_{22}H_{21}F_3N_2O_4S$



fexapotidum

fexapotide — L-isoleucyl-L-α-aspartyl-L-glutaminyl-L-glutaminyl-L-valyl-L-leucyl-L-seryl-L-arginyl-L-isoleucyl-L-lysyl-L-leucyl-L-α-glutamyl-L-isoleucyl-L-lysyl-L-arginyl-L-cysteinyl-L-leucine

fexapotide — L-isoleucyl-L-α-aspartyl-L-glutaminyl-L-glutaminyl-L-valyl-L-leucyl-L-séryl-L-arginyl-L-isoleucyl-L-lysyl-L-leucyl-L-α-glutamyl-L-isoleucyl-L-lysyl-L-arginyl-L-cystéinyl-L-leucine

fexapotida — L-isoleucil-L-α-aspartil-L-glutaminil-L-glutaminil-L-valil-L-leucil-L-seril-L-arginil-L-isoleucil-L-lisil-L-leucil-L-α-glutamil-L-isoleucil-L-lisil-L-arginil-L-cisteinil-L-leucina

$C_{90}H_{163}N_{27}O_{25}S$

H-Ile-Asp-Gln-Gln-Val-Leu-Ser-Arg-Ile-
Lys-Leu-Glu-Ile-Lys-Arg-Cys-Leu-OH
10 17

flortaucipirum (^{18}F)

flortaucipir (^{18}F) — 7-[6-(^{18}F)fluoropyridin-3-yl]-5*H*-pyrido[4,3-*b*]indole

flortaucipir (^{18}F) — 7-[6-(^{18}F)fluoropyridin-3-yl]-5*H*-pyrido[4,3-*b*]indole

flortaucipir (^{18}F) — 7-[6-(^{18}F)fluoropiridin-3-il]-5*H*-pirido[4,3-*b*]indol

$C_{16}H_{10}{}^{18}FN_3$



fonadelparum

fonadelpar — {[5-methyl-3-(2-{4-(propan-2-yl)-2-[4-(trifluoromethyl)phenyl]-1,3-thiazol-5-yl}ethyl)-1,2-benzoxazol-6-yl]oxy}acetic acid

fonadelpar	acide {[5-méthyl-3-(2-{4-(propan-2-yl)-2-[4-(trifluorométhyl)phényl]-1,3-thiazol-5-yl}éthyl)-1,2-benzoxazol-6-yl]oxy}acétique
fonadelpar	ácido {[5-metil-3-(2-{4-(propan-2-il)-2-[4-(trifluorometil)fenil]-1,3-tiazol-5-il}etil)-1,2-benzoxazol-6-il]oxi}acético

$C_{25}H_{23}F_3N_2O_4S$



galcanezumabum #

galcanezumab	immunoglobulin G4-kappa, anti-[*Homo sapiens* CALCA (calcitonin-related polypeptide alpha, calcitonin 1, CALC1) and *Homo sapiens* CALCB (calcitonin-related polypeptide beta, calcitonin 2, CALC2)], humanized monoclonal antibody; gamma4 heavy chain (1-445) [humanized VH (*Homo sapiens* IGHV1-69*01 (82.70%) -(IGHD) -IGHJ6*01) [8.8.12] (1-119)), IGHG4*01 (CH1 (120-217), hinge S10>P (227)(218-229), CH2 F1.3>A (233), L1.2>A (234) (230-339), CH3 (340-444), CHS K2>del (445)) (120-445)], (133-214')-disulfide with kappa light chain (1'-214') [humanized V-KAPPA (*Homo sapiens* IGKV1-39*01 (87.40%) -IGKJ4*01) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01, Km3 (108'-214')]; dimer (225-225":228-228")-bisdisulfide
galcanézumab	immunoglobuline G4-kappa, anti-[*Homo sapiens* CALCA (polypeptide alpha apparenté à la calcitonine, calcitonine 1, CALC1) et *Homo sapiens* CALCB (polypeptide beta apparenté à la calcitonine, calcitonine 2, CALC2)], anticorps monoclonal humanisé; chaîne lourde gamma4 (1-445) [VH humanisé (*Homo sapiens* IGHV1-69*01 (82.70%) -(IGHD) -IGHJ6*01) [8.8.12] (1-119)), IGHG4*01 (CH1 (120-217), charnière S10>P (227)(218-229), CH2 F1.3>A (233), L1.2>A (234) (230-339), CH3 (340-444), CHS K2>del (445)) (120-445)], (133-214')-disulfure avec la chaîne légère kappa (1'-214') [V-KAPPA humanisé (*Homo sapiens* IGKV1-39*01 (87.40%) -IGKJ4*01) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01, Km3 (108'-214')]; dimère (225-225":228-228") bisdisulfure

galcanezumab

inmunoglobulina G4-kappa, anti-[*Homo sapiens* CALCA (polipéptido alfa relacionado con la calcitonina, calcitonina 1, CALC1) y *Homo sapiens* CALCB (polipéptido beta relacionado con la calcitonina, calcitonina 2, CALC2)], anticuerpo monoclonal humanizado;
cadena pesada gamma4 (1-445) [VH humanizado (*Homo sapiens* IGHV1-69*01 (82.70%) -(IGHD) -IGHJ6*01) [8.8.12] (1-119)), IGHG4*01 (CH1 (120-217), bisagra S10>P (227)(218-229), CH2 F1.3>A (233), L1.2>A (234) (230-339), CH3 (340-444), CHS K2>del (445)) (120-445)], (133-214')-disulfuro con la cadena ligera kappa (1'-214') [V-KAPPA humanizado (*Homo sapiens* IGKV1-39*01 (87.40%) -IGKJ4*01) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01, Km3 (108'-214')]; dímero (225-225":228-228")-bisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada

```
QVQLVQSGAE VKKPGSSVKV SCKASGYTFG NYWMQWVRQA PGQGLEWMGA  50
IYEGTGKTVY IQKFADRVTI TADKSTSTAY MELSSLRSED TAVYYCARLS 100
DYVSGFGYWG QGTTVTVSSA STKGPSVFPL APCSRSTSES TAALGCLVKD 150
YFPEPVTVSW NSGALTSGVH TFPAVLQSSG LYSLSSVVTV PSSSLGTKTY 200
TCNVDHKPSN TKVDKRVESK YGPPCPPCPA PEAAGGPSVF LFPPKPKDTL 250
MISRTPEVTC VVVDVSQEDP EVQFNWYVDG VEVHNAKTKP REEQFNSTYR 300
VVSVLTVLHQ DWLNGKEYKC KVSNKGLPSS IEKTISKAKG QPREPQVYTL 350
PPSQEEMTKN QVSLTCLVKG FYPSDIAVEW ESNGQPENNY KTTPPVLDSD 400
GSFFLYSRLT VDKSRWQEGN VFSCSVMHEA LHNHYTQKSL SLSLG      445
```

Light chain / Chaîne légère / Cadena ligera

```
DIQMTQSPSS LSASVGDRVT ITCRASKDIS KYLNWYQQKP GKAPKLLIYY  50
TSGYHSGVPS RFSGSGSGTD FTLTISSLQP EDFATYYCQQ GDALPPTFGG 100
GTKVEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV 150
DNALQSGNSQ ESVTEQDSKD STYSLSSTLT LSKADYEKHK VYACEVTHQG 200
LSSPVTKSFN RGEC                                        214
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H (C23-C104)	22-96	146-202	260-320	366-424
	22"-96"	146"-202"	260"-320"	366"-424"
Intra-L (C23-C104)	23'-88'	134'-194'		
	23'"-88'"	134'"-194'"		
Inter-H-L (CH1 10-CL 126)	133-214'	133"-214'"		
Inter-H-H (h 8, h 11)	225-225"	228-228"		

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
H CH2 N84.4:
296, 296"
Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires complexes fucosylés / glicanos de tipo CHO biantenarios complejos fucosilados

galidesivirum

galidesivir

(2*S*,3*S*,4*R*,5*R*)-2-(4-amino-5*H*-pyrrolo[3,2-*d*]pyrimidin-7-yl)-5-(hydroxymethyl)pyrrolidine-3,4-diol

galidésivir

(2*S*,3*S*,4*R*,5*R*)-2-(4-amino-5*H*-pyrrolo[3,2-*d*]pyrimidin-7-yl)-5-(hydroxyméthyl)pyrrolidine-3,4-diol

galidesivir

(2*S*,3*S*,4*R*,5*R*)-2-(4-amino-5*H*-pirrolo[3,2-*d*]pirimidin-7-il)-5-(hidroximetil)pirrolidina-3,4-diol

$C_{11}H_{15}N_5O_3$



givosiranum

givosiran	duplex of [(2*S*,4*R*)-1-{1-[(2-acetamido-2-deoxy-β-D-galactopyranosyl)oxy]-16,16-bis({3-[(3-{5-[(2-acetamido-2-deoxy-β-D-galactopyranosyl)oxy]pentanamido}propyl)amino]-3-oxopropoxy}methyl)-5,11,18-trioxo-14-oxa-6,10,17-triazanonacosan-29-oyl}-4-hydroxypyrrolidin-2-yl]methyl hydrogen *all-P-ambo*-2'-*O*-methyl-*P*-thiocytidylyl-(3'→5')-2'-*O*-methyl-*P*-thioadenylyl-(3'→5')-2'-*O*-methylguanylyl-(3'→5')-2'-*O*-methyladenylyl-(3'→5')-2'-*O*-methyladenylyl-(3'→5')-2'-*O*-methyladenylyl-(3'→5')-2'-deoxy-2'-fluoroguanylyl-(3'→5')-2'-*O*-methyladenylyl-(3'→5')-2'-deoxy-2'-fluoroguanylyl-(3'→5')-2'-*O*-methyluridylyl-(3'→5')-2'-deoxy-2'-fluoroguanylyl-(3'→5')-2'-*O*-methyluridylyl-(3'→5')-2'-deoxy-2'-fluorocytidylyl-(3'→5')-2'-*O*-methyluridylyl-(3'→5')-2'-deoxy-2'-fluorocytidylyl-(3'→5')-2'-*O*-methyladenylyl-(3'→5')-2'-*O*-methyluridylyl-(3'→5')-2'-*O*-methylcytidylyl-(3'→5')-2'-*O*-methyluridylyl-(3'→5')-2'-*O*-methyluridylyl-(3'→5')-2'-*O*-methyl-3'-adenylate and *all-P-ambo*-2'-*O*-methyl-*P*-thiouridylyl-(5'→3')-2'-*O*-methyl-*P*-thioguanylyl-(5'→3')-2'-*O*-methylguanylyl-(5'→3')-2'-deoxy-2'-fluorouridylyl-(5'→3')-2'-*O*-methylcytidylyl-(5'→3')-2'-deoxy-2'-fluorouridylyl-(5'→3')-2'-*O*-methyluridylyl-(5'→3')-2'-deoxy-2'-fluorouridylyl-(5'→3')-2'-*O*-methylcytidylyl-(5'→3')-2'-deoxy-2'-fluorouridylyl-(5'→3')-2'-*O*-methylcytidylyl-(5'→3')-2'-deoxy-2'-fluoroadenylyl-(5'→3')-2'-*O*-methylcytidylyl-(5'→3')-2'-deoxy-2'-fluoroadenylyl-(5'→3')-2'-*O*-methylguanylyl-(5'→3')-2'-deoxy-2'-fluoroadenylyl-(5'→3')-2'-*O*-methylguanylyl-(5'→3')-2'-deoxy-2'-fluorouridylyl-(5'→3')-2'-*O*-methyladenylyl-(5'→3')-2'-deoxy-2'-fluoroguanylyl-(5'→3')-2'-deoxy-2'-fluoro-*P*-thioadenylyl-(5'→3')-2'-deoxy-2'-fluoro-*P*-thioadenylyl-(5'→3')-2'-*O*-methyluridine
givosiran	duplex de l'hydrogéno-*tout-P-ambo*-2'-*O*-méthyl-*P*-thiocytidylyl-(3'→5')-2'-*O*-méthyl-*P*-thioadénylyl-(3'→5')-2'-*O*-méthylguanylyl-(3'→5')-2'-*O*-méthyladénylyl-(3'→5')-2'-*O*-méthyladénylyl-(3'→5')-2'-*O*-méthyladénylyl-(3'→5')-2'-déoxy-2'-fluoroguanylyl-(3'→5')-2'-*O*-méthyladénylyl-(3'→5')-2'-déoxy-2'-fluoroguanylyl-(3'→5')-2'-*O*-méthyluridylyl-(3'→5')-2'-déoxy-2'-fluoroguanylyl-(3'→5')-2'-*O*-méthyluridylyl-(3'→5')-2'-déoxy-2'-fluorocytidylyl-(3'→5')-2'-*O*-méthyluridylyl-(3'→5')-2'-déoxy-2'-fluorocytidylyl-(3'→5')-2'-*O*-méthyladénylyl-(3'→5')-2'-*O*-méthyluridylyl-(3'→5')-2'-*O*-méthylcytidylyl-(3'→5')-2'-*O*-méthyluridylyl-(3'→5')-2'-*O*-méthyluridylyl-(3'→5')-2'-*O*-méthyl-3'-adénylate de [(2*S*,4*R*)-1-{1-[(2-acétamido-2-déoxy-β-D-galactopyranosyl)oxy]-16,16-bis({3-[(3-{5-[(2-acétamido-2-déoxy-β-D-galactopyranosyl)oxy]pentanamido}propyl)amino]-3-oxopropoxy}méthyl)-5,11,18-trioxo-14-oxa-6,10,17-triazanonacosan-29-oyl}-4-hydroxypyrrolidin-2-yl]méthyle et

	du *tout-P-ambo*-2'-*O*-méthyl-*P*-thiouridylyl-(5'→3')-2'-*O*-méthyl-*P*-thioguanylyl-(5'→3')-2'-*O*-méthylguanylyl-(5'→3')-2'-déoxy-2'-fluorouridylyl-(5'→3')-2'-*O*-méthylcytidylyl-(5'→3')-2'-déoxy-2'-fluorouridylyl-(5'→3')-2'-*O*-méthyluridylyl-(5'→3')-2'-déoxy-2'-fluorouridylyl-(5'→3')-2'-*O*-méthylcytidylyl-(5'→3')-2'-déoxy-2'-fluorouridylyl-(5'→3')-2'-*O*-méthylcytidylyl-(5'→3')-2'-déoxy-2'-fluoroadénylyl-(5'→3')-2'-*O*-méthylcytidylyl-(5'→3')-2'-déoxy-2'-fluoroadénylyl-(5'→3')-2'-*O*-méthylguanylyl-(5'→3')-2'-déoxy-2'-fluoroadénylyl-(5'→3')-2'-*O*-méthylguanylyl-(5'→3')-2'-déoxy-2'-fluorouridylyl-(5'→3')-2'-*O*-méthyladénylyl-(5'→3')-2'-déoxy-2'-fluoroguanylyl-(5'→3')-2'-déoxy-2'-fluoro-*P*-thioadénylyl-(5'→3')-2'-déoxy-2'-fluoro-*P*-thioadénylyl-(5'→3')-2'-*O*-méthyluridine
givosirán	dúplex del hidrógeno-*todo-P-ambo*-2'-*O*-metil-*P*-tiocitidilil-(3'→5')-2'-*O*-metil-*P*-tioadenilil-(3'→5')-2'-*O*-metilguanilil-(3'→5')-2'-*O*-metiladenilil-(3'→5')-2'-*O*-metiladenilil-(3'→5')-2'-*O*-metiladenilil-(3'→5')-2'-desoxi-2'-fluoroguanilil-(3'→5')-2'-*O*-metiladenilil-(3'→5')-2'-desoxi-2'-fluoroguanilil-(3'→5')-2'-*O*-metiluridilil-(3'→5')-2'-desoxi-2'-fluoroguanilil-(3'→5')-2'-*O*-metiluridilil-(3'→5')-2'-desoxi-2'-fluorocitidilil-(3'→5')-2'-*O*-metiluridilil-(3'→5')-2'-desoxi-2'-fluorocitidilil-(3'→5')-2'-*O*-metiladenilil-(3'→5')-2'-*O*-metiluridilil-(3'→5')-2'-*O*-metilcitidilil-(3'→5')-2'-*O*-metiluridilil-(3'→5')-2'-*O*-metiluridilil-(3'→5')-2'-*O*-metil-3'-adenilato de [(2*S*,4*R*)-1-{1-[(2-acetamido-2-desoxi-β-D-galactopiranosil)oxi]-16,16-bis({3-[(3-{5-[(2-acetamido-2-desoxi-β-D-galactopiranosil)oxi]pentanamido}propil)amino]-3-oxopropoxi}metil)-5,11,18-trioxo-14-oxa-6,10,17-triazanonacosan-29-oil}-4-hidroxipirrolidin-2-il]metilo y del *todo-P-ambo*-2'-*O*-metil-*P*-tiouridilil-(5'→3')-2'-*O*-metil-*P*-tioguanilil-(5'→3')-2'-*O*-metilguanilil-(5'→3')-2'-desoxi-2'-fluorouridilil-(5'→3')-2'-*O*-metilcitidilil-(5'→3')-2'-desoxi-2'-fluorouridilil-(5'→3')-2'-*O*-metiluridilil-(5'→3')-2'-desoxi-2'-fluorouridilil-(5'→3')-2'-*O*-metilcitidilil-(5'→3')-2'-desoxi-2'-fluorouridilil-(5'→3')-2'-*O*-metilcitidilil-(5'→3')-2'-desoxi-2'-fluoroadenilil-(5'→3')-2'-*O*-metilcitidilil-(5'→3')-2'-desoxi-2'-fluoroadenilil-(5'→3')-2'-*O*-metilguanilil-(5'→3')-2'-desoxi-2'-fluoroadenilil-(5'→3')-2'-*O*-metilguanilil-(5'→3')-2'-desoxi-2'-fluorouridilil-(5'→3')-2'-*O*-metiladenilil-(5'→3')-2'-desoxi-2'-fluoroguanilil-(5'→3')-2'-desoxi-2'-fluoro-*P*-tioadenilil-(5'→3')-2'-desoxi-2'-fluoro-*P*-tioadenilil-(5'→3')-2'-*O*-metiluridina

$C_{524}H_{694}F_{16}N_{173}O_{316}P_{43}S_6$



glecaprevirum

glecaprevir

(3a*R*,7*S*,10*S*,12*R*,21*E*,24a*R*)-7-*tert*-butyl-*N*-{(1*R*,2*R*)-2-(difluoromethyl)-1-[(1-methylcyclopropane-1-sulfonyl)carbamoyl]cyclopropyl}-20,20-difluoro-5,8-dioxo-2,3,3a,5,6,7,8,11,12,20,23,24a-dodecahydro-1*H*,10*H*-9,12-methanocyclopenta[18,19][1,10,17,3,6]trioxadiazacyclononadecino[11,12-*b*]quinoxaline-10-carboxamide

glécaprévir

(3a*R*,7*S*,10*S*,12*R*,21*E*,24a*R*)-7-*tert*-butyl-*N*-{(1*R*,2*R*)-2-(difluorométhyl)-1-[(1-méthylcyclopropane-1-sulfonyl)carbamoyl]cyclopropyl}-20,20-difluoro-5,8-dioxo-2,3,3a,5,6,7,8,11,12,20,23,24a-dodécahydro-1*H*,10*H*-9,12-méthanocyclopenta[18,19][1,10,17,3,6]trioxadiazacyclononadécino[11,12-*b*]quinoxaline-10-carboxamide

glecaprevir

(3a*R*,7*S*,10*S*,12*R*,21*E*,24a*R*)-7-*tert*-butil-*N*-{(1*R*,2*R*)-2-(difluorometil)-1-[(1-metilciclopropano-1-sulfonil)carbamoil]ciclopropil}-20,20-difluoro-5,8-dioxo-2,3,3a,5,6,7,8,11,12,20,23,24a-dodecahidro-1*H*,10*H*-9,12-metanociclopenta[18,19][1,10,17,3,6]trioxadiazaciclononadecino[11,12-*b*]quinoxalina-10-carboxamida

$C_{38}H_{46}F_4N_6O_9S$



glesatinibum

glesatinib

N-[(3-fluoro-4-{[2-(5-{[(2-methoxyethyl)amino]methyl}pyridin-2-yl)thieno[3,2-*b*]pyridin-7-yl]oxy}phenyl)carbamothioyl]-2-(4-fluorophenyl)acetamide

glésatinib

N-[(3-fluoro-4-{[2-(5-{[(2-méthoxyéthyl)amino]méthyl}pyridin-2-yl)thiéno[3,2-*b*]pyridin-7-yl]oxy}phényl)carbamothioyl]-2-(4-fluorophényl)acétamide

glesatinib

N-[(3-fluoro-4-{[2-(5-{[(2-metoxietil)amino]metil}piridin-2-il)tieno[3,2-*b*]piridin-7-il]oxi}fenil)carbamotioil]-2-(4-fluorofenil)acetamida

$C_{31}H_{27}F_2N_5O_3S_2$



inclisiranum

inclisiran

duplex of [(2*S*,4*R*)-1-{1-[(2-acetamido-2-deoxy-β-D-galactopyranosyl)oxy]-16,16-bis({3-[(3-{5-[(2-acetamido-2-deoxy-β-D-galactopyranosyl)oxy]pentanamido}propyl)amino]-3-oxopropoxy}methyl)-5,11,18-trioxo-14-oxa-6,10,17-triazanonacosan-29-oyl}-4-hydroxypyrrolidin-2-yl]methyl hydrogen *all-P-ambo*-2'-*O*-methyl-*P*-thiocytidylyl-(3'→5')-2'-*O*-methyl-*P*-thiouridylyl-(3'→5')-2'-*O*-methyladenylyl-(3'→5')-2'-*O*-methylguanylyl-(3'→5')-2'-*O*-methyladenylyl-(3'→5')-2'-*O*-methylcytidylyl-(3'→5')-2'-deoxy-2'-fluorocytidylyl-(3'→5')-2'-*O*-methyluridylyl-(3'→5')-2'-deoxy-2'-fluoroguanylyl-(3'→5')-2'-*O*-methyluridylyl-(3'→5')-thymidylyl-(3'→5')-2'-*O*-methyluridylyl-(3'→5')-2'-*O*-methyluridylyl-(3'→5')-2'-*O*-methylguanylyl-(3'→5')-2'-*O*-methylcytidylyl-(3'→5')-2'-*O*-methyluridylyl-(3'→5')-2'-*O*-methyluridylyl-(3'→5')-2'-*O*-methyluridylyl-(3'→5')-2'-*O*-methylguanylyl-(3'→5')-2'-*O*-methyl-3'-uridylate and *all-P-ambo*-2'-*O*-methyl-*P*-thioadenylyl-(5'→3')-2'-*O*-methyl-*P*-thioadenylyl-(5'→3')-2'-*O*-methylguanylyl-(5'→3')-2'-*O*-methyladenylyl-(5'→3')-2'-*O*-methyluridylyl-(5'→3')-2'-deoxy-2'-fluorocytidylyl-(5'→3')-2'-*O*-methyluridylyl-(5'→3')-2'-deoxy-2'-fluoroguanylyl-(5'→3')-2'-*O*-methylguanylyl-(5'→3')-2'-deoxy-2'-fluoroadenylyl-(5'→3')-2'-*O*-methylcytidylyl-(5'→3')-2'-deoxy-2'-fluoroadenylyl-(5'→3')-2'-*O*-methyladenylyl-(5'→3')-2'-deoxy-2'-fluoroadenylyl-(5'→3')-2'-*O*-methyladenylyl-(5'→3')-2'-deoxy-2'-fluorocytidylyl-(5'→3')-2'-*O*-methylguanylyl-(5'→3')-2'-deoxy-2'-fluoroadenylyl-(5'→3')-2'-deoxy-2'-fluoroadenylyl-(5'→3')-2'-deoxy-2'-fluoroadenylyl-(5'→3')-2'-*O*-methyl-*P*-thioadenylyl-(5'→3')-2'-deoxy-2'-fluoro-*P*-thiocytidylyl-(5'→3')-2'-*O*-methyladenosine

inclisiran

duplex de l'hydrogéno-*tout-P-ambo*-2'-*O*-méthyl-*P*-thiocytidylyl-(3'→5')-2'-*O*-méthyl-*P*-thiouridylyl-(3'→5')-2'-*O*-méthyladénylyl-(3'→5')-2'-*O*-méthylguanylyl-(3'→5')-2'-*O*-méthyladénylyl-(3'→5')-2'-*O*-méthylcytidylyl-(3'→5')-2'-déoxy-2'-fluorocytidylyl-(3'→5')-2'-*O*-méthyluridylyl-(3'→5')-2'-déoxy-2'-fluoroguanylyl-(3'→5')-2'-*O*-méthyluridylyl-(3'→5')-thymidylyl-(3'→5')-2'-*O*-méthyluridylyl-(3'→5')-2'-*O*-méthyluridylyl-(3'→5')-2'-*O*-méthylguanylyl-(3'→5')-2'-*O*-méthylcytidylyl-(3'→5')-2'-*O*-méthyluridylyl-(3'→5')-2'-*O*-méthyluridylyl-(3'→5')-2'-*O*-méthyluridylyl-(3'→5')-2'-*O*-méthylguanylyl-(3'→5')-2'-*O*-méthyl-3'-uridylate de

	[(2*S*,4*R*)-1-{1-[(2-acétamido-2-déoxy-β-D-galactopyranosyl)oxy]-16,16-bis({3-[(3-{5-[(2-acétamido-2-déoxy-β-D-galactopyranosyl)oxy] pentanamido}propyl)amino]-3-oxopropoxy}méthyl)-5,11,18-trioxo-14-oxa-6,10,17-triazanonacosan-29-oyl}-4-hydroxypyrrolidin-2-yl]méthyle et du *tout-P-ambo*-2'-*O*-méthyl-*P*-thioadénylyl-(5'→3')-2'-*O*-méthyl-*P*-thioadénylyl-(5'→3')-2'-*O*-méthylguanylyl-(5'→3')-2'-*O*-méthyladénylyl-(5'→3')-2'-*O*-méthyluridylyl-(5'→3')-2'-déoxy-2'-fluorocytidylyl-(5'→3')-2'-*O*-méthyluridylyl-(5'→3')-2'-déoxy-2'-fluoroguanylyl-(5'→3')-2'-*O*-méthylguanylyl-(5'→3')-2'-déoxy-2'-fluoroadénylyl-(5'→3')-2'-*O*-méthylcytidylyl-(5'→3')-2'-déoxy-2'-fluoroadénylyl-(5'→3')-2'-*O*-méthyladénylyl-(5'→3')-2'-déoxy-2'-fluoroadénylyl-(5'→3')-2'-*O*-méthyladénylyl-(5'→3')-2'-déoxy-2'-fluorocytidylyl-(5'→3')-2'-*O*-méthylguanylyl-(5'→3')-2'-déoxy-2'-fluoroadénylyl-(5'→3')-2'-déoxy-2'-fluoroadénylyl-(5'→3')-2'-déoxy-2'-fluoroadénylyl-(5'→3')-2'-*O*-méthyl-*P*-thioadénylyl-(5'→3')-2'-déoxy-2'-fluoro-*P*-thiocytidylyl-(5'→3')-2'-*O*-méthyladénosine
inclisirán	dúplex del hidrógeno-*todo-P-ambo*-2'-*O*-metil-*P*-tiocitidilil-(3'→5')-2'-*O*-metil-*P*-tiouridilil-(3'→5')-2'-*O*-metiladenilil-(3'→5')-2'-*O*-metilguanilil-(3'→5')-2'-*O*-metiladenilil-(3'→5')-2'-*O*-metilcitidilil-(3'→5')-2'-desoxi-2'-fluorocitidilil-(3'→5')-2'-*O*-metiluridilil-(3'→5')-2'-desoxi-2'-fluoroguanilil-(3'→5')-2'-*O*-metiluridilil-(3'→5')-timidilil-(3'→5')-2'-*O*-metiluridilil-(3'→5')-2'-*O*-metiluridilil-(3'→5')-2'-*O*-metilguanilil-(3'→5')-2'-*O*-metilcitidilil-(3'→5')-2'-*O*-metiluridilil-(3'→5')-2'-*O*-metiluridilil-(3'→5')-2'-*O*-metiluridilil-(3'→5')-2'-*O*-metiluridilil-(3'→5')-2'-*O*-metilguanilil-(3'→5')-2'-*O*-metil-3'-uridilato de [(2*S*,4*R*)-1-{1-[(2-acetamido-2-desoxi-β-D-galactopiranosil)oxi]-16,16-bis({3-[(3-{5-[(2-acetamido-2-desoxi-β-D-galactopiranosil)oxi]pentanamido}propil)amino]-3-oxopropoxi}metil)-5,11,18-trioxo-14-oxa-6,10,17-triazanonacosan-29-oil}-4-hidroxipirrolidin-2-il]metilo y del *todo-P-ambo*-2'-*O*-metil-*P*-tioadenilil-(5'→3')-2'-*O*-metil-*P*-tioadenilil-(5'→3')-2'-*O*-metilguanilil-(5'→3')-2'-*O*-metiladenilil-(5'→3')-2'-*O*-metiluridilil-(5'→3')-2'-desoxi-2'-fluorocitidilil-(5'→3')-2'-*O*-metiluridilil-(5'→3')-2'-desoxi-2'-fluoroguanilil-(5'→3')-2'-*O*-metilguanilil-(5'→3')-2'-desoxi-2'-fluoroadenilil-(5'→3')-2'-*O*-metilcitidilil-(5'→3')-2'-desoxi-2'-fluoroadenilil-(5'→3')-2'-*O*-metiladenilil-(5'→3')-2'-desoxi-2'-fluoroadenilil-(5'→3')-2'-desoxi-2'-fluorocitidilil-(5'→3')-2'-*O*-metilguanilil-(5'→3')-2'-desoxi-2'-fluoroadenilil-(5'→3')-2'-desoxi-2'-fluoroadenilil-(5'→3')-2'-*O*-metil-*P*-tioadenilil-(5'→3')-2'-desoxi-2'-fluoro-*P*-tiocitidilil-(5'→3')-2'-*O*-metiladenosina $C_{529}H_{707}F_{12}N_{176}O_{316}P_{43}S_6$



intepirdinum

intepirdine	3-(benzenesulfonyl)-8-(piperazin-1-yl)quinolone
intépirdine	3-(benzènesulfonyl)-8-(pipérazin-1-yl)quinolone
intepirdina	3-(bencenosulfonil)-8-(piperazin-1-il)quinolina

$C_{19}H_{19}N_3O_2S$



ivosidenibum

ivosidenib	(2*S*)-*N*-{(1*S*)-1-(2-chlorophenyl)-2-[(3,3-difluorocyclobutyl)amino]-2-oxoethyl}-1-(4-cyanopyridin-2-yl)-*N*-(5-fluoropyridin-3-yl)-5-oxopyrrolidine-2-carboxamide
ivosidénib	(2*S*)-*N*-{(1*S*)-1-(2-chlorophenyl)-2-[(3,3-difluorocyclobutyl)amino]-2-oxoethyl}-1-(4-cyanopyridin-2-yl)-*N*-(5-fluoropyridin-3-yl)-5-oxopyrrolidine-2-carboxamide
ivosidenib	(2*S*)-*N*-{(1*S*)-1-(2-clorofenil)-2-[(3,3-difluorociclobutil)amino]-2-oxoetil}-1-(4-cianopiridin-2-il)-*N*-(5-fluoropiridin-3-il)-5-oxopirrolidina-2-carboxamida

$C_{28}H_{22}ClF_3N_6O_3$



lanadelumabum #

lanadelumab	immunoglobulin G1-kappa, anti-[*Homo sapiens* KLKB1 (kallikrein B 1, plasma prekallikrein (zymogen), kininogenin, Fletcher factor) proteolytically cleaved by F12 (factor FXII), active plasma kallikrein (EC 3.4.21.34)], *Homo sapiens* monoclonal antibody; gamma1 heavy chain (1-451) [*Homo sapiens* VH (IGHV3-23*03 (91.80%) -(IGHD) -IGHJ3*02) [8.8.15] (1-122) -IGHG1*03, G1m3 (CH1 (123-220), hinge (221-235), CH2 (236-345), CH3 (346-450), CHS K2>del (451))(123-451)], (225-213')-disulfide with kappa light chain (1'-213') [*Homo sapiens* V-KAPPA (IGKV1-5*03 (97.90%) -IGKJ1*01) [6.3.8] (1'-106') -IGKC*01, Km3 (107'-213')]; dimer (231-231'':234-234'')-bisdisulfide
lanadélumab	immunoglobuline G1-kappa, anti-[*Homo sapiens* KLKB1 (kallikréine B 1, prékallikréine plasmatique (zymogène), kininogénine, facteur de Fletcher) clivé protéolytiquement par F12 (facteur FXII), kallikréine plasmatique active (EC 3.4.21.34)], *Homo sapiens* anticorps monoclonal; chaîne lourde gamma1 (1-451) [*Homo sapiens* VH (IGHV3-23*03 (91.80%) -(IGHD) -IGHJ3*02) [8.8.15] (1-122) -IGHG1*03, G1m3 (CH1 (123-220), charnière (221-235), CH2 (236-345), CH3 (346-450), CHS K2>del (451)) (123-451)], (225-213')-disulfure avec la chaîne légère kappa (1'-213') [*Homo sapiens* V-KAPPA (IGKV1-5*03 (97.90%) -IGKJ1*01) [6.3.8] (1'-106') -IGKC*01, Km3 (107'-213')]; dimère (231-231'':234-234'')-bisdisulfure
lanadelumab	inmunoglobulina G1-kappa, anti-[*Homo sapiens* KLKB1 (kalikreína B 1, prekalikreína plasmática (zimógeno), kininogenina, factor de Fletcher) dividida proteolíticamente por F12 (factor FXII), kalikreína plasmática activa (EC 3.4.21.34)], *Homo sapiens* anticuerpo monoclonal; cadena pesada gamma1 (1-451) [*Homo sapiens* VH (IGHV3-23*03 (91.80%) -(IGHD) -IGHJ3*02) [8.8.15] (1-122) -IGHG1*03, G1m3 (CH1 (123-220), bisagra (221-235), CH2 (236-345), CH3 (346-450), CHS K2>del (451)) (123-451)], (225-213')-disulfuro con la cadena ligera kappa (1'-213') [*Homo sapiens* V-KAPPA (IGKV1-5*03 (97.90%) -IGKJ1*01) [6.3.8] (1'-106') -IGKC*01, Km3(107'-213')]; dímeo (231-231'':234-234'')-bisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada

```
EVQLLESGGG LVQPGGSLRL SCAASGFTFS HYIMMWVRQA PGKGLEWVSG  50
IYSSGGITVY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAYRR 100
IGVPRRDEFD IWGQGTMVTV SSASTKGPSV FPLAPSSKST SGGTAALGCL 150
VKDYFPEPVT VSWNSGALTS GVHTFPAVLQ SSGLYSLSSV VTVPSSSLGT 200
QTYICNVNHK PSNTKVDKRV EPKSCDKTHT CPPCPAPELL GGPSVFLFPP 250
KPKDTLMISR TPEVTCVVVD VSHEDPEVKF NWYVDGVEVH NAKTKPREEQ 300
YNSTYRVVSV LTVLHQDWLN GKEYKCKVSN KALPAPIEKT ISKAKGQPRE 350
PQVYTLPPSR EEMTKNQVSL TCLVKGFYPS DIAVEWESNG QPENNYKTTP 400
PVLDSDGSFF LYSKLTVDKS RWQQGNVFSC SVMHEALHNH YTQKSLSLSP 450
G                                                       451
```

Light chain / Chaîne légère / Cadena ligera

```
DIQMTQSPST LSASVGDRVT ITCRASQSIS SWLAWYQQKP GKAPKLLIYK  50
ASTLESGVPS RFSGSGSGTE FTLTISSLQP DDFATYYCQQ YNTYWTFGQG 100
TKVEIKRTVA APSVFIFPPS DEQLKSGTAS VVCLLNNFYP REAKVQWKVD 150
NALQSGNSQE SVTEQDSKDS TYSLSSTLTL SKADYEKHKV YACEVTHQGL 200
SSPVTKSFNR GEC                                         213
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H (C23-C104)	22-96	149-205	266-326	372-430
	22"-96"	149"-205"	266"-326"	372"-430"
Intra-L (C23-C104)	23'-88'	133'-193'		
	23"'-88"'	133"'-193"'		
Inter-H-L (h 5-CL 126)	225-213'	225"-213"'		
Inter-H-H (h 11, h 14)	231-231"	234-234"		

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
H CH2 N84.4:
302, 302"
Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires complexes fucosylés / glicanos de tipo CHO biantenarios complejos fucosilados

lapriximabum #

laprituximab	immunoglobulin G1-kappa, anti-[*Homo sapiens* EGFR (epidermal growth factor receptor, receptor tyrosine-protein kinase erbB-1, ERBB1, HER1, HER-1, ERBB)], chimeric monoclonal antibody; gamma1 heavy chain (1-448) [*Mus musculus* VH (IGHV1-7*01 -(IGHD) -IGHJ4*01) [8.8.12] (1-119) -*Homo sapiens* IGHG1*01, Gm17,1 (CH1 (120-217), hinge (218-232), CH2 (233-342), CH3 (343-447), CHS K2>del (448)) (120-448)], (222-214')-disulfide with kappa light chain (1'-214') [*Mus musculus* V-KAPPA (IGKV19-93*01 -IGKJ2*03) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01, Km3 (108'-214')]; dimer (228-228":231-231")-bisdisulfide
laprituximab	immunoglobuline G1-kappa, anti-[*Homo sapiens* EGFR (récepteur du facteur de croissance épidermique, récepteur tyrosine-protéine kinase erb-1, ERBB1, HER1, HER-1, ERBB)], anticorps monoclonal chimérique; chaîne lourde gamma1 (1-448) [*Mus musculus* VH (IGHV1-7*01 -(IGHD) -IGHJ4*01) [8.8.12] (1-119) -*Homo sapiens* IGHG1*01, Gm17,1 (CH1 (120-217), charnière (218-232), CH2 (233-342), CH3 (343-447), CHS K2>del (448)) (120-448)], (222-214')-disulfure avec la chaîne légère kappa (1'-214') [*Mus musculus* V-KAPPA (IGKV19-93*01 - IGKJ2*03) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01, Km3 (108'-214')]; dimère (228-228":231-231")-bisdisulfure.
laprituximab	inmunoglobulina G1-kappa, anti-[*Homo sapiens* EGFR (receptor del factor de crecimiento epidérmico, receptor tirosina-proteína kinasa erbB-1, ERBB1, HER1, HER-1, ERBB)], anticuerpo monoclonal quimérico;

cadena pesada gamma1 (1-448) [*Mus musculus* VH (IGHV1-7*01 -(IGHD) -IGHJ4*01) [8.8.12] (1-119) -*Homo sapiens* IGHG1*01, Gm17,1 (CH1 (120-217), bisagra (218-232), CH2 (233-342), CH3 (343-447), CHS K2>del (448)) (120-448)], (222-214')-disulfuro con la cadena ligera kappa (1'-214') [*Mus musculus* V-KAPPA (IGKV19-93*01 - IGKJ2*03) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01, Km3 (108'-214')]; dímero (228-228'':231-231'')-bisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada

```
QVQLVQSGAE VAKPGASVKL SCKASGYTFT SYWMQWVKQR PGQGLECIGT  50
IYPGDGDTTY TQKFQGKATL TADKSSSTAY MQLSSLRSED SAVYYCARYD 100
APGYAMDYWG QGTLVTVSSA STKGPSVFPL APSSKSTSGG TAALGCLVKD 150
YFPEPVTVSW NSGALTSGVH TFPAVLQSSG LYSLSSVVTV PSSSLGTQTY 200
ICNVNHKPSN TKVDKKVEPK SCDKTHTCPP CPAPELLGGP SVFLFPPKPK 250
DTLMISRTPE VTCVVVDVSH EDPEVKFNWY VDGVEVHNAK TKPREEQYNS 300
TYRVVSVLTV LHQDWLNGKE YKCKVSNKAL PAPIEKTISK AKGQPREPQV 350
YTLPPSRDEL TKNQVSLTCL VKGFYPSDIA VEWESNGQPE NNYKTTPPVL 400
DSDGSFFLYS KLTVDKSRWQ QGNVFSCSVM HEALHNHYTQ KSLSLSPG   448
```

Light chain / Chaîne légère / Cadena ligera

```
DIQMTQSPSS LSASVGDRVT ITCRASQDIN NYLAWYQHKP GKGPKLLIHY  50
TSTLHPGIPS RFSGSGSGRD YSFSISSLEP EDIATYYCLQ YDNLLYTFGQ 100
GTKLEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV 150
DNALQSGNSQ ESVTEQDSKD STYSLSSTLT LSKADYEKHK VYACEVTHQG 200
LSSPVTKSFN RGEC                                        214
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H (C23-C104)	22-96	146-202	263-323	369-427
	22''-96''	146''-202''	263''-323''	369''-427''
Intra-L (C23-C104)	23'-88'	134'-194'		
	23'''-88'''	134'''-194'''		
Inter-H-L (h 5-CL 126)	222-214'	222''-214'''		
Inter-H-H (h 11, h 14)	228-228''	231-231''		

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
H CH2 N84.4:
299, 299''
Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires complexes fucosylés / glicanos de tipo CHO biantenarios complejos fucosilados

laprituximabum emtansinum #
lapri**t**uximab emtansine

immunoglobulin G1-kappa, anti-[*Homo sapiens* EGFR (epidermal growth factor receptor, receptor tyrosine-protein kinase erbB-1, ERBB1, HER1, HER-1, ERBB)], chimeric monoclonal antibody conjugated to maytansinoid DM1; gamma1 heavy chain (1-448) [*Mus musculus* VH (IGHV1-7*01 -(IGHD)-IGHJ4*01) [8.8.12] (1-119) -*Homo sapiens* IGHG1*01, Gm17,1 (CH1 (120-217), hinge (218-232), CH2 (233-342), CH3 (343-447), CHS K2>del (448) (120-448)], (222-214')-disulfide with kappa light chain (1'-214') [*Mus musculus* V-KAPPA (IGKV19-93*01-IGKJ2*03) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01, Km3 (108'-214')]; dimer (228-228'':231-231'')-bisdisulfide; conjugated, on an average of 3 to 4 lysyl, to maytansinoid DM1 via a succinimidyl-4-(*N*-maleimidomethyl) cyclohexane-1-carboxylate (SMCC) linker forming a nonreducible thioether bond
For the *emtansine* part, please refer to the document *"INN for pharmaceutical substances: Names for radicals, groups and others"*.

lapri**t**uximab emtansine

immunoglobuline G1-kappa, anti-[*Homo sapiens* EGFR (Récepteur du facteur de croissance épidermique, récepteur tyrosine-protéine kinase erb-1, ERBB1, HER1, HER-1, ERBB)], anticorps monoclonal chimérique conjugué au maytansinoïde DM1;

	chaîne lourde gamma1 (1-448) [*Mus musculus* VH (IGHV1-7*01 -(IGHD)-IGHJ4*01) [8.8.12] (1-119) -*Homo sapiens* IGHG1*01, Gm17,1 (CH1 (120-217), charnière (218-232), CH2 (233-342), CH3 (343-447), CHS K2>del (448) (120-448)], (222-214')-disulfure avec la chaîne légère kappa (1'-214') [*Mus musculus* V-KAPPA (IGKV19-93*01-IGKJ2*03) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01, Km3 (108'-214')]; dimère (228-228":231-231")-bisdisulfure; conjugué, sur 3 à 4 lysyl en moyenne, au maytansinoïde DM1 via un linker succinimidyl-4-(*N*-maléimidométhyl) cyclohexane-1-carboxylate (SMCC) formant une liaison thioéther non réductible Pour la partie *emtansine*, veuillez-vous référer au document *"INN for pharmaceutical substances: Names for radicals, groups and others"*.
laprituximab emtansina	inmunoglobulina G1-kappa, anti-[*Homo sapiens* EGFR (receptor del factor de crecimiento epidérmico, receptor tirosina-proteína kinasa erbB-1, ERBB1, HER1, HER-1, ERBB)], anticuerpo monoclonal quimérico conjugado con el maitansinoide DM1; cadena pesada gamma1 (1-448) [*Mus musculus* VH (IGHV1-7*01 -(IGHD)-IGHJ4*01) [8.8.12] (1-119) -*Homo sapiens* IGHG1*01, Gm17,1 (CH1 (120-217), bisagra (218-232), CH2 (233-342), CH3 (343-447), CHS K2>del (448) (120-448)], (222-214')-disulfuro con la cadena ligera kappa (1'-214') [*Mus musculus* V-KAPPA (IGKV19-93*01-IGKJ2*03) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01, Km3 (108'-214')]; dímero (228-228":231-231")-bisdisulfuro; conjugado, de 3 a 4 restos lisil por término medio, con el maitansinoide DM1 mediante el conector succinimidil-4-(*N*-maleimidometil) ciclohexano-1-carboxilato (SMCC) formando una unión tioéter no reducible La fracción *emtensina* se pueden encontrar en el documento "*INN for pharmaceutical substances: Names for radicals, groups and others*"*.

Structure

Heavy chain / Chaîne lourde / Cadena pesada

```
QVQLVQSGAE VAKPGASVKL SCKASGYTFT SYWMQWVKQR PGQGLECIGT  50
IYPGDGDTTY TQKFQGKATL TADKSSSTAY MQLSSLRSED SAVYYCARYD 100
APGYAMDYWG QGTLVTVSSA STKGPSVFPL APSSKSTSGG TAALGCLVKD 150
YFPEPVTVSW NSGALTSGVH TFPAVLQSSG LYSLSSVVTV PSSSLGTQTY 200
ICNVNHKPSN TKVDKKVEPK SCDKTHTCPP CPAPELLGGP SVFLFPPKPK 250
DTLMISRTPE VTCVVVDVSH EDPEVKFNWY VDGVEVHNAK TKPREEQYNS 300
TYRVVSVLTV LHQDWLNGKE YKCKVSNKAL PAPIEKTISK AKGQPREPQV 350
YTLPPSRDEL TKNQVSLTCL VKGFYPSDIA VEWESNGQPE NNYKTTPPVL 400
DSDGSFFLYS KLTVDKSRWQ QGNVFSCSVM HEALHNHYTQ KSLSLSPG   448
```

Light chain / Chaîne légère / Cadena ligera

```
DIQMTQSPSS LSASVGDRVT ITCRASQDIN NYLAWYQHKP GKGPKLLIHY  50
TSTLHPGIPS RFSGSGSGRD YSFSISSLEP EDIATYYCLQ YDNLLYTFGQ 100
GTKLEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV 150
DNALQSGNSQ ESVTEQDSKD STYSLSSTLT LSKADYEKHK VYACEVTHQG 200
LSSPVTKSFN RGEC                                        214
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H (C23-C104) 22-96 146-202 263-323 369-427
22"-96" 146"-202" 263"-323" 369"-427"
Intra-L (C23-C104) 23'-88' 134'-194'
23'"-88'" 134'"-194'"
Inter-H-L (h 5-CL 126) 222-214' 222"-214"
Inter-H-H (h 11, h 14) 228-228" 231-231"

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación

H CH2 N84.4:
299, 299"

Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires complexes fucosylés / glicanos de tipo CHO biantenarios complejos fucosilados

An average of 3 to 4 lysyl being conjugated each to a drug linker / 3 à 4 lysyl en moyenne sont conjugués à un linker-principe actif / Una media de 3 a 4 lisil están conjugadas a conectores-principio activo.

lenadogenum nolparvovecum #

lenadogene nolparvovec — a non-replicating single stranded DNA recombinant adeno-associated virus (rAAV) serotype 2 containing human wt MT-*ND4* cDNA that encodes NADH Dehydrogenase subunit 4, under the control of the cytomegalovirus immediate early (CMVie) promoter in an intron-containing expression cassette (beta globin intron, *HBB2*), flanked by the viral inverted terminal repeats from AAV2/2.

lénadogène nolparvovec — vecteur viral adéno-associé de sérotype 2 recombinant (rAAV) non-répliquant, avec un ADN monocaténaire contenant le gène wt MT-*ND4* codant pour la sous-unité 4 de la NADH déshydrogénase humaine, sous le contrôle d'un cytomégalovirus immédiat précoce dans un intron contenant la cassette d'expression (intron bêta-globine, *HBB2*), flanqué de répétitions inverses dérivées du virus adéno-associé de sérotype 2

lenadogén nolparvovec — vector viral adeno-asociado de serotipo 2 recombinante (rAAV) no replicativo, con un ADN monocatenario que contiene el gen wt MT-*ND4* que codifica para la subunidad 4 de la NADH deshidrogenasa humano, bajo el control de un promotor inmediato temprano del citomegalovirus en un intron que contiene el cassette de expresión (intron beta-globin, *HBB2*), flanqueado de repeticiones inversas derivadas del virus adeno-asociado del serotipo 2

leniolisibum

leniolisib — 1-[(3*S*)-3-({6-[6-methoxy-5-(trifluoromethyl)pyrimidin-3-yl]-5,6,7,8-tetrahydropyrido[4,3-*d*]pyrimidin-4-yl}amino)pyrrolidin-1-yl]propan-1-one

léniolisib — 1-[(3*S*)-3-({6-[6-méthoxy-5-(trifluorométhyl)pyrimidin-3-yl]-5,6,7,8-tétrahydropyrido[4,3-*d*]pyrimidin-4-yl}amino)pyrrolidin-1-yl]propan-1-one

leniolisib — 1-[(3*S*)-3-({6-[6-metoxi-5-(trifluorometil)pirimidin-3-il]-5,6,7,8-tetrahidropirido[4,3-*d*]pirimidin-4-il}amino)pirrolidin-1-il]propan-1-ona

$C_{21}H_{25}F_3N_6O_2$



levoketoconazolum

levoketoconazole — 1-{4-[4-({(2*S*,4*R*)-2-(2,4-dichlorophenyl)-2-[(1*H*-imidazol-1-yl)methyl]-1,3-dioxolan-4-yl}methoxy)phenyl]piperazin-1-yl}ethan-1-one

lévokétoconazole	1-{4-[4-({(2*S*,4*R*)-2-(2,4-dichlorophényl)-2-[(1*H*-imidazol-1-yl)méthyl]-1,3-dioxolan-4-yl}méthoxy)phényl]pipérazin-1-yl}éthan-1-one
levoketoconazol	1-{4-[4-({(2*S*,4*R*)-2-(2,4-diclorofenil)-2-[(1*H*-imidazol-1-il)metil]-1,3-dioxolan-4-il}metoxi)fenil]piperazin-1-il}etan-1-ona

$C_{26}H_{28}Cl_2N_4O_4$



lorlatinibum

lorlatinib	(10*R*)-7-amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2*H*-4,8-methenopyrazolo[4,3-*h*][2,5,11]benzoxadiazacyclotetradecine-3-carbonitrile
lorlatinib	(10*R*)-7-amino-12-fluoro-2,10,16-triméthyl-15-oxo-10,15,16,17-tétrahydro-2*H*-4,8-méthénopyrazolo[4,3-*h*][2,5,11]benzoxadiazacyclotétradécine-3-carbonitrile
lorlatinib	(10*R*)-7-amino-12-fluoro-2,10,16-trimetil-15-oxo-10,15,16,17-tetrahidro-2*H*-4,8-metenopirazolo[4,3-*h*][2,5,11]benzoxadiazaciclotetradecina-3-carbonitrilo

$C_{21}H_{19}FN_6O_2$



lumateperonum

lumateperone	1-(4-fluorophenyl)-4-[(6b*R*,10a*S*)-3-methyl-2,3,6b,9,10,10a-hexahydro-1*H*-pyrido[3',4':4,5]pyrrolo[1,2,3-*de*]quinoxalin-8(7*H*)-yl]butan-1-one
lumatépérone	1-(4-fluorophényl)-4-[(6b*R*,10a*S*)-3-méthyl-2,3,6b,9,10,10a-hexahydro-1*H*-pyrido[3',4':4,5]pyrrolo[1,2,3-*de*]quinoxalin-8(7*H*)-yl]-butan-1-one
lumateperona	1-(4-fluorofenil)-4-[(6b*R*,10a*S*)-3-metil-2,3,6b,9,10,10a-hexahidro-1*H*-pirido[3',4':4,5]pirrolo[1,2,3-*de*]quinoxalin-8(7*H*)-il]butan-1-ona

$C_{24}H_{28}FN_3O$



mesmulogenum ancovacivecum #

mesmulogene ancovacivec	a non-replicating recombinant vaccinia virus, based on the Modified Vaccinia Virus Ankara (MVA) strain, carrying sequences coding for the expression of the human Mucine 1 (MUC1) antigen and human Interleukin 2 (IL2), under the control of pH5R and p7.5 vaccinia promoters, respectively.
mesmulogène ancovacivec	vecteur viral recombinant non-répliquant de la vaccine, dérivé du virus de la vaccine modifié Ankara, contenant les séquences d'ADN codant pour l'expression de l'antigène de la Mucine 1 et de l'interleukine 2 humaine, sous le contrôle des promoteurs pH5R et p7.5, respectivement
mesmulogén ancovacivec	vector viral recombinante no replicativo de la vacuna, derivado de la cepa del virus de la vacuna modificada Ankara, que contiene las secuencias del ADN que codifica para la expresión del antígeno de la Mucina 1 (MUC1) y de la interleukina 2 humana (IL2), bajo el control de los promotores vaccinia pH5R y p7.5, respectivamente

mipeginterferonum alfa-2b #

mipeginterferon alfa-2b	$N^{2.1}$,$N^{6.Lys}$-oligo(*N*-{2-[ω-methoxypoly(oxyethylene)-α-yl]acetyl}-*N*-[α-methylpoly(oxyethylene)-ω-yl]glycyl)human interferon alpha-2b, with an average number of 5 substituted among 11 amino groups (one *N*-terminal and 10 lysine N^6), the protein part being produced in *Pichia pastoris* (*Komagataella pastoris*) The relative molecular mass of the polyethylene glycol part can be indicated after the INN, for example: mipeginterferon alfa-2b (40 kDa)
mipèginterféron alfa-2b	$N^{2.1}$,$N^{6.Lys}$-oligo(*N*-{2-[ω-méthoxypoly(oxyéthylène)-α-yl]acétyl}-*N*-[α-méthylpoly(oxyéthylène)-ω-yl]glycyl)interféron alpha-2b humain, une moyenne de 5 azotes parmi les 11 (un *N*-terminal et 10 lysines N^6) sont substitués, la partie protéique étant produite par *Pichia pastoris* (*Komagataella pastoris*) La masse molaire de la partie polyéthylène glycol peut être indiquée après la DCI, par exemple: mipèginterféron alfa-2b (40 kDa)

mipeginterferón alfa-2b

$N^{2.1}$,$N^{6.Lys}$-oligo(*N*-{2-[ω-metoxipoli(oxietileno)-α-il]acetil}-*N*-[α-metilpoli(oxietileno)-ω-il]glicil)interferón alpha-2b humano, con una media de 5 grupos amino sustituidos entre los 11 (un *N*-terminal y 10 lisinas N^{6}), la parte proteica es producida por *Pichia pastoris* (*Komagataella pastoris*)
La masa molar de la parte polietilen glicol puede ser indicada después de la DCI, por ejemplo: mipeginterferón alfa-2b (40 kDa).



mirvetuximabum #
mirvetuximab

immunoglobulin G1-kappa, anti-[*Homo sapiens* FOLR1 (folate receptor 1, folate receptor alpha, FR-alpha, adult folate-binding protein, FBP, ovarian tumor-associated antigen MOv18)], chimeric monoclonal antibody;
gamma1 heavy chain (1-447) [*Mus musculus* VH (IGHV1-37*01 -(IGHD) -IGHJ4*01) [8.8.11] (1-118) -*Homo sapiens* IGHG1*01, Gm17,1 (CH1 (119-216), hinge (217-231), CH2 (232-341), CH3 (342-446), CHS K2>del (447)) (119-447)], (221-218')-disulfide with kappa light chain (1'-218') [*Mus musculus* V-KAPPA (IGKV3-9*01 -IGKJ2*01) [10.3.9] (1'-111') -*Homo sapiens* IGKC*01, Km3 (112'-218')]; dimer (227-227''':230-230'')-bisdisulfide

mirvétuximab

immunoglobuline G1-kappa, anti-[*Homo sapiens* FOLR1 (récepteur 1 du folate, récepteur alpha du folate, FR-alpha, protéine de l'adulte liant le folate, FBP, antigène MOv18 associé à des tumeurs ovariennes)], anticorps monoclonal chimérique;
chaîne lourde gamma1 (1-447) [*Mus musculus* VH (IGHV1-37*01 -(IGHD) -IGHJ4*01) [8.8.11] (1-118) -*Homo sapiens* IGHG1*01, Gm17,1 (CH1 (119-216), charnière (217-231), CH2 (232-341), CH3 (342-446), CHS K2>del (447)) (119-447)], (221-218')-disulfure avec la chaîne légère kappa (1'-218') [*Mus musculus* V-KAPPA (IGKV3-9*01 -IGKJ2*01) [10.3.9] (1'-111') -*Homo sapiens* IGKC*01, Km3 (112'-218')]; dimère (227-227''':230-230'')-bisdisulfure

mirvetuximab

inmunoglobulina G1-kappa, anti-[*Homo sapiens* FOLR1 (receptor 1 de folato, receptor alfa de folato, FR-alpha, proteína del adulto que liga el folato, FBP, antígeno Mov18 asociado a tumores ováricos)], anticuerpo monoclonal quimérico;
cadena pesada gamma1 (1-447) [*Mus musculus* VH (IGHV1-37*01 -(IGHD) -IGHJ4*01) [8.8.11] (1-118) -*Homo sapiens* IGHG1*01, Gm17,1 (CH1 (119-216), bisagra (217-231), CH2 (232-341), CH3 (342-446), CHS K2>del (447)) (119-447)], (221-218')-disulfuro con la cadena ligera kappa (1'-218') [*Mus musculus* V-KAPPA (IGKV3-9*01 - IGKJ2*01) [10.3.9] (1'-111') -*Homo sapiens* IGKC*01, Km3 (112'-218')]; dímero (227-227''':230-230''')-bisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada

```
QVQLVQSGAE VVKPGASVKI SCKASGYTFT GYFMNWVKQS PGQSLEWIGR  50
IHPYDGDTFY NQKFQGKATL TVDKSSNTAH MELLSLTSED FAVYYCTRYD 100
GSRAMDYWGQ GTTVTVSSAS TKGPSVFPLA PSSKSTSGGT AALGCLVKDY 150
FPEPVTVSWN SGALTSGVHT FPAVLQSSGL YSLSSVVTVP SSSLGTQTYI 200
CNVNHKPSNT KVDKKVEPKS CDKTHTCPPC PAPELLGGPS VFLFPPKPKD 250
TLMISRTPEV TCVVVDVSHE DPEVKFNWYV DGVEVHNAKT KPREEQYNST 300
YRVVSVLTVL HQDWLNGKEY KCKVSNKALP APIEKTISKA KGQPREPQVY 350
TLPPSRDELT KNQVSLTCLV KGFYPSDIAV EWESNGQPEN NYKTTPPVLD 400
SDGSFFLYSK LTVDKSRWQQ GNVFSCSVMH EALHNHYTQK SLSLSPG    447
```

Light chain / Chaîne légère / Cadena ligera

```
DIVLTQSPLS LAVSLGQPAI ISCKASQSVS FAGTSLMHWY HQKPGQQPRL  50
LIYRASNLEA GVPDRFSGSG SKTDFTLTIS PVEAEDAATY YCQQSREYPY 100
TFGGGTKLEI KRTVAAPSVF IFPPSDEQLK SGTASVVCLL NNFYPREAKV 150
QWKVDNALQS GNSQESVTEQ DSKDSTYSLS STLTLSKADY EKHKVYACEV 200
THQGLSSPVT KSFNRGEC                                    218
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H (C23-C104)	22-96	145-201	262-322	368-426
	22''-96''	145''-201''	262''-322''	368''-426''
Intra-L (C23-C104)	23'-92'	138'-198'		
	23'''-92'''	138'''-198'''		
Inter-H-L (h 5-CL 126)	221-218'	221''-218'''		
Inter-H-H (h 11, h 14)	227-227''	230-230''		

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
H CH2 N84.4:
298, 298''
Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires complexes fucosylés / glicanos de tipo CHO biantenarios complejos fucosilados

mizagliflozinum

mizagliflozin

3-{[3-(4-{[3-(β-D-glucopyranosyloxy)-5-(propan-2-yl)-1*H*-pyrazol-4-yl]methyl}-3-methylphenoxy)propyl]amino}-2,2-dimethylpropanamide

mizagliflozine

3-{[3-(4-{[3-(β-D-glucopyranosyloxy)-5-(propan-2-yl)-1*H*-pyrazol-4-yl]méthyl}-3-méthylphénoxy)propyl]amino}-2,2-diméthylpropanamide

mizagliflozina

3-{[3-(4-{[3-(β-D-glucopiranosiloxi)-5-(propan-2-il)-1*H*-pirazol-4-il]metil}-3-metilfenoxi)propil]amino}-2,2-dimetilpropanamida

$C_{28}H_{44}N_4O_8$



nafithromycinum

nafithromycin

(3*R*,3[1]*Z*,3a*S*,4*R*,6*R*,8*R*,9*R*,10*R*,12*R*,15*R*,15a*S*)-15-ethyl-8-methoxy-4,6,8,10,12,15a-hexamethyl-2,5,11,13-tetraoxo-*N*′-{(1*S*)-1-[5-(pyridin-2-yl)-1,3,4-thiadiazol-2-yl]ethoxy}-9-{[3,4,6-trideoxy-3-(dimethylamino)-β-D-*xylo*-hexopyranosyl]oxy}tetradecahy-dro-2*H*-furo[2,3-*c*]oxacyclotetradecine-3-carboximidamide

nafithromycine

(3*R*,3[1]*Z*,3a*S*,4*R*,6*R*,8*R*,9*R*,10*R*,12*R*,15*R*,15a*S*)-15-éthyl-8-méthoxy-4,6,8,10,12,15a-hexaméthyl-2,5,11,13-tétraoxo-*N*′-{(1*S*)-1-[5-(pyridin-2-yl)-1,3,4-thiadiazol-2-yl]éthoxy}-9-{[3,4,6-tridéoxy-3-(diméthylamino)-β-D-*xylo*-hexopyranosyl]oxy}tétradecahy-dro-2*H*-furo[2,3-*c*]oxacyclotétradécine-3-carboximidamide

nafitromicina

(3*R*,3[1]*Z*,3a*S*,4*R*,6*R*,8*R*,9*R*,10*R*,12*R*,15*R*,15a*S*)-15-etil-8-metoxi-4,6,8,10,12,15a-hexametil-2,5,11,13-tetraoxo-*N*′-{(1*S*)-1-[5-(piridin-2-il)-1,3,4-tiadiazol-2-il]etoxi}-9-{[3,4,6-tridesoxi-3-(dimetilamino)-β-D-*xilo*-hexopiranosil]oxi}tetradecahidro-2*H*-furo[2,3-*c*]oxaciclotetradecina-3-carboximidamida

$C_{42}H_{62}N_6O_{11}S$



naratuximabum #

naratuximab

immunoglobulin G1-kappa, anti-[*Homo sapiens* CD37 (tetraspanin-26, TSPAN26)], chimeric monoclonal antibody;

	gamma1 heavy chain (1-444) [*Mus musculus* VH (IGHV2-3*01 -(IGHD) -IGHJ3*01) [8.7.9] (1-115) -*Homo sapiens* IGHG1*01, Gm17,1 (CH1 (116-213), hinge (214-228), CH2 (229-338), CH3 (339-443), CHS K2>del (444) (116-444)], (218-214')-disulfide with kappa light chain (1'-214') [*Mus musculus* V-KAPPA (IGKV12-46*01 -IGKJ1*01)[6.3.9] (1'-107') -*Homo sapiens* IGKC*01, Km3 (108'-214')]; dimer (224-224'':227-227'')-bisdisulfide
naratuximab	immunoglobuline G1-kappa, anti-[*Homo sapiens* CD37 (tétraspanine-26, TSPAN26)], anticorps monoclonal chimérique; chaîne lourde gamma1 (1-444) [*Mus musculus* VH (IGHV2-3*01 -(IGHD) -IGHJ3*01) [8.7.9] (1-115) -*Homo sapiens* IGHG1*01, Gm17,1 (CH1 (116-213), charnière (214-228), CH2 (229-338), CH3 (339-443), CHS K2>del (444) (116-444)], (218-214')-disulfure avec la chaîne légère kappa (1'-214') [*Mus musculus* V-KAPPA (IGKV12-46*01 -IGKJ1*01)[6.3.9] (1'-107') -*Homo sapiens* IGKC*01, Km3 (108'-214')]; dimère (224-224'':227-227'')-bisdisulfure
naratuximab	inmunoglobulina G1-kappa, anti-[*Homo sapiens* CD37 (tetraspanina-26, TSPAN26)], anticuerpo monoconal quimérico; cadena pesada gamma1 (1-444) [*Mus musculus* VH (IGHV2-3*01 -(IGHD) -IGHJ3*01) [8.7.9] (1-115) -*Homo sapiens* IGHG1*01, Gm17,1 (CH1 (116-213), bisagra (214-228), CH2 (229-338), CH3 (339-443), CHS K2>del (444) (116-444)], (218-214')-disulfuro con cadena ligera kappa (1'-214') [*Mus musculus* V-KAPPA (IGKV12-46*01 -IGKJ1*01)[6.3.9] (1'-107') -*Homo sapiens* IGKC*01, Km3 (108'-214')]; dímero (224-224'':227-227'')-bisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada

```
QVQVQESGPG LVAPSQTLSI TCTVSGFSLT TSGVSWVRQP PGKGLEWLGV  50
IWGDGSTNYH PSLKSRLSIK KDHSKSQVFL KLNSLTAADT ATYYCAKGGY 100
SLAHWGQGTL VTVSSASTKG PSVFPLAPSS KSTSGGTAAL GCLVKDYFPE 150
PVTVSWNSGA LTSGVHTFPA VLQSSGLYSL SSVVTVPSSS LGTQTYICNV 200
NHKPSNTKVD KKVEPKSCDK THTCPPCPAP ELLGGPSVFL FPPKPKDTLM 250
ISRTPEVTCV VVDVSHEDPE VKFNWYVDGV EVHNAKTKPR EEQYNSTYRV 300
VSVLTVLHQD WLNGKEYKCK VSNKALPAPI EKTISKAKGQ PREPQVYTLP 350
PSRDELTKNQ VSLTCLVKGF YPSDIAVEWE SNGQPENNYK TTPPVLDSDG 400
SFFLYSKLTV DKSRWQQGNV FSCSVMHEAL HNHYTQKSLS LSPG       444
```

Light chain / Chaîne légère / Cadena ligera

```
DIQMTQSPSS LSVSVGERVT ITCRASENIR SNLAWYQQKP GKSPKLLVNV  50
ATNLADGVPS RFSGSGSGTD YSLKINSLQP EDFGTYYCQH YWGTTWTFGQ 100
GTKLEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV 150
DNALQSGNSQ ESVTEQDSKD STYSLSSTLT LSKADYEKHK VYACEVTHQG 200
LSSPVTKSFN RGEC                                        214
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H (C23-C104)	22-95	142-198	259-319	365-423
	22''-95''	142''-198''	259''-319''	365''-423''
Intra-L (C23-C104)	23'-88'	134'-194'		
	23'''-88'''	134'''-194'''		
Inter-H-L (h 5-CL 126)	218-214'	218''-214'''		
Inter-H-H (h 11, h 14)	224-224''	227-227''		

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
H CH2 N84.4:
295, 295''
Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires complexes fucosylés / glicanos de tipo CHO biantenarios complejos fucosilados

naratuximabum emtansinum #

naratuximab emtansine	immunoglobulin G1-kappa, anti-[*Homo sapiens*CD37 (tetraspanin-26, TSPAN26)], chimeric monoclonal antibody conjugated to maytansinoid DM1; gamma1 heavy chain (1-444) [*Mus musculus* VH (IGHV2-3*01 -(IGHD)- IGHJ3*01) [8.7.9] (1-115) -*Homo sapiens* IGHG1*01, Gm17,1 (CH1 (116-213), hinge (214-228), CH2 (229-338), CH3 (339-443), CHS K2>del (444)) (116-444)], (218-214')-disulfide with kappa light chain (1'-214') [*Mus musculus* V-KAPPA (IGKV12-46*01 - IGKJ1*01) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01, Km3 (108'-214')]; dimer (224-224'':227-227'')-bisdisulfide; conjugated, on an average of 3 to 4 lysyl, to maytansinoid DM1 via a succinimidyl-4-(*N*-maleimidomethyl) cyclohexane-1-carboxylate (SMCC) linker forming a nonreducible thioether bond For the *emtansine* part, please refer to the document *"INN for pharmaceutical substances: Names for radicals, groups and others"*.
naratuximab emtansine	immunoglobuline G1-kappa, anti-[*Homo sapiens*CD37 (tétraspanine-26, TSPAN26)], anticorps monoclonal chimérique conjugué au maytansinoïde DM1; chaîne lourde gamma1 (1-444) [*Mus musculus* VH (IGHV2-3*01 -(IGHD)- IGHJ3*01) [8.7.9] (1-115) -*Homo sapiens* IGHG1*01, Gm17,1 (CH1 (116-213), charnière (214-228), CH2 (229-338), CH3 (339-443), CHS K2>del (444)) (116-444)], (218-214')-disulfure avec la chaîne légère kappa (1'-214') [*Mus musculus* V-KAPPA (IGKV12-46*01 - IGKJ1*01) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01, Km3 (108'-214')]; dimère (224-224'':227-227'')-bisdisulfure; conjugué, sur 3 à 4 lysyl en moyenne, au maytansinoïde DM1 via un linker succinimidyl-4-(*N*-maléimidométhyl) cyclohexane-1-carboxylate (SMCC) formant une liaison thioéther non réductible Pour la partie *emtansine*, veuillez-vous référer au document *"INN for pharmaceutical substances: Names for radicals, groups and others"*.
naratuximab emtansina	inmunoglobulina G1-kappa, anti-[*Homo sapiens*CD37 (tetraspanina-26, TSPAN26)], anticuerpo monoclonal quimérico conjugado con maitansinoide DM1; cadena pesada gamma1 (1-444) [*Mus musculus* VH (IGHV2-3*01 -(IGHD)- IGHJ3*01) [8.7.9] (1-115) -*Homo sapiens* IGHG1*01, Gm17,1 (CH1 (116-213), bisagra (214-228), CH2 (229-338), CH3 (339-443), CHS K2>del (444)) (116-444)], (218-214')-disulfuro con cadena ligera kappa (1'-214') [*Mus musculus* V-KAPPA (IGKV12-46*01 - IGKJ1*01) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01, Km3 (108'-214')]; dímero (224-224'':227-227'')-bisdisulfuro; conjugado, en una media de 3 a 4 restos lisil, con maitansinoide DM1 mediante un conector succinimidil -4-(*N*-maleimidometil) ciclohexano-1-carboxilato (SMCC) formando una unión tioéter no reducible La fracción *emtensina* se pueden encontrar en el documento "*INN for pharmaceutical substances: Names for radicals, groups and others"*.

Heavy chain / Chaîne lourde / Cadena pesada

```
QVQVQESGPG LVAPSQTLSI TCTVSGFSLT TSGVSWVRQP PGKGLEWLGV  50
IWGDGSTNYH PSLKSRLSIK KDHSKSQVFL KLNSLTAADT ATYYCAKGGY 100
SLAHWGQGTL VTVSSASTKG PSVFPLAPSS KSTSGGTAAL GCLVKDYFPE 150
PVTVSWNSGA LTSGVHTFPA VLQSSGLYSL SSVVTVPSSS LGTQTYICNV 200
NHKPSNTKVD KKVEPKSCDK THTCPPCPAP ELLGGPSVFL FPPKPKDTLM 250
ISRTPEVTCV VVDVSHEDPE VKFNWYVDGV EVHNAKTKPR EEQYNSTYRV 300
VSVLTVLHQD WLNGKEYKCK VSNKALPAPI EKTISKAKGQ PREPQVYTLP 350
PSRDELTKNQ VSLTCLVKGF YPSDIAVEWE SNGQPENNYK TTPPVLDSDG 400
SFFLYSKLTV DKSRWQQGNV FSCSVMHEAL HNHYTQKSLS LSPG       444
```

Light chain / Chaîne légère / Cadena ligera

```
DIQMTQSPSS LSVSVGERVT ITCRASENIR SNLAWYQQKP GKSPKLLVNV 50
ATNLADGVPS RFSGSGSGTD YSLKINSLQP EDFGTYYCQH YWGTTWTFGQ 100
GTKLEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV 150
DNALQSGNSQ ESVTEQDSKD STYSLSSTLT LSKADYEKHK VYACEVTHQG 200
LSSPVTKSFN RGEC                                        214
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H (C23-C104)	22-95	142-198	259-319	365-423
	22"-95"	142"-198"	259"-319"	365"-423"
Intra-L (C23-C104)	23'-88'	134'-194'		
	23"'-88"'	134"'-194"'		
Inter-H-L (h 5-CL 126)	218-214'	218"-214"'		
Inter-H-H (h 11, h 14)	224-224"	227-227"		

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación

H CH2 N84.4:
295, 295"

Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires complexes fucosylés / glicanos de tipo CHO biantenarios complejos fucosilados

An average of 3 to 4 lysyl being conjugated each to a drug linker / 3 à 4 lysyl en moyenne sont conjugués à un linker-principe actif / Una media de 3 a 4 lisil están conjugadas a conectores-principio activo.

navamepentum

navamepent — propan-2-yl (5*S*,8*E*,10*E*,12*R*)-5,12-dihydroxypentadeca-8,10-diene-6,14-diynoate

navamépent — (5*S*,8*E*,10*E*,12*R*)-5,12-dihydroxypentadéca-8,10-diène-6,14-diynoate de propan-2-yle

navamepent — (5*S*,8*E*,10*E*,12*R*)-5,12-dihidroxipentadeca-8,10-dieno-6,14-diinoato de propan-2-ilo

$C_{18}H_{24}O_4$



navicixizumabum #

navicixizumab — immunoglobulin G2-kappa, anti-[*Homo sapiens* DLL4 (delta-like 4)] and anti-[*Homo sapiens* VEGFA (vascular endothelial growth factor A,VEGF-A, VEGF)], humanized and chimeric monoclonal antibody, bispecific;

	gamma2 heavy chain, humanized anti-DLL4 (1-445) [humanized VH (*Homo sapiens* IGHV1-18*01 (84.70%) -(IGHD)-IGHJ4*01) [8.8.12] (1-119) -*Homo sapiens* IGHG2*01 (CH1 (120-217), hinge (218-229), CH2 (230-338), CH3 (339-443) K26>E (368), K88>E (407), CHS (444-445)) (120-445)],(133-218')-disulfide with kappa light chain, chimeric (1'-218') [chimeric V-KAPPA (*Mus musculus* IGKV3-2*01 -*Homo sapiens* IGKJ1*01) [10.3.9] (1'-111') -*Homo sapiens* IGKC*01, Km3 (112'-218')]; gamma2 heavy chain, humanized anti-VEGFA (1-447) [humanized VH (*Homo sapiens* IGHV1-46*01 (83.30%) -(IGHD)-IGHJ4*01) [8.8.14] (1-121) -*Homo sapiens* IGHG2*01 (CH1(122-219), hinge (220-231), CH2 (232-340), CH3 (341-445) E13>K(357), D84.2>K (399), CHS (446-447)) (122-447)], (135'-218'")-disulfide with kappa light chain, chimeric (1'"-218'") [chimeric V-KAPPA (*Mus musculus* IGKV3-2*01 -*Homo sapiens* IGKJ1*01) [10.3.9] (1'"-111'") -*Homo sapiens* IGKC*01, Km3 (112'"-218'")]; dimer (221-223":222-224":225-227":228-230")-tetrakisdisulfide
navicixizumab	immunoglobuline G2-kappa, anti-[*Homo sapiens* DLL4 (delta-like 4)] et anti-[*Homo sapiens* VEGFA (facteur de croissance A de l'endothélium vasculaire, VEGF-A, VEGF)], anticorps monoclonal humanisé et chimérique, bispécifique; chaîne lourde gamma2, humanisée anti-DLL4 (1-445) [VH humanisé (*Homo sapiens* IGHV1-18*01 (84.70%) -(IGHD)-IGHJ4*01) [8.8.12] (1-119) -*Homo sapiens* IGHG2*01 (CH1 (120-217), charnière (218-229), CH2 (230-338), CH3 (339-443) K26>E (368), K88>E (407), CHS (444-445)) (120-445)], (133-218')-disulfure avec la chaîne légère kappa, chimérique (1'-218') [V-KAPPA chimérique (*Mus musculus* IGKV3-2*01 -*Homo sapiens* IGKJ1*01) [10.3.9] (1'-111') -*Homo sapiens* IGKC*01, Km3 (112'-218')]; chaîne lourde gamma2, humanisée anti-VEGFA (1-447) [VH humanisé (*Homo sapiens* IGHV1-46*01 (83.30%) -(IGHD)-IGHJ4*01) [8.8.14] (1-121) -*Homo sapiens* IGHG2*01 (CH1 (122-219), charnière (220-231), CH2 (232-340), CH3 (341-445) E13>K (357), D84.2>K (399), CHS (446-447)) (122-447)], (135'-218'")-disulfure avec la chaîne légère kappa, chimérique (1'"-218'") [V-KAPPA chimérique (*Mus musculus* IGKV3-2*01 -*Homo sapiens* IGKJ1*01) [10.3.9] (1'"-111'") -*Homo sapiens* IGKC*01, Km3 (112'"-218'")]; dimère (221-223":222-224":225-227":228-230")-tétrakisdisulfure
navicixizumab	inmunoglobulina G2-kappa, anti-[*Homo sapiens* DLL4 (delta-like 4)] y anti-[*Homo sapiens* VEGFA (factor de crecimiento A del endotelio vascular,VEGF-A, VEGF)], anticuerpo humanizado y quimérico, biespecífico;

cadena pesada gamma2, humanizada anti-DLL4 (1-445) [VH humanizado (*Homo sapiens* IGHV1-18*01 (84.70%) -(IGHD)-IGHJ4*01) [8.8.12] (1-119) -*Homo sapiens* IGHG2*01 (CH1 (120-217), bisagra (218-229), CH2 (230-338), CH3 (339-443) K26>E (368), K88>E (407), CHS (444-445)) (120-445)], (133-218')-disulfuro con la cadena ligera kappa, quimérica (1'-218') [V-KAPPA quimérico (*Mus musculus* IGKV3-2*01 -*Homo sapiens* IGKJ1*01) [10.3.9] (1'-111') -*Homo sapiens* IGKC*01, Km3 (112'-218')]; cadena pesada gamma2, humanizada anti-VEGFA (1-447) [VH humanizado (*Homo sapiens* IGHV1-46*01 (83.30%) -(IGHD)-IGHJ4*01) [8.8.14] (1-121) -*Homo sapiens* IGHG2*01 (CH1(122-219), bisagra (220-231), CH2 (232-340), CH3 (341-445) E13>K(357), D84.2>K (399), CHS (446-447)) (122-447)], (135'-218'")-disulfuro con la cadena ligera kappa, quimérica (1'"-218'") [V-KAPPA quimérico (*Mus musculus* IGKV3-2*01 -*Homo sapiens* IGKJ1*01) [10.3.9] (1'"-111'") -*Homo sapiens* IGKC*01, Km3 (112'"-218'")]; dímero (221-223":222-224":225-227":228-230")-tetrakisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada (anti-DLL4, 1-445)
QVQLVQSGAE VKKPGASVKI SCKASGYSFT AYYIHWVKQA PGQGLEWIGY 50
ISNYNRATNY NQKFKGRVTF TTDTSTSTAY MELRSLRSDD TAVYYCARDY 100
DYDVGMDYWG QGTLVTVSSA STKGPSVFPL APCSRSTSES TAALGCLVKD 150
YFPEPVTVSW NSGALTSGVH TFPAVLQSSG LYSLSSVVTV PSSNFGTQTY 200
TCNVDHKPSN TKVDKTVERK CCVECPPCPA PPVAGPSVFL FPPKPKDTLM 250
ISRTPEVTCV VVDVSHEDPE VQFNWYVDGV EVHNAKTKPR EEQFNSTFRV 300
VSVLTVVHQD WLNGKEYKCK VSNKGLPAPI EKTISKTKGQ PREPQVYTLP 350
PSREEMTKNQ VSLTCLVKGF YPSDIAVEWE SNGQPENNYK TTPPMLDSDG 400
SFFLYSELTV DKSRWQQGNV FSCSVMHEAL HNHYTQKSLS LSPGK 445

Heavy chain / Chaîne lourde / Cadena pesada (anti-VEGFA, 1"-447")
QVQLVQSGAE VKKPGASVKV SCKASGYTFT NYWMHWVRQA PGQGLEWMGD 50
INPSNGRTSY KEKFKRRVTL SVDKSSSTAY MELSSLRSED TAVYFCTIHY 100
DDKYYPLMDY WGQGTLVTVS SASTKGPSVF PLAPCSRSTS ESTAALGCLV 150
KDYFPEPVTV SWNSGALTSG VHTFPAVLQS SGLYSLSSVV TVPSSNFGTQ 200
TYTCNVDHKP SNTKVDKTVE RKCCVECPPC PAPPVAGPSV FLFPPKPKDT 250
LMISRTPEVT CVVVDVSHED PEVQFNWYVD GVEVHNAKTK PREEQFNSTF 300
RVVSVLTVVH QDWLNGKEYK CKVSNKGLPA PIEKTISKTK GQPREPQVYT 350
LPPSREKMTK NQVSLTCLVK GFYPSDIAVE WESNGQPENN YKTTPPMLKS 400
DGSFFLYSKL TVDKSRWQQG NVFSCSVMHE ALHNHYTQKS LSLSPGK 447

Light chain / Chaîne légère / Cadena ligera
DIVMTQSPDS LAVSLGERAT ISCRASESVD NYGISFMKWF QQKPGQPPKL 50
LIYAASNQGS GVPDRFSGSG SGTDFTLTIS SLQAEDVAVY YCQQSKEVPW 100
TFGGGTKVEI KRTVAAPSVF IFPPSDEQLK SGTASVVCLL NNFYPREAKV 150
QWKVDNALQS GNSQESVTEQ DSKDSTYSLS STLTLSKADY EKHKVYACEV 200
THQGLSSPVT KSFNRGEC 218

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
Intra-H (C23-C104) 22-96 146-202 259-319 365-423
22"-96" 148"-204" 261"-321" 367"-425"
Intra-L (C23-C104) 23'-92' 138'-198'
23'"-92'" 138'"-198'"
Inter-H-L (CH1 10-CL 126) 133-218' 135"-218'"
Inter-H-H (h 4, h 5, h 11, h 14) 221-223" 222-224" 225-227" 228-230"

*In addition to the isoform A, isoform B characterized by two inter-H-H (h 5-CH1 10) (222-135", 224"-133) and two inter-H-L (h 4-CL 126) (221-218', 223"-218'"), instead of the inter-H-H (h 4-h 4, h 5-h 5) and the two inter-H-L (CH1 10-CL 126), and two isoforms A/B characterized by one inter-H-H (h 4-CH1 10) and one inter-H-L (h 4-CL 126) (221-135" and 223"-218'", respectively, in one isoform A/B, 223"-133 and 221-218', respectively, in the other one), instead of the inter-H-H (h 4-h 4) and one inter-H-L (CH1 10-CL 126). It is not excluded that other disulfide bridges may occur between the same cysteines.
*En plus de l'isoforme A, isoforme B caractérisée par un inter-H-H (h 5-CH1 10) (222-135", 224"-133) et deux inter-H-L (h 4-CL 126) (221-218', 223"-218'"), au lieu des inter-H-H (h 4-h 4, h 5-h 5) et des deux inter-H-L (CH1 10-CL 126), et deux isoformes A/B caractérisées par un inter-H-H (h 4-CH1 10) et un inter-H-L (h 4-CL 126) (221-135" et 223"-218'", respectivement, dans une isoforme A/B, 223"-133 et 221-218', respectivement, dans l'autre), au lieu de l'inter-H-H (h 4-h 4) et d'un inter-H-L (CH1 10-CL 126). Il n'est pas exclu que d'autres ponts disulfures existent entre les mêmes cystéines.
* Además de la isoforma A, isoforma B caracterizada por un inter-H-H (h 5-CH1 10) (222-135", 224"-133) y dos inter-H-L (h 4-CL 126) (221-218', 223"-218'"), en lugar de los inter-H-H (h 4-h 4, h 5-h 5) y de los dos inter-H-L (CH1 10-CL 126), y dos isoformas A/B caracterizadas por un inter-H-H (h 4-CH1 10) y un inter-H-L (h 4-CL 126) (221-135" et 223"-218'", respectivamente, dentro una isoforma A/B, 223"-133 et 221-218', respectivamente, dentro el otra), en lugar de l'inter-H-H (h 4-h 4) y de uno inter-H-L (CH1 10-CL 126). No se excluye que otros puentes disulfuro existan entre las mismas cisteínas.

nazartinibum

nazartinib — *N*-(7-chloro-1-{(3*R*)-1-[(2*E*)-4-(dimethylamino)but-2-enoyl]azepan-3-yl}-1*H*-benzimidazol-2-yl)-2-methylpyridine-4-carboxamide

nazartinib — *N*-(7-chloro-1-{(3*R*)-1-[(2*E*)-4-(diméthylamino)but-2-énoyl]azépan-3-yl}-1*H*-benzimidazol-2-yl)-2-méthylpyridine-4-carboxamide

nazartinib

N-(7-cloro-1-{(3*R*)-1-[(2*E*)-4-(dimetilamino)but-2-enoil]azepan-3-il}-1*H*-benzimidazol-2-il)-2-metilpiridina-4-carboxamida

$C_{26}H_{31}ClN_6O_2$



nicodicosapentum

nicodicosapent

N-{2-[(5*Z*,8*Z*,11*Z*,14*Z*,17*Z*)-icosa-5,8,11,14,17-pentaenamido]ethyl}pyridine-3-carboxamide

nicodicosapent

N-{2-[(5*Z*,8*Z*,11*Z*,14*Z*,17*Z*)-icosa-5,8,11,14,17-pentaénamido]éthyl}pyridine-3-carboxamide

nicodicosapent

N-{2-[(5*Z*,8*Z*,11*Z*,14*Z*,17*Z*)-icosa-5,8,11,14,17-pentaenamido]etil}piridina-3-carboxamida

$C_{28}H_{39}N_3O_2$



nolasibanum

nolasiban

[(2*S*,4*Z*)-2-(hydroxymethyl)-4-(methoxyimino)pyrrolidin-1-yl](2'-methyl[1,1'-biphenyl]-4-yl)methanone

nolasiban

[(2*S*,4*Z*)-2-(hydroxyméthyl)-4-(méthoxyimino)pyrrolidin-1-yl](2'-méthyl[1,1'-biphényl]-4-yl)méthanone

nolasibán

(2*S*,4*Z*)-2-(hidroximetil)-4-(metoxiimino)pirrolidin-1-il](2'-metil[1,1'-bifenil]-4-il)metanona

$C_{20}H_{22}N_2O_3$



oliceridinum

oliceridine

N-[(3-methoxythiophen-2-yl)methyl]-2-[(9*R*)-9-(pyridin-2-yl)-6-oxaspiro[4.5]decan-9-yl]ethan-1-amine

olicéridine *N*-[(3-méthoxythiophén-2-yl)méthyl]-2-[(9*R*)-9-(pyridin-2-yl)-6-oxaspiro[4.5]décan-9-yl]éthan-1-amine

oliceridina *N*-[(3-metoxitiofen-2-il)metil]-2-[(9*R*)-9-(piridin-2-il)-6-oxaspiro[4.5]decan-9-il]etan-1-amina

$C_{22}H_{30}N_2O_2S$



olmutinibum

olmutinib *N*-[3-({2-[4-(4-methylpiperazin-1-yl)anilino]thieno[3,2-*d*]pyrimidin-4-yl}oxy)phenyl]prop-2-enamide

olmutinib *N*-[3-({2-[4-(4-méthylpipérazin-1-yl)anilino]thiéno[3,2-*d*]pyrimidin-4-yl}oxy)phényl]prop-2-énamide

olmutinib *N*-[3-({2-[4-(4-metilpiperazina-1-il)anilino]tieno[3,2-*d*]pirimidin-4-il}oxi)fenil]prop-2-enamida

$C_{26}H_{26}N_6O_2S$



olumacostatum glasaretilum

olumacostat glasaretil 2-[(2-ethoxy-2-oxoethyl)(methyl)amino]-2-oxoethyl 5-(tetradecyloxy)furan-2-carboxylate

olumacostat glasarétil 5-(tétradécyloxy)furane-2-carboxylate de 2-[(2-éthoxy-2-oxoéthyl)(méthyl)amino]-2-oxoéthyle

olumacostat glasaretilo 5-(tetradeciloxi)furan-2-carboxilato de 2-[(2-etoxi-2-oxoetil)(metil)amino]-2-oxoetilo

$C_{26}H_{43}NO_7$



omidenepagum

omidenepag

({6-[(*N*-{[4-(1*H*-pyrazol-1-yl)phenyl]methyl}pyridine-3-sulfonamido)methyl]pyridin-2-yl}amino)acetic acid

omidénépag

acide ({6-[(*N*-{[4-(1*H*-pyrazol-1-yl)phényl]méthyl}pyridine-3-sulfonamido)méthyl]pyridin-2-yl}amino)acétique

omidenepag

ácido ({6-[(*N*-{[4-(1*H*-pirazol-1-il)fenil]metil}piridina-3-sulfonamido)metil]piridin-2-il}amino)acético

$C_{23}H_{22}N_6O_4S$



oteseconazolum

oteseconazole

(2*R*)-2-(2,4-difluorophenyl)-1,1-difluoro-3-(1*H*-1,2,3,4-tetrazol-1-yl)-1-{5-[4-(2,2,2-trifluoroethoxy)phenyl]pyridin-2-yl}propan-2-ol

otéséconazole

(2*R*)-2-(2,4-difluorophényl)-1,1-difluoro-3-(1*H*-1,2,3,4-tétrazol-1-yl)-1-{5-[4-(2,2,2-trifluoroéthoxy)phényl]pyridin-2-yl}propan-2-ol

oteseconazol

(2*R*)-2-(2,4-difluorofenil)-1,1-difluoro-3-(1*H*-1,2,3,4-tetrazol-1-il)-1-{5-[4-(2,2,2-trifluoroetoxi)fenil]piridin-2-il}propan-2-ol

$C_{23}H_{16}F_7N_5O_2$



pibrentasvirum

pibrentasvir

dimethyl *N*,*N*'-([(2*R*,5*R*)-1-{3,5-difluoro-4-[4-(4-fluorophenyl)piperidin-1-yl]phenyl}pyrrolidine-2,5-diyl]bis{(6-fluoro-1*H*-benzimidazole-5,2-diyl)[(2*S*)-pyrrolidine-2,1-diyl][(2*S*,3*R*)-3-methoxy-1-oxobutane-1,2-diyl]})dicarbamate

pibrentasvir

N,*N*'-([(2*R*,5*R*)-1-{3,5-difluoro-4-[4-(4-fluorophényl)pipéridin-1-yl]phényl}pyrrolidine-2,5-diyl]bis{(6-fluoro-1*H*-benzimidazole-5,2-diyl)[(2*S*)-pyrrolidine-2,1-diyl][(2*S*,3*R*)-3-méthoxy-1-oxobutane-1,2-diyl]})dicarbamate de diméthyle

pibrentasvir

N,*N*'-([(2*R*,5*R*)-1-{3,5-difluoro-4-[4-(4-fluorofenil)piperidin-1-il]fenil}pirrolidina-2,5-diil]bis{(6-fluoro-1*H*-benzimidazol-5,2-diil)[(2*S*)-pirrolidina-2,1-diil][(2*S*,3*R*)-3-metoxi-1-oxobutano-1,2-diil]})dicarbamato de dimetil

$C_{57}H_{65}F_6N_{10}O_8$



prexasertibum

prexasertib

5-({5-[2-(3-aminopropoxy)-6-methoxyphenyl]-1*H*-pyrazol-3-yl}amino)pyrazine-2-carbonitrile

prexasertib

5-({5-[2-(3-aminopropoxy)-6-méthoxyphényl]-1*H*-pyrazol-3-yl}amino)pyrazine-2-carbonitrile

prexasertib

5-({5-[2-(3-aminopropoxi)-6-metoxifenil]-1*H*-pirazol-3-il}amino)pirazina-2-carbonitrilo

$C_{18}H_{19}N_7O_2$



prexigebersenum

prexigebersen

2'-deoxyadenylyl-(3'→5')-thymidylyl-(3'→5')-2'-deoxyadenylyl-(3'→5')-thymidylyl-(3'→5')-thymidylyl-(3'→5')-thymidylyl-(3'→5')-2'-deoxyguanylyl-(3'→5')-2'-deoxyguanylyl-(3'→5')-2'-deoxycytidylyl-(3'→5')-2'-deoxyguanylyl-(3'→5')-2'-deoxyadenylyl-(3'→5')-thymidylyl-(3'→5')-2'-deoxyguanylyl-(3'→5')-2'-deoxyguanylyl-(3'→5')-2'-deoxycytidylyl-(3'→5')-thymidylyl-(3'→5')-thymidylyl-(3'→5')-2'-deoxycytidine

prexigébersen

2'-déoxyadénylyl-(3'→5')-thymidylyl-(3'→5')-2'-déoxyadénylyl-(3'→5')-thymidylyl-(3'→5')-thymidylyl-(3'→5')-thymidylyl-(3'→5')-2'-déoxyguanylyl-(3'→5')-2'-déoxyguanylyl-(3'→5')-2'-déoxycytidylyl-(3'→5')-2'-déoxyguanylyl-(3'→5')-2'-déoxyadénylyl-(3'→5')-thymidylyl-(3'→5')-2'-déoxyguanylyl-(3'→5')-2'-déoxyguanylyl-(3'→5')-2'-déoxycytidylyl-(3'→5')-thymidylyl-(3'→5')-thymidylyl-(3'→5')-2'-déoxycytidine

prexigebersén

2'-desoxiadenilil-(3'→5')-timidilil-(3'→5')-2'-desoxiadenilil-(3'→5')-timidilil-(3'→5')-timidilil-(3'→5')-timidilil-(3'→5')-2'-desoxiguanilil-(3'→5')-2'-desoxiguanilil-(3'→5')-2'-desoxicitidilil-(3'→5')-2'-desoxiguanilil-(3'→5')-timidilil-(3'→5')-timidilil-(3'→5')-2'-desoxiguanilil-(3'→5')-2'-desoxicitidilil-(3'→5')-timidilil-(3'→5')-timidilil-(3'→5')-2'-desoxicitidina

$C_{177}H_{224}N_{63}O_{110}P_{17}$

(3'-5')d(A-T-A-T-T-T-G-G-C-G-A-T-G-G-C-T-T-C)

prezalumabum #

prezalumab

immunoglobulin G2-kappa, anti-[*Homo sapiens* ICOSL (inducible T-cell co-stimulatory ligand, B7 homologue 2, B7H2, B7-H2, B7-related protein 1, B7RP1, B7RP-1, CD275)], *Homo sapiens* monoclonal antibody;
gamma2 heavy chain (1-447) [*Homo sapiens* VH (IGHV3-7*01 (98.00%) -(IGHD) -IGHJ2*01) [8.8.14] (1-121) -IGHG2*01, G2m.. (CH1 (122-219), hinge (220-231), CH2 (232-340), CH3 (341-445), CHS (446-447)) (122-447)], (135-214')-disulfide with kappa light chain (1'-214') [*Homo sapiens* V-KAPPA (IGKV2D-16*01 (97.90%) -IGKJ1*01) [6.3.9] (1'-107') -IGKC*01, Km3 (108'-214')]; dimer (223-223'':224-224'':227-227'':230-230'')-tetrakisdisulfide

prézalumab

immunoglobuline G2-kappa, anti-[*Homo sapiens* ICOSL (ligand inductible co-stimulateur des cellules T, homologue 2 du B7, B7H2, B7-H2, protéine 1 apparentée au B7, B7RP1, B7RP-1, CD275)], *Homo sapiens* anticorps monoclonal;
chaîne lourde gamma2 (1-447) [*Homo sapiens* VH (IGHV3-7*01 (98.00%) -(IGHD) -IGHJ2*01) [8.8.14] (1-121) -IGHG2*01, G2m.. (CH1 (122-219), charnière (220-231), CH2 (232-340), CH3 (341-445), CHS (446-447)) (122-447)], (135-214')-disulfure avec la chaîne légère kappa (1'-214') [*Homo sapiens* V-KAPPA (IGKV2D-16*01 (97.90%) -IGKJ1*01) [6.3.9] (1'-107') -IGKC*01, Km3 (108'-214')]; dimère (223-223'':224-224'':227-227'':230-230'')-tétrakisdisulfure

prezalumab

inmunoglobulina G2-kappa, anti-[*Homo sapiens* ICOSL (ligando inducible co-estimulador de las células T, B7 homólogo 2, B7H2, B7-H2, proteína 1 relacionada con la B7, B7RP1, B7RP-1, CD275)], *Homo sapiens* anticuerpo monoclonal;
cadena pesada gamma2 (1-447) [*Homo sapiens* VH (IGHV3-7*01 (98.00%) -(IGHD) -IGHJ2*01) [8.8.14] (1-121) -IGHG2*01, G2m.. (CH1 (122-219), bisagra (220-231), CH2 (232-340), CH3 (341-445), CHS (446-447)) (122-447)], (135-214')-disulfuro con la cadena ligera kappa (1'-214') [*Homo sapiens* V-KAPPA (IGKV2D-16*01 (97.90%) -IGKJ1*01) [6.3.9] (1'-107') -IGKC*01, Km3 (108'-214')]; dímero (223-223'':224-224'':227-227'':230-230'')-tetrakisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada

```
EVQLVESGGG LVQPGGSLRL SCAASGFTFS SYWMSWVRQA PGKGLEWVAY  50
IKQDGNEKYY VDSVKGRFTI SRDNAKNSLY LQMNSLRAED TAVYYCAREG 100
ILWFGDLPTF WGQGTLVTVS SASTKGPSVF PLAPCSRSTS ESTAALGCLV 150
KDYFPEPVTV SWNSGALTSG VHTFPAVLQS SGLYSLSSVV TVPSSNFGTQ 200
TYTCNVDHKP SNTKVDKTVE RKCCVECPPC PAPPVAGPSV FLFPPKPKDT 250
LMISRTPEVT CVVVDVSHED PEVQFNWYVD GVEVHNAKTK PREEQFNSTF 300
RVVSVLTVVH QDWLNGKEYK CKVSNKGLPA PIEKTISKTK GQPREPQVYT 350
LPPSREEMTK NQVSLTCLVK GFYPSDIAVE WESNGQPENN YKTTPPMLDS 400
DGSFFLYSKL TVDKSRWQQG NVFSCSVMHE ALHNHYTQKS LSLSPGK    447
```

Light chain / Chaîne légère / Cadena ligera

```
DIQMTQSPSS LSASVGDRVT ITCRASQGIS NWLAWYQQKP EKAPKSLIYA  50
ASSLQSGVPS RFSGSGSGTD FTLTISSLQP EDFATYYCQQ YDSYPRTFGQ 100
GTKVEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV 150
DNALQSGNSQ ESVTEQDSKD STYSLSSTLT LSKADYEKHK VYACEVTHQG 200
LSSPVTKSFN RGEC                                        214
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H (C23-C104)	22-96	148-204	261-321	367-425
	22''-96''	148''-204''	261''-321''	367''-425''
Intra-L (C23-C104)	23'-88'	134'-194'		
	23'''-88'''	134'''-194'''		
Inter-H-L (CH1 10-CL 126)	135-214'	135''-214'''		
Inter-H-H (h 4, h 5, h 8, h 11)	223-223''	224-224''	227-227''	230-230''

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
H CH2 N84.4:
297, 297''
Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires complexes fucosylés / glicanos de tipo CHO biantenarios complejos fucosilados

redaporfinum

redaporfin

3,3',3'',3'''-(7,8,17,18-tetrahydroporphyrin-5,10,15,20-tetrayl)tetrakis(2,4-difluoro-*N*-methylbenzenesulfonamide)

rédaporfine

3,3',3'',3'''-(7,8,17,18-tétrahydroporphyrin-5,10,15,20-tétrayl)tétrakis(2,4-difluoro-*N*-méthylbenzènesulfonamide)

redaporfina

3,3',3'',3'''-(7,8,17,18-tetrahidroporfirin-5,10,15,20-tetrail)tetrakis(2,4-difluoro-*N*-metilbencenosulfonamida)

$C_{48}H_{38}F_8N_8O_8S_4$



refanezumabum #

refanezumab	immunoglobulin G1-kappa, anti-[*Homo sapiens* MAG (myelin associated glycoprotein, sialic acid binding Ig-like lectin 4A, SIGLEC4A, SIGLEC-4A)], humanized monoclonal antibody; gamma1 heavy chain (1-456) [humanized VH (*Homo sapiens* IGHV7-4-1*02 (93.90%) -(IGHD)-IGHJ4*01) [8.8.19] (1-126) -*Homo sapiens* IGHG1*01, G1m17,1 (CH1 (127-224), hinge (225-239), CH2 L1.2>A (244), G1>A (246) (240-349), CH3 (350-454), CHS (455-456)) (127-456)], (229-219')-disulfide with kappa light chain (1'-219') [humanized V-KAPPA (*Homo sapiens* IGKV4-1*01 (95.00%) -IGKJ2*01) [12.3.8] (1'-112') -*Homo sapiens* IGKC*01, Km3 (113'-219')]; dimer (235-235":238-238")-bisdisulfide
réfanézumab	immunoglobuline G1-kappa, anti-[*Homo sapiens* MAG (glycoprotéine associée à la myéline, lectine 4A Ig-like liant l'acide sialique, SIGLEC4A, SIGLEC-4A)], anticorps monoclonal humanisé; chaîne lourde gamma1 (1-456) [humanisé VH (*Homo sapiens* IGHV7-4-1*02 (93.90%) -(IGHD)-IGHJ4*01) [8.8.19] (1-126) -*Homo sapiens* IGHG1*01, G1m17,1 (CH1 (127-224), charnière (225-239), CH2 L1.2>A (244), G1>A (246) (240-349), CH3 (350-454), CHS (455-456)) (127-456)], (229-219')- disulfure avec la chaîne légère kappa (1'-219') [V-KAPPA humanisé (*Homo sapiens* IGKV4-1*01 (95.00%) -IGKJ2*01) [12.3.8] (1'-112') -*Homo sapiens* IGKC*01, Km3 (113'-219')]; dimère (235-235":238-238")-bisdisulfure

refanezumab

inmunoglobulina G1-kappa, anti-[*Homo sapiens* MAG (glicoproteína asociada a la mielina, lectina de tipo inmunoglobulina 4A que se une al ácido siálico, SIGLEC4A, SIGLEC-4A)], anticuerpo monoclonal humanizado;
cadena pesada gamma1 (1-456) [VH humanizado (*Homo sapiens* IGHV7-4-1*02 (93.90%) -(IGHD)-IGHJ4*01) [8.8.19] (1-126) -*Homo sapiens* IGHG1*01, G1m17,1 (CH1 (127-224), bisagra (225-239), CH2 L1.2>A (244), G1>A (246) (240-349), CH3 (350-454), CHS (455-456)) (127-456)], (229-219')-disulfuro con la cadena ligera kappa (1'-219') [V-KAPPA humanizado (*Homo sapiens* IGKV4-1*01 (95.00%) -IGKJ2*01) [12.3.8] (1'-112') -*Homo sapiens* IGKC*01, Km3 (113'-219')]; dímero (235-235":238-238")-bisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada

```
QVQLVQSGSE LKKPGASVKV SCKASGYTFT NYGMNWVRQA PGQGLEWMGW  50
INTYTGEPTY ADDFTGRFVF SLDTSVSTAY LQISSLKAED TAVYYCARNP 100
INYYGINYEG YVMDYWGQGT LVTVSSASTK GPSVFPLAPS SKSTSGGTAA 150
LGCLVKDYFP EPVTVSWNSG ALTSGVHTFP AVLQSSGLYS LSSVVTVPSS 200
SLGTQTYICN VNHKPSNTKV DKKVEPKSCD KTHTCPPCPA PELAGAPSVF 250
LFPPKPKDTL MISRTPEVTC VVVDVSHEDP EVKFNWYVDG VEVHNAKTKP 300
REEQYNSTYR VVSVLTVLHQ DWLNGKEYKC KVSNKALPAP IEKTISKAKG 350
QPREPQVYTL PPSRDELTKN QVSLTCLVKG FYPSDIAVEW ESNGQPENNY 400
KTTPPVLDSD GSFFLYSKLT VDKSRWQQGN VFSCSVMHEA LHNHYTQKSL 450
SLSPGK                                                  456
```

Light chain / Chaîne légère / Cadena ligera

```
DIVMTQSPDS LAVSLGERAT INCKSSHSVL YSSNQKNYLA WYQQKPGQPP  50
KLLIYWASTR ESGVPDRFSG SGSGTDFTLT ISSLQAEDVA VYYCHQYLSS 100
LTFGQGTKLE IKRTVAAPSV FIFPPSDEQL KSGTASVVCL LNNFYPREAK 150
VQWKVDNALQ SGNSQESVTE QDSKDSTYSL SSTLTLSKAD YEKHKVYACE 200
VTHQGLSSPV TKSFNRGEC                                    219
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H (C23-C104)	22-96	153-209	270-330	376-434
	22"-96"	153"-209"	270"-330"	376"-434"
Intra-L (C23-C104)	23'-94'	139'-199'		
	23'"-94'"	139'"-199'"		
Inter-H-L (h 5-CL 126)	229-219'	229"-219'"		
Inter-H-H (h 11, h 14)	235-235"	238-238"		

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
H CH2 N84.4:
306, 306"
Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires complexes fucosylés / glicanos de tipo CHO biantenarios complejos fucosilados

revefenacinum

revefenacin

1-(2-{4-[(4-carbamoylpiperidin-1-yl)methyl]-*N*-methylbenzamido}ethyl)piperidin-4-yl *N*-([1,1'-biphenyl]-2-yl)carbamate

révéfénacine

N-([1,1'-biphényl]-2-yl)carbamate de 1-(2-{4-[(4-carbamoylpipéridin-1-yl)méthyl]-*N*-méthylbenzamido}éthyl)pipéridin-4-yle

revefenacina

N-([1,1'-bifenil]-2-il)carbamato de 1-(2-{4-[(4-carbamoilpiperidin-1-il)metil]-*N*-metilbenzamida}etil)piperidin-4-il

$C_{35}H_{43}N_5O_4$



rivabazumabum #

rivabazumab	immunoglobulin Fab' G1-kappa, anti-[*Pseudomonas aeruginosa* type III secretion system (TTSS) PcrV protein], humanized monoclonal antibody; gamma1 heavy chain fragment VH-(CH1-hinge) (1-238) [humanized VH (*Homo sapiens* IGHV3-30*06 (92.90%) -(IGHD) -IGHJ6*01) [8.8.17] (1-124) -*Homo sapiens* IGHG1*01 (CH1 (125-222), hinge C5>S (227) (223-237), CH2 (238)) (125-238)], noncovalently associated with kappa light chain (1'-214') [humanized V-KAPPA (*Homo sapiens* IGKV1-5*01 (84.60%) -IGKJ2*01) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01 C126>S (214') (108'-214')]
rivabazumab	immunoglobuline Fab' G1-kappa, anti-[protéine PcrV du système de sécrétion type III (TTSS) de *Pseudomonas aeruginosa*], anticorps monoclonal humanisé; fragment VH-(CH1-charnière) de la chaîne lourde gamma1 (1-238) [VH humanisé (*Homo sapiens* IGHV3-30*06 (92.90%) -(IGHD) -IGHJ6*01) [8.8.17] (1-124) -*Homo sapiens* IGHG1*01 (CH1 (125-222), charnière C5>S (227) (223-237), CH2 (238)) (125-238)], associé de manière non covalente avec la chaîne légère kappa (1'-214') [V-KAPPA humanisé (*Homo sapiens* IGKV1-5*01 (84.60%) -IGKJ2*01) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01 C126>S (214') (108'-214')]
rivabazumab	inmunoglobulina Fab' G1-kappa, anti-[proteína PcrV del sistema de secreción tipo III (TTSS) de *Pseudomonas aeruginosa*], anticuerpo monoclonal humanizado; fragmento VH-(CH1-bisagra) de la cadena pesada gamma1 (1-238) [VH humanizado (*Homo sapiens* IGHV3-30*06 (92.90%) -(IGHD) -IGHJ6*01) [8.8.17] (1-124) -*Homo sapiens* IGHG1*01 (CH1 (125-222), bisagra C5>S (227) (223-237), CH2 (238)) (125-238)], asociado de modo nocovalente con la cadena ligera kappa (1'-214') [V-KAPPA humanizado (*Homo sapiens* IGKV1-5*01 (84.60%) -IGKJ2*01) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01 C126>S (214') (108'-214')]

Heavy chain / Chaîne lourde / Cadena pesada

```
EVQLVESGGG VVQPGRSLRL SCAASGFTFS NYPMHWVRQA PGKGLEWVAV  50
ISYDGSEKWY ADSVKGRFTI SRDNSKNTLY LEMNSLRPED TAVYYCARNR 100
GDIYYDFTYA MDIWGQGTTV TVSSASTKGP SVFPLAPSSK STSGGTAALG 150
CLVKDYFPEP VTVSWNSGAL TSGVHTFPAV LQSSGLYSLS SVVTVPSSSL 200
GTQTYICNVN HKPSNTKVDK KVEPKSSDKT HTCPPCPA              238
```

Light chain / Chaîne légère / Cadena ligera

```
DIQLTQSPST LSASVGDSVT ITCRASEGVD RWLAWYQQKP GRAPKLLIYD  50
ASTLQSGVPS RFSGSGSGTE FSLTISSLQP DDVATYYCQH FWGTPYTFGQ 100
GTKLEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV 150
DNALQSGNSQ ESVTEQDSKD STYSLSSTLT LSKADYEKHK VYACEVTHQG 200
LSSPVTKSFN RGES                                       214
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
Intra-H (C23-C104) 22-96 151-207
Intra-L (C23-C104) 23'-88' 134'-194'

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
None

ruclosporinum

ruclosporin

8-[(2*R*)-*N*-methyl-2-[2-(4-morpholinyl)ethoxy]glycine]cyclosporin A: cyclo[L-alanyl-D-alanyl-*N*-methyl-L-leucyl-*N*-methyl-L-leucyl-*N*-methyl-L-valyl-(3*R*,4*R*,6*E*)-3-hydroxy-*N*,4-dimethyl-L-2-aminooct-6-enoyl-L-2-aminobutanoyl-(2*R*)-*N*-methyl-2-[2-(morpholin-4-yl)ethoxy]glycyl-*N*-methyl-L-leucyl-L-valyl-*N*-methyl-L-leucyl]

ruclosporine

8-[(2*R*)-*N*-méthyl-2-[2-(4-morpholinyl)éthoxy]glycine]cyclosporine A: cyclo[L-alanyl-D-alanyl-*N*-méthyl-L-leucyl-*N*-méthyl-L-leucyl-*N*-méthyl-L-valyl-(3*R*,4*R*,6*E*)-3-hydroxy-*N*,4-diméthyl-L-2-aminooct-6-énoyl-L-2-aminobutanoyl-(2*R*)-*N*-méthyl-2-[2-(morpholin-4-yl)éthoxy]glycyl-*N*-méthyl-L-leucyl-L-valyl-*N*-méthyl-L-leucyl]

ruclosporina

8-[(2*R*)-*N*-metil-2-[2-(4-morfolinil)etoxi]glicina]ciclosporina A: ciclo[L-alanil-D-alanil-*N*-metil-L-leucil-*N*-metil-L-leucil-*N*-metil-L-valil-(3*R*,4*R*,6*E*)-3-hidroxi-*N*,4-dimetil-L-2-aminooct-6-enoil-L-2-aminobutanoil-(2*R*)-*N*-metil-2-[2-(morfolin-4-il)etoxi]glicil-*N*-metil-L-leucil-L-valil-*N*-metil-L-leucil]

$C_{68}H_{122}N_{12}O_{14}$



ruzasvirum

ruzasvir — dimethyl *N*,*N*′-([(6*S*)-6-(2-cyclopropyl-1,3-thiazol-5-yl)-1-fluoro-6*H*-indolo[1,2-*c*][1,3]benzoxazine-3,10-diyl]bis{(1*H*-imidazole-4,2-diyl)[(2*S*)-pyrrolidine-2,1-diyl][(2*S*)-3-methyl-1-oxobutane-1,2-diyl]})dicarbamate

ruzasvir — *N*,*N*′-([(6*S*)-6-(2-cyclopropyl-1,3-thiazol-5-yl)-1-fluoro-6*H*-indolo[1,2-*c*][1,3]benzoxazine-3,10-diyl]bis{(1*H*-imidazole-4,2-diyl)[(2*S*)-pyrrolidine-2,1-diyl][(2*S*)-3-méthyl-1-oxobutane-1,2-diyl]})dicarbamate de diméthyle

ruzasvir — *N*,*N*′-([(6*S*)-6-(2-ciclopropil-1,3-tiazol-5-il)-1-fluoro-6*H*-indolo[1,2-*c*][1,3]benzoxazina-3,10-diil]bis{(1*H*-imidazol-4,2-diil)[(2*S*)-pirrolidina-2,1-diil][(2*S*)-3-metil-1-oxobutano-1,2-diil]})dicarbamato de dimetilo

$C_{49}H_{55}FN_{10}O_7S$



satoreotidum trizoxetanum

satoreotide trizoxetan — S^2,S^7-cyclo[*N*-{(4*RS*)-4-[4,7-bis(carboxymethyl)-1,4,7-triazonan-1-yl]-4-carboxybutanoyl}-4-chloro-L-phenylalanyl-D-cysteinyl-4-[(4*S*)-2,6-dioxo-1,3-diazinane-4-carb-oxamido]-L-phenylalanyl-4-(carbamoylamino)-D-phenylalanyl-L-lysyl-L-threonyl-L-cysteinyl-D-tyrosinamide]

satoréotide trizoxétan — S^2,S^7-cyclo[*N*-{(4*RS*)-4-[4,7-bis(carboxyméthyl)-1,4,7-triazonan-1-yl]-4-carboxybutanoyl}-4-chloro-L-phénylalanyl-D-cystéinyl-4-[(4*S*)-2,6-dioxo-1,3-diazinane-4-carb-oxamido]-L-phénylalanyl-4-(carbamoylamino)-D-phénylalanyl-L-lysyl-L-thréonyl-L-cystéinyl-D-tyrosinamide]

satoreotida trizoxetán — S^2,S^7-ciclo[*N*-{(4*RS*)-4-[4,7-bis(carboximetil)-1,4,7-triazonan-1-il]-4-carboxibutanoil}-4-cloro-L-fenilalanil-D-cisteinil-4-[(4*S*)-2,6-dioxo-1,3-diazinano-4-carboxamido]-L-fenilalanyl-4-(carbamoilamino)-D-fenilalanil-L-lisil-L-treonil-L-cisteinil-D-tirosinamida]

$C_{73}H_{95}ClN_{18}O_{21}S_2$



seviteronelum

seviteronel	(1*S*)-1-[6,7-bis(difluoromethoxy)naphthalen-2-yl]-2-methyl-1-(1*H*-1,2,3-triazole-4-yl)propan-1-ol
sevitéronel	(1*S*)-1-[6,7-bis(difluorométhoxy)naphtalén-2-yl]-2-méthyl-1-(1*H*-1,2,3-triazole-4-yl)propan-1-ol
seviteronel	(1*S*)-1-[6,7-bis(difluorometoxi)naftalen-2-il]-2-metil-1-(1*H*-1,2,3-triazol-4-il)propan-1-ol

$C_{18}H_{17}F_4N_3O_3$



sitravatinibum

sitravatinib	*N*-(3-fluoro-4-{[2-(5-{[(2-methoxyethyl)amino]methyl}pyridin-2-yl)thieno[3,2-*b*]pyridin-7-yl]oxy}phenyl)-*N*'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide
sitravatinib	*N*-(3-fluoro-4-{[2-(5-{[(2-méthoxyéthyl)amino]méthyl}pyridin-2-yl)thiéno[3,2-*b*]pyridin-7-yl]oxy}phényl)-*N*'-(4-fluorophényl)cyclopropane-1,1-dicarboxamide
sitravatinib	*N*-(3-fluoro-4-{[2-(5-{[(2-metoxietil)amino]metil}piridin-2-il)tieno[3,2-*b*]piridin-7-il]oxi}fenil)-*N*'-(4-fluorofenil)ciclopropano-1,1-dicarboxamida

$C_{33}H_{29}F_2N_5O_4S$



talinexomerum

talinexomer — poly[(prop-2-enoic acid)-*co*-{2-ethyl-2-[(prop-2-enoyloxy)methyl]propane-1,3-diyl di(prop-2-enoate)}]

talinexomère — poly[(acide prop-2-énoïque)-*co*-{di(prop-2-énoate) de 2-éthyl-2-[(prop-2-énoyloxy)méthyl]propane-1,3-diyle}]

talinexómero — poli[(ácido prop-2-enoico)-*co*-{di(prop-2-enoato de 2-etil-2-[(prop-2-enoiloxi)metil]propano-1,3-diilo}]

$[[C_{15}H_{20}O_6]_x \cdot [C_3H_4O_2]_y]_n$ $y/x \approx 1000$



tamtuvetmabum #

tamtuvetmab — immunoglobulin G2_V-kappa-C-lambda, anti-[*Homo sapiens* CD52], caninized monoclonal antibody; gamma2 heavy chain chimeric (1-456) [chimeric VH (*Rattus norvegicus* IGHV7S6*01 (97.00%) -(IGHD) -*Canis lupus familiaris* IGHJ-E2RCC8) [8.10.12] (1-121) -*Canis lupus familiaris* IGHG2*02 (CH1 (122-219), hinge (220-237), CH2 (238-347), CH3 (348-454), CHS (455-456))(122-456)], (136-212')-disulfide with V-kappa-C-lambda light chain chimeric (1'-213') [*Rattus norvegicus* V-KAPPA (*Rattus norvegicus* IGKV22S7 (93.70%) -IGKJ1*01) [6.3.9] (1'-107') -*Canis lupus familiaris* IGLC1S1*01 V45.3>I (156) (108'-213')]; dimer (233-233'':236-236'')-bisdisulfide

tamtuvetmab — immunoglobuline G2_V-kappa-C-lambda, anti-[*Homo sapiens* CD52], anticorps monoclonal caninisé; chaîne lourde gamma2 chimérique (1-456) [VH chimérique (*Rattus norvegicus* IGHV7S6*01 (97.00%) -(IGHD) -*Canis lupus familiaris* IGHJ-E2RCC8) [8.10.12] (1-121) -*Canis lupus familiaris* IGHG2*02 (CH1 (122-219), charnière (220-237), CH2 (238-347), CH3 (348-454), CHS (455-456)) (122-456)], (136-212')-disulfure avec la chaîne légère V-kappa-C-lambda chimérique (1'-213') [*Rattus norvegicus* V-KAPPA (*Rattus norvegicus* IGKV22S7 (93.70%) -IGKJ1*01) [6.3.9] (1'-107') -*Canis lupus familiaris* IGLC1S1*01 V45.3>I (156) (108'-213')]; dimère (233-233'':236-236'')-bisdisulfure

tamtuvetmab — inmunoglobulina G2_V-kappa-C-lambda, anti-[*Homo sapiens* CD52], anticuerpo monoclonal caninizado;

cadena pesada gamma2 quimérica (1-456) [VH quimérico (*Rattus norvegicus* IGHV7S6*01 (97.00%) -(IGHD) -*Canis lupus familiaris* IGHJ-E2RCC8) [8.10.12] (1-121) -*Canis lupus familiaris* IGHG2*02 (CH1 (122-219), bisagra (220-237), CH2 (238-347), CH3 (348-454), CHS (455-456))(122-456)], (136-212')-disulfuro con la cadena ligera V-kappa-C-lambda quimérica (1'-213') [*Rattus norvegicus* V-KAPPA (*Rattus norvegicus* IGKV22S7 (93.70%) -IGKJ1*01) [6.3.9] (1'-107') -*Canis lupus familiaris* IGLC1S1*01 V45.3>I (156) (108'-213')]; dímero (233-233":236-236")-bisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada

```
EVKLLESGGG LVQPGGSMRL SCAGSGFTFT DFYMNWIRQP AGKAPEWLGF  50
IRDKAKGYTT EYNPSVKGRF TISRDNTQNM LYLQMNTLRA EDTATYYCAR 100
EGHTAAPFDY WGQGTLVTVS SASTTAPSVF PLAPSCGSTS GSTVALACLV 150
SGYFPEPVTV SWNSGSLTSG VHTFPSVLQS SGLYSLSSMV TVPSSRWPSE 200
TFTCNVAHPA SKTKVDKPVP KRENGRVPRP PDCPKCPAPE MLGGPSVFIF 250
PPKPKDTLLI ARTPEVTCVV VDLDPEDPEV QISWFVDGKQ MQTAKTQPRE 300
EQFNGTYRVV SVLPIGHQDW LKGKQFTCKV NNKALPSPIE RTISKARGQA 350
HQPSVYVLPP SREELSKNTV SLTCLIKDFF PPDIDVEWQS NGQQEPESKY 400
RTTPPQLDED GSYFLYSKLS VDKSRWQRGD TFICAVMHEA LHNHYTQKSL 450
SHSPGK                                                 456
```

Light chain / Chaîne légère / Cadena ligera

```
DIKMTQSPSF LSASVGDRVT LNCKASQNID KYLNWYQQKL GESPKLLIYN  50
TNNLQTGIPS RFSGSGSGTD FTLTISSLQP EDVATYFCLQ HISRPRTFGG 100
GTHLTVLGQP KASPSVTLFP PSSEELGANK ATLVCLISDF YPSGVTVAWK 150
ADGSPITQGV ETTKPSKQSN NKYAASSYLS LTPDKWKSHS SFSCLVTHEG 200
STVEKKVAPA ECS                                         213
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H (C23-C104)	22-98	148-204	268-328	374-434
	22"-98"	148"-204"	268"-328"	374"-434"
Intra-L (C23-C104)	23'-88'	135'-194'		
	23'"-88'"	135'"-194'"		
Inter-H-L (CH1 11-CL 126)	136-212'	136"-212'"		
Inter-H-H (h 14, h 17)	233-233"	236-236"		

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
H CH2 N84.4:
304, 304"

tarloxotinibi bromidum

tarloxotinib bromide

(2*E*)-4-{[4-(3-bromo-4-chloroanilino)pyrido[3,4-*d*]pyrimidin-6-yl]amino}-*N*,*N*-dimethyl-*N*-[(1-methyl-4-nitro-1*H*-imidazol-5-yl)methyl]-4-oxobut-2-en-1-aminium bromide

bromure de tarloxotinib

bromure de (2*E*)-4-{[4-(3-bromo-4-chloroanilino)pyrido[3,4-*d*]pyrimidin-6-yl]amino}-*N*,*N*-diméthyl-*N*-[(1-méthyl-4-nitro-1*H*-imidazol-5-yl)méthyl]-4-oxobut-2-én-1-aminium

bromuro de tarloxotinib

bromuro de (2*E*)-4-{[4-(3-bromo-4-cloroanilino)pirido[3,4-*d*]pirimidin-6-il]amino}-*N*,*N*-dimetil-*N*-[(1-metil-4-nitro-1*H*-imidazol-5-il)metil]-4-oxobut-2-en-1-aminium

$C_{24}H_{24}Br_2ClN_9O_3$



tenalisibum

tenalisib — 3-(3-fluorophenyl)-2-{(1*S*)-1-[(7*H*-purin-6-yl)amino]propyl}-4*H*-1-benzopyran-4-one

ténalisib — 3-(3-fluorophényl)-2-{(1*S*)-1-[(7*H*-purin-6-yl)amino]propyl}-4*H*-1-benzopyran-4-one

tenalisib — 3-(3-fluorofenil)-2-{(1*S*)-1-[(7*H*-purin-6-il)amino]propil}-4*H*-1-benzopiran-4-ona

$C_{23}H_{18}FN_5O_2$



tetrodotoxinum

tetrodotoxin — (4*R*,4a*R*,5*R*,7*S*,9*S*,10*S*,10a*R*,11*S*,12*S*)-2-amino-12-(hydroxymethyl)-1,4,4a,5,9,10-hexahydro-7*H*-5,9:7,10a-dimethano[1,3]dioxocino[6,5-*d*]pyrimidine-4,7,10,11,12-pentol

tétrodotoxine — (4*R*,4a*R*,5*R*,7*S*,9*S*,10*S*,10a*R*,11*S*,12*S*)-2-amino-12-(hydroxyméthyl)-1,4,4a,5,9,10-hexahydro-7*H*-5,9:7,10a-diméthano[1,3]dioxocino[6,5-*d*]pyrimidine-4,7,10,11,12-pentol

tetrodotoxina — (4*R*,4a*R*,5*R*,7*S*,9*S*,10*S*,10a*R*,11*S*,12*S*)-2-amino-12-(hidroximetil)-1,4,4a,5,9,10-hexahidro-7*H*-5,9:7,10a-dimetano[1,3]dioxocino[6,5-*d*]pirimidina-4,7,10,11,12-pentol

$C_{11}H_{17}N_3O_8$



tezacaftorum

tezacaftor — 1-(2,2-difluoro-2*H*-1,3-benzodioxol-5-yl)-*N*-{1-[(2*R*)-2,3-dihydroxypropyl]-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1*H*-indol-5-yl}cyclopropane-1-carboxamide

tezacaftor	1-(2,2-difluoro-2*H*-1,3-benzodioxol-5-yl)-*N*-{1-[(2*R*)-2,3-dihydroxypropyl]-6-fluoro-2-(1-hydroxy-2-méthylpropan-2-yl)-1*H*-indol-5-yl}cyclopropane-1-carboxamide
tezacaftor	1-(2,2-difluoro-2*H*-1,3-benzodioxol-5-il)-*N*-{1-[(2*R*)-2,3-dihidroxipropil]-6-fluoro-2-(1-hidroxi-2-metilpropan-2-il)-1*H*-indol-5-il}ciclopropano-1-carboxamida

$C_{26}H_{27}F_3N_2O_6$



timolumabum #

timolumab	immunoglobulin G4-kappa, anti-[*Homo sapiens* AOC3 (amine oxidase copper containing 3 (EC 1.4.3.21), vascular adhesion protein 1, VAP1, VAP-1)],*Homo sapiens* monoclonal antibody; gamma4 heavy chain (1-444) [*Homo sapiens* VH (IGHV3-30*01 (91.80%) -(IGHD) -IGHJ4*01) [8.8.10] (1-117) -IGHG4*01 (CH1 (118-215), hinge S10>P (225) (216-227), CH2 L1.2>A (232) (228-337), CH3 (338-442), CHS (443-444)) (118-444)], (131-214')-disulfide with kappa light chain (1'-214') [*Homo sapiens* (V-KAPPA (IGKV1-13*02 (97.90%) -IGKJ4*01) [6.3.9] (1'-107') -IGKC*01, Km3 (108'-214')]; dimer (223-223":226-226")-bisdisulfide
timolumab	immunoglobuline G4-kappa, anti-[*Homo sapiens* AOC3 (amine oxydase à cuivre 3 (EC 1.4.3.21), VAP-1, protéine d'adhérence vasculaire 1, VAP1, VAP-1)], *Homo sapiens* anticorps monoclonal; chaîne lourde gamma4 (1-444) [*Homo sapiens* VH (IGHV3-30*01 (91.80%) -(IGHD) -IGHJ4*01) [8.8.10] (1-117) -IGHG4*01 (CH1 (118-215), charnière S10>P (225) (216-227), CH2 L1.2>A (232) (228-337), CH3 (338-442), CHS (443-444)) (118-444)], (131-214')-disulfure avec la chaîne légère kappa (1'-214') [*Homo sapiens* (V-KAPPA (IGKV1-13*02 (97.90%) -IGKJ4*01) [6.3.9] (1'-107') -IGKC*01, Km3 (108'-214')]; dimère (223-223":226-226")-bisdisulfure
timolumab	inmunoglobulina G4-kappa, anti-[*Homo sapiens* AOC3 (amina oxidasa con cobre 3 (EC 1.4.3.21), proteína de adhesión vascular 1, VAP1, VAP-1)],*Homo sapiens* anticuerpomonoclonal ;

cadena pesada gamma4 (1-444) [*Homo sapiens* VH (IGHV3-30*01 (91.80%) -(IGHD) -IGHJ4*01) [8.8.10] (1-117) -IGHG4*01 (CH1 (118-215), bisagra S10>P (225) (216-227), CH2 L1.2>A (232) (228-337), CH3 (338-442), CHS (443-444)) (118-444)], (131-214')-disulfuro con la cadena ligera kappa (1'-214') [*Homo sapiens* (V-KAPPA (IGKV1-13*02 (97.90%) -IGKJ4*01) [6.3.9] (1'-107') -IGKC*01, Km3 (108'-214')]; dímero (223-223":226-226")-bisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada

```
QVQLVESGGG VVQPGRSLRL SCAASGFTFF SYAMHWVRQT PGKGLEWVAV  50
IWFDGSNENY VDSVKGRFTI SRDNSKNTLY LQMNTLRAED TAVYYCARDA 100
WSYFDYWGQG TLVTVSSAST KGPSVFPLAP CSRSTSESTA ALGCLVKDYF 150
PEPVTVSWNS GALTSGVHTF PAVLQSSGLY SLSSVVTVPS SSLGTKTYTC 200
NVDHKPSNTK VDKRVESKYG PPCPPCPAPE FAGGPSVFLF PPKPKDTLMI 250
SRTPEVTCVV VDVSQEDPEV QFNWYVDGVE VHNAKTKPRE EQFNSTYRVV 300
SVLTVLHQDW LNGKEYKCKV SNKGLPSSIE KTISKAKGQP REPQVYTLPP 350
SQEEMTKNQV SLTCLVKGFY PSDIAVEWES NGQPENNYKT TPPVLDSDGS 400
FFLYSRLTVD KSRWQEGNVF SCSVMHEALH NHYTQKSLSL SLGK       444
```

Light chain / Chaîne légère / Cadena ligera

```
VIQLTQSPSS LSASVGDRVT ITCRASQGIS RALAWYQQKP GKGPKLLIYD  50
ASSLESGVPS RFSGSGSGTD FTLTISSLQP EDFATYYCQQ FNSYPLTFGG 100
GTKVEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV 150
DNALQSGNSQ ESVTEQDSKD STYSLSSTLT LSKADYEKHK VYACEVTHQG 200
LSSPVTKSFN RGEC                                        214
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H (C23-C104)	22-96	144-200	258-318	364-422
	22"-96"	144"-200"	258"-318"	364"-422"
Intra-L (C23-C104)	23'-88'	134'-194'		
	23'"-88'"	134'"-194'"		
Inter-H-L (CH1 10-CL 126)	131-214'	131"-214'"		
Inter-H-H (h 8, h 11)	223-223"	226-226"		

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
H CH2 N84.4:
294, 294"
Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires complexes fucosylés / glicanos de tipo CHO biantenarios complejos fucosilados

vadadustatum
vadadustat — [5-(3-chlorophenyl)-3-hydroxypyridine-2-carboxamido]acetic acid

vadadustat — acide [5-(3-chlorophényl)-3-hydroxypyridine-2-carboxamido]acétique

vadadustat — ácido [5-(3-clorofenil)-3-hidroxipiridina-2-carboxamido]acético

$C_{14}H_{11}ClN_2O_4$



vadastuximabum #
vadastuximab — immunoglobulin G1-kappa, anti-[*Homo sapiens* CD33 (sialic acid binding Ig-like lectin 3, SIGLEC3, SIGLEC-3, gp67, p67)], chimeric monoclonal antibody;
gamma1 heavy chain (1-447) [*Mus musculus* VH (IGHV1-85*01 -(IGHD) -IGHJ4*01) [8.8.10] (1-117) -*Homo sapiens* IGHG1*01, Gm17,1 (CH1 (118-215), hinge (216-230), CH2

S3>C (239) (231-340),CH3 (341-445), CHS (446-447)) (118-447)], (220-214')-disulfide with kappa light chain (1'-214') [*Mus musculus* V-KAPPA (IGKV14-111*01 - IGKJ1*01) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01, Km3 (108'-214')]; dimer (226-226":229-229")-bisdisulfide

vadastuximab

immunoglobuline G1-kappa, anti-[*Homo sapiens* CD33 (lectine 3 de type Ig-like liant l'acide sialique, SIGLEC3, SIGLEC-3, gp67, p67)], anticorps monoclonal chimérique; chaîne lourde gamma1 (1-447) [*Mus musculus* VH (IGHV1-85*01 -(IGHD) -IGHJ4*01) [8.8.10] (1-117) -*Homo sapiens* IGHG1*01, Gm17,1 (CH1 (118-215), charnière (216-230), CH2 S3>C (239) (231-340),CH3 (341-445), CHS (446-447)) (118-447)], (220-214')-disulfure avec la chaîne légère kappa (1'-214') [*Mus musculus* V-KAPPA (IGKV14-111*01 -IGKJ1*01) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01, Km3 (108'-214')]; dimère (226-226":229-229")-bisdisulfure

vadastuximab

inmunoglobulina G1-kappa, anti-[*Homo sapiens* CD33 (lectina de tipo inmunoglobulina 3 que se une al ácido siálico, SIGLEC3, SIGLEC-3, gp67, p67)], anticuerpo monoclonal quimérico;
cadena pesada gamma1 (1-447) [*Mus musculus* VH (IGHV1-85*01 -(IGHD) -IGHJ4*01) [8.8.10] (1-117) -*Homo sapiens* IGHG1*01, Gm17,1 (CH1 (118-215), bisagra (216-230), CH2 S3>C (239) (231-340),CH3 (341-445), CHS (446-447)) (118-447)], (220-214')-disulfuro con la cadena ligera kappa (1'-214') [*Mus musculus* V-KAPPA (IGKV14-111*01 -IGKJ1*01) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01, Km3 (108'-214')]; dímero (226-226":229-229")-bisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada

```
QVQLVQSGAE VKKPGASVKV SCKASGYTFT NYDINWVRQA PGQGLEWIGW  50
IYPGDGSTKY NEKFKAKATL TADTSTSTAY MELRSLRSDD TAVYYCASGY 100
EDAMDYWGQG TTVTVSSAST KGPSVFPLAP SSKSTSGGTA ALGCLVKDYF 150
PEPVTVSWNS GALTSGVHTF PAVLQSSGLY SLSSVVTVPS SSLGTQTYIC 200
NVNHKPSNTK VDKKVEPKSC DKTHTCPPCP APELLGGPCV FLFPPKPKDT 250
LMISRTPEVT CVVVDVSHED PEVKFNWYVD GVEVHNAKTK PREEQYNSTY 300
RVVSVLTVLH QDWLNGKEYK CKVSNKALPA PIEKTISKAK GQPREPQVYT 350
LPPSRDELTK NQVSLTCLVK GFYPSDIAVE WESNGQPENN YKTTPPVLDS 400
DGSFFLYSKL TVDKSRWQQG NVFSCSVMHE ALHNHYTQKS LSLSPGK    447
```

Light chain / Chaîne légère / Cadena ligera

```
DIQMTQSPSS LSASVGDRVT INCKASQDIN SYLSWFQQKP GKAPKTLIYR  50
ANRLVDGVPS RFSGSGSGQD YTLTISSLQP EDFATYYCLQ YDEFPLTFGG 100
GTKVEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV 150
DNALQSGNSQ ESVTEQDSKD STYSLSSTLT LSKADYEKHK VYACEVTHQG 200
LSSPVTKSFN RGEC                                        214
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H (C23-C104)	22-96	144-200	261-321	367-425
	22"-96"	144"-200"	261"-321"	367"-425"
Intra-L (C23-C104)	23'-88'	134'-194'		
	23'"-88'"	134'"-194'"		
Inter-H-L (h 5-CL 126)	220-214'	220"-214'"		
Inter-H-H (h 11, h 14)	226-226"	229-229"		

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
H CH2 N84.4:
297, 297"
Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires complexes fucosylés / glicanos de tipo CHO biantenarios complejos fucosilados

Other post-translational modifications / Autres modifications post-traductionnelles / Otras modificaciones post-traduccionales
N-terminal pyroglutamyl (pE) by cyclisation of the *N*-terminal glutaminyl (Q)
H VH Q1>pE:
1, 1"
C-terminal trimming of the *C*-terminal lysine (K)
H CHS K2:
447, 447"

venglustatum

venglustat — (3*S*)-1-azabicyclo[2.2.2]octan-3-yl *N*-{2-[2-(4-fluorophenyl)-1,3-thiazol-4-yl]propan-2-yl}carbamate

venglustat — *N*-{2-[2-(4-fluorophényl)-1,3-thiazol-4-yl]propan-2-yl}carbamate de (3*S*)-1-azabicyclo[2.2.2]octan-3-yle

venglustat — *N*-{2-[2-(4-fluorofenil)-1,3-tiazol-4-il]propan-2-il}carbamato de (3*S*)-1-azabiciclo[2.2.2]octan-3-ilo

$C_{20}H_{24}FN_3O_2S$



verdiperstatum

verdiperstat — 1-[2-(propan-2-yloxy)ethyl]-2-sulfanylidene-1,2,3,5-tetrahydro-4*H*-pyrrolo[3,2-*d*]pyrimidin-4-one

verdiperstat — 1-[2-(propan-2-yloxy)éthyl]-2-sulfanylidène-1,2,3,5-tétrahydro-4*H*-pyrrolo[3,2-*d*]pyrimidin-4-one

verdiperstat — 1-[2-(propan-2-iloxi)etil]-2-sulfanilideno-1,2,3,5-tetrahidro-4*H*-pirrolo[3,2-*d*]pirimidin-4-ona

$C_{11}H_{15}N_3O_2S$



vobarilizumabum #

vobarilizumab — immunoglobulin scFv VH-VH', anti-[*Homo sapiens* IL6R (interleukin 6 receptor, IL-6R, CD126)] and anti-[*Homo sapiens* ALB (albumin, human serum albumin, HSA)], humanized monoclonal antibody bispecific single chain; scFv (1-245) [humanized VH anti-IL6R (*Homo sapiens* IGHV3-66*01 (83.30%) -(IGHD) -IGHJ4*01) [8.7.15] (1-121) -9-mer tetraglycyl-seryl-triglycyl-seryl linker (122-130) -humanized VH' anti-ALB (*Homo sapiens* IGKV3-23*04 (89.60%) -(IGHD) -IGHJ1*01) [8.8.9] (131-245)]

vobarilizumab — immunoglobuline scFv VH-VH', anti-[*Homo sapiens* IL6R (récepteur de l'interleukine 6, IL-6R, CD126)] et anti-[*Homo sapiens* ALB (albumine, sérum-albumine humaine, SAH)], anticorps monoclonal humanisé et bispécifique à chaîne unique;
scFv (1-245) [VH humanisé anti-IL6R (*Homo sapiens* IGHV3-66*01 (83.30%) -(IGHD) -IGHJ4*01) [8.7.15] (1-121) -9-mer tétraglycyl-séryl-triglycyl-séryl linker (122-130) -VH' humanisé anti-ALB (*Homo sapiens* IGKV3-23*04 (89.60%) -(IGHD) -IGHJ1*01) [8.8.9] (131-245)]

vobarilizumab	inmunoglobulina scFv VH-VH', anti-[*Homo sapiens* IL6R (receptor de la interleukina 6, IL-6R, CD126)] y anti-[*Homo sapiens* ALB (albúmina, albúmina sérica humana, ASH)], anticuerpo monoclonal humanizado biespecífico monocatenario; scFv (1-245) [VH humanizado anti-IL6R (*Homo sapiens* IGHV3-66*01 (83.30%) -(IGHD) -IGHJ4*01) [8.7.15] (1-121) -9-mer tetraglicil-seril-triglicil-seril vínculo (122-130) -VH' humanizado anti-ALB (*Homo sapiens* IGKV3-23*04 (89.60%) -(IGHD) -IGHJ1*01) [8.8.9] (131-245)]

```
EVQLVESGGG LVQPGGSLRL SCAASGSVFK INVMAWYRQA PGKGRELVAG  50
IISGGSTSYA DSVKGRFTIS RDNAKNTLYL QMNSLRPEDT AVYYCAFITT 100
ESDYDLGRRY WGQGTLVTVS SGGGGSGGGS EVQLVESGGG LVQPGNSLRL 150
SCAASGFTFS SFGMSWVRQA PGKGLEWVSS ISGSGSDTLY ADSVKGRFTI 200
SRDNAKTTLY LQMNSLRPED TAVYYCTIGG SLSRSSQGTL VTVSS      245
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
Intra-chain C23 C104 22-95 152-226

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
None

xentuzumabum #

xentuzumab	immunoglobulin G1-lambda1, anti-[*Homo sapiens* IGF1 (insulin-like growth factor 1, somatomedin C) and IGF2 (insulin-like growth factor 2, somatomedin A)], humanized monoclonal antibody; gamma1 heavy chain (1-447) [humanized VH (*Homo sapiens* IGHV3-23*03 (88.80%) -(IGHD) -IGHJ5*01) [8.8.10] (1-117) -IGHG1*01, Gm17,1 (CH1 (118-215), hinge (216-230), CH2 (231-340), CH3 (341-445), CHS (446-447)) (118-447)], (220-215')-disulfide with lambda1 light chain (1'-216') [humanized V-LAMBDA (*Homo sapiens* IGLV1-40*01 (88.20%) -IGLJ2*01) [8.3.11] (1'-110') -IGLC2*01 A43>G (154) (111'-216')]; dimer (226-226'':229-229'')-bisdisulfide
xentuzumab	immunoglobuline G1-lambda1, anti-[*Homo sapiens* IGF1 (facteur de croissance 1 analogue à l'insuline, somatomédine C) et IGF2 (facteur de croissance 2 analogue à l'insuline, somatomédine A)], anticorps monoclonal humanisé; chaîne lourde gamma1 (1-447) [VH humanisé (*Homo sapiens* IGHV3-23*03 (88.80%) -(IGHD) -IGHJ5*01) [8.8.10] (1-117) -IGHG1*01, Gm17,1 (CH1 (118-215), charnière (216-230), CH2 (231-340), CH3 (341-445), CHS (446-447)) (118-447)], (220-215')-disulfure avec la chaîne légère lambda1 (1'-216') [V-LAMBDA humanisé (*Homo sapiens* IGLV1-40*01 (88.20%) -IGLJ2*01) [8.3.11] (1'-110') -IGLC2*01 A43>G (154) (111'-216')]; dimère (226-226'':229-229'')-bisdisulfure
xentuzumab	inmunoglobulina G1-lambda1, anti-[*Homo sapiens* IGF1 (factor de crecimiento 1 análogo a la insulina, somatomedina C) y IGF2 (factor de crecimiento 2 análogo a la insulina, somatomedina A)], anticuerpo monoclonal humanizado;

cadena pesada gamma1 (1-447) [VH humanizado (*Homo sapiens* IGHV3-23*03 (88.80%) -(IGHD) -IGHJ5*01) [8.8.10] (1-117) -IGHG1*01, Gm17,1 (CH1 (118-215), bisagra (216-230), CH2 (231-340), CH3 (341-445), CHS (446-447)) (118-447)], (220-215')-disulfuro con la cadena ligera lambda1 (1'-216') [V-LAMBDA humanizado (*Homo sapiens* IGLV1-40*01 (88.20%) -IGLJ2*01) [8.3.11] (1'-110') -IGLC2*01 A43>G (154) (111'-216')]; dímero (226-226'':229-229'')-bisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada

```
QVELVESGGG LVQPGGSLRL SCAASGFTFT SYWMSWVRQA PGKGLELVSS  50
ITSYGSFTYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCARNM 100
YTHFDSWGQG TLVTVSSAST KGPSVFPLAP SSKSTSGGTA ALGCLVKDYF 150
PEPVTVSWNS GALTSGVHTF PAVLQSSGLY SLSSVVTVPS SSLGTQTYIC 200
NVNHKPSNTK VDKKVEPKSC DKTHTCPPCP APELLGGPSV FLFPPKPKDT 250
LMISRTPEVT CVVVDVSHED PEVKFNWYVD GVEVHNAKTK PREEQYNSTY 300
RVVSVLTVLH QDWLNGKEYK CKVSNKALPA PIEKTISKAK GQPREPQVYT 350
LPPSRDELTK NQVSLTCLVK GFYPSDIAVE WESNGQPENN YKTTPPVLDS 400
DGSFFLYSKL TVDKSRWQQG NVFSCSVMHE ALHNHYTQKS LSLSPGK    447
```

Light chain / Chaîne légère / Cadena ligera

```
DIVLTQPPSV SGAPGQRVTI SCSGSSSNIG SNSVSWYQQL PGTAPKLLIY  50
DNSKRPSGVP DRFSGSKSGT SASLAITGLQ SEDEADYYCQ SRDTYGYYWV 100
FGGGTKLTVL GQPKAAPSVT LFPPSSEELQ ANKATLVCLI SDFYPGAVTV 150
AWKGDSSPVK AGVETTTPSK QSNNKYAASS YLSLTPEQWK SHRSYSCQVT 200
HEGSTVEKTV APTECS                                      216
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H (C23-C104)	22-96	144-200	261-321	367-425
	22''-96''	144''-200''	261''-321''	367''-425''
Intra-L (C23-C104)	22'-89'	138'-197'		
	22'''-89'''	138'''-197'''		
Inter-H-L (h 5-CL 126)	220-215'	220''-215'''		
Inter-H-H (h 11, h 14)	226-226'	229-229''		

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
H CH2 N84.4:
297, 297''
Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires complexes fucosylés / glicanos de tipo CHO biantenarios complejos fucosilados

zoliflodacinum

zoliflodacin

(2'*R*,4'*S*,4'a*S*)-11'-fluoro-2',4'-dimethyl-8'-[(4*S*)-4-methyl-2-oxo-1,3-oxazolidin-3-yl]-1',2',4',4'a-tetrahydro-6'*H*-spiro[1,3-diazinane-5,5'-[1,4]oxazino[4,3-*a*][1,2]oxaz-olo[4,5-*g*]quinoline]-2,4,6-trione

zoliflodacine

(2'*R*,4'*S*,4'a*S*)-11'-fluoro-2',4'-diméthyl-8'-[(4*S*)-4-méthyl-2-oxo-1,3-oxazolidin-3-yl]-1',2',4',4'a-tétrahydro-6'*H*-spiro[1,3-diazinane-5,5'-[1,4]oxazino[4,3-*a*][1,2]oxaz-olo[4,5-*g*]quinoline]-2,4,6-trione

zoliflodacina

(2'*R*,4'*S*,4'a*S*)-11'-fluoro-2',4'-dimetil-8'-[(4*S*)-4-metil-2-oxo-1,3-oxazolidin-3-il]-1',2',4',4'a-tetrahidro-6'*H*-spiro[1,3-diazinano-5,5'-[1,4]oxazino[4,3-*a*][1,2]oxaz-olo[4,5-*g*]quinolina]-2,4,6-triona

$C_{22}H_{22}FN_5O_7$



AMENDMENTS TO PREVIOUS LISTS
MODIFICATIONS APPORTÉES AUX LISTES ANTÉRIEURES
MODIFICACIONES A LAS LISTAS ANTERIORES

Recommended International Nonproprietary Names (Rec. INN): List 59
Dénominations communes internationales recommandées (DCI Rec.): Liste 59
Denominaciones Comunes Internacionales Recomendadas (DCI Rec.): Lista 59
(WHO Drug Information, Vol. 22, No. 1, 2008)

p. 58 **lonaprisanum**

lonaprisan	*replace the chemical name by the following one*
lonaprisan	*remplacer le nom chimique par le suivant*
lonaprisán	*sustitúyase el nombre químico por el siguiente*

11β-(4-acetylphenyl)-20,20,21,21,21-pentafluoro-17-hydroxy-19-nor-17α-pregna-4,9-dien-3-one

11β-(4-acétylphényl)-20,20,21,21,21-pentafluoro-17-hydroxy-19-nor-17α-prégna-4,9-dién-3-one

11β-(4-acetylfenil)-20,20,21,21,21-pentafluoro-17-hidroxi-19-nor-17α-pregna-4,9-dien-3-ona

Recommended International Nonproprietary Names (Rec. INN): List 67
Dénominations communes internationales recommandées (DCI Rec.): Liste 67
Denominaciones Comunes Internacionales Recomendadas (DCI Rec.): Lista 67
(WHO Drug Information, Vol. 26, No. 1, 2012)

p. 58 **daclatasvirum**

daclatasvir	*replace the chemical name by the following one*
daclatasvir	*remplacer le nom chimique par le suivant*
daclatasvir	*sustitúyase el nombre químico por el siguiente*

dimethyl *N*,*N*′-([1,1'-biphenyl]-4,4'-diylbis{1*H*-imidazole-5,2-diyl-[(2*S*)-pyrrolidine-2,1-diyl][(2*S*)-3-methyl-1-oxobutane-1,2-diyl]})dicarbamate
N,*N*′-([1,1'-biphényl]-4,4'-diylbis{1*H*-imidazole-5,2-diyl-[(2*S*)-pyrrolidine-2,1-diyl][(2*S*)-3-méthyl-1-oxobutane-1,2-diyl]})dicarbamate de diméthyle

N,*N*′-([1,1'-bifenil]-4,4'-diilbis{1*H*-imidazol-5,2-diil-[(2*S*)-pirrolidina-2,1-diil][(2*S*)-3-metil-1-oxobutano-1,2-diil]})dicarbamato de dimetilo

Recommended International Nonproprietary Names (Rec. INN): List 71
Dénominations communes internationales recommandées (DCI Rec.): Liste 71
Denominaciones Comunes Internacionales Recomendadas (DCI Rec.): Lista 71
(WHO Drug Information, Vol. 28, No. 1, 2014)

p. 90 **idarucizumabum**
- 91 idarucizumab *replace the description by the following one*
idarucizumab *remplacer la description par la suivante*
idarucizumab *sustitúyase la descripción por la siguiente*

immunoglobulin Fab G1-kappa, anti-[dabigatran], humanized monoclonal antibody;
VH-(CH1-hinge) gamma1 heavy chain (1-225) [humanized VH (*Homo sapiens* IGHV4-59*01 (82.30%) -(IGHD)-IGHJ4*01) [8.7.16] (1-122) -*Homo sapiens* IGHG1*01 (CH1 (123-220), hinge 1-5 (221-225)) (123-225)], (225-219')-disulfide with kappa light chain (1'-219') [humanized V-KAPPA (*Homo sapiens* IGKV2-30*01 (88.00%) -IGKJ4*01) [11.3.9] (1'-112') -*Homo sapiens* IGKC*01 (113'-219')]

immunoglobuline Fab G1-kappa, anti-[dabigatran], anticorps monoclonal humanisé;
chaîne lourde VH-(CH1-charnière) gamma1 (1-225) [VH humanisé(*Homo sapiens* IGHV4-59*01 (82.30%) -(IGHD)-IGHJ4*01) [8.7.16](1-122) -*Homo sapiens* IGHG1*01 (CH1 (123-220), charnière 1-5 (221-225)) (123-225)], (225-219')-disulfure avec la chaîne légère kappa (1'-219') [V-KAPPA humanisé (*Homo sapiens* IGKV2-30*01 (88.00%) -IGKJ4*01) [11.3.9] (1'-112') -*Homo sapiens* IGKC*01 (113'-219')]

inmunoglobulina Fab G1-kappa, anti-[dabigatrán], anticuerpo monoclonal humanizado;
cadena pesada VH-(CH1-bisagra) gamma1 (1-225) [VH humanizado (*Homo sapiens* IGHV4-59*01 (82.30%) -(IGHD)-IGHJ4*01) [8.7.16] (1-122) -*Homo sapiens* IGHG1*01 (CH1 (123-220), bisagra 1-5 (221-225)) (123-225)], (225-219')-disulfuro con la cadena ligera kappa (1'-219') [V-KAPPA humanizado (*Homo sapiens* IGKV2-30*01 (88.00%)-IGKJ4*01) [11.3.9] (1'-112') -*Homo sapiens* IGKC*01 (113'-219')]

Procedure and Guiding Principles / Procédure et Directives / Procedimientos y principios generales

The text of the *Procedures for the Selection of Recommended International Nonproprietary Names for Pharmaceutical Substances* and *General Principles for Guidance in Devising International Nonproprietary Names for Pharmaceutical Substances* will be reproduced in proposed INN lists only.

Les textes de la *Procédure à suivre en vue du choix de dénominations communes internationales recommandées pour les substances pharmaceutiques* et des *Directives générales pour la formation de dénominations communes internationales applicables aux substances pharmaceutiques* seront publiés seulement dans les listes des DCI proposées.

El texto de los *Procedimientos de selección de denominaciones comunes internacionales recomendadas para las sustancias farmacéuticas* y de los *Principios generales de orientación para formar denominaciones comunes internacionales para sustancias farmacéuticas* aparece solamente en las listas de DCI propuestas.